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Abstract
The availability of exome sequence data for thousands of cancer samples has enabled the
investigation of the sequence-level mutations that contribute to cancer. There is a need for
strategies to analyse sequence data to gain new biological and clinical insights. This thesis
investigates the use of machine learning and network-based methods to identify the mutated
genes associated with important clinical features and cancer types, and to aid candidate
gene prioritisation in colorectal cancer, and rheumatoid arthritis.
Firstly, tumour / normal exome sequence data was analysed to identify the mutated
genes associated with cancer grade and cancer stage across and within three adenocarcino-
mas. Tumour grading is an important prognostic indicator which is based upon subjective
assessment by pathologists, and is not standardised across cancer types. Despite this, this
study found that protein coding mutations within TP53 were indicative of high grade status
across three adenocarcinomas once adjusted for age, gender, stage, and tumour type.
Secondly, Random Forest models were used to identify the mutations that discriminate
each of ﬁve high-order cancer types. Based on this work a Random Forest approach was
used to investigate whether exome sequence data could be used to assign cancers to their
tissue of origin without prior knowledge, for future use as a classiﬁer for cancers of unknown
primary origin.
Finally, a network-based method to perform candidate disease gene prioritisation called
‘k-pseudo cliques analysis’ was developed. The method identiﬁes sets of highly interacting
proteins that are enriched for low gene-level p-values. In tests, the identiﬁed gene sets
outperformed a univariate test for general cancer gene enrichment. As part of the ﬁnal
chapter a network-based method called ‘Region Growing Analysis’ was used to perform
candidate disease gene prioritisation of rheumatoid arthritis genome-wide association study
data.
The ﬁndings and methods developed in this thesis can provide insights to the genetic
correlates of cancer phenotypes and suggest new candidate disease genes.
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In the last decade there has been an explosion in the amount of DNA sequence data available.
This is due to the development of next generation sequencing technologies that can generate
gigabases of sequence data and provide sequence level characterisation of an individual’s
genome. The decline in the cost of this technology has allowed the successful large scale
study of sequence level variation of cancers. However, the complete set of mutated genes
that are associated with cancer types and important clinical features has not yet been
discovered. Throughout this thesis I will investigate these issues using machine learning
and systems-biology methods to analyse mutations discovered from whole exome sequence
analysis of thousands of tumour samples.
I will use logistic regression analyses in Chapter 3 to identify the mutated genes associated
with tumour grade and cancer stage across three types of cancer. Tumour grading is a
subjective measure of prognosis and is not standardised across cancer types. By establishing
mutated genes associated with tumour grade across cancer types the foundations for a single
tumour grading system can be established.
The Pan-Cancer analysis of twelve cancers is composed of ﬁve high-order cancer types
(adenocarcinomas, squamous cell carcinomas, urothelial carcinomas, blood cancers, and
cancers of the central nervous system). However, the sets of mutated genes that discriminate
between these high-order types have not been identiﬁed. I will use Random Forest analyses
in Chapter 4.1 to identify sets of mutated genes that discriminate each high-order cancer
type from others, and to uncover new genes that are important for the progression for each
cancer type.
A further Random Forest model will be applied to address the problem of cancers of
unknown primary origin in Chapter 4.2. Around three percent of cancers are diagnosed as
stage IV with an unknown primary origin. To provide a prediction of the origin of the primary
tumour may aid patient care. I will use multi-class Random Forest models to assign the
Pan-Cancer cancer types to their tissue of origin using exome sequence data.
The problem of prioritising genes that contribute to cancer and other complex diseases
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is addressed in Chapter 5. Tests to identify genes contributing to cancer conducted at the
gene level may be underpowered to detect some of the contributing genes due to genetic
heterogeneity, where samples may carry mutations in diﬀerent genes that have the same
phenotypic eﬀect. In Chapter 5.1 I will describe how I developed a method called k-pseudo
cliques analysis which can prioritise disease genes using gene level test statistics and a protein
interaction network. A further demonstration of the utility of protein interaction networks
for prioritising candidate disease genes will be provided by applying Region Growing Analysis
to a rheumatoid arthritis genome-wide association study dataset in Chapter 5.2.
Finally I will conclude with the ﬁndings from these investigations. I will discuss the
limitations of these analyses and how they can be further reﬁned.
Most of the analyses in this thesis relate to cancers. First I will give some background
to cancer biology. I will go on to describe provide an overview of areas important for each
chapter in this thesis including cancer grading and staging, high order cancer types, and
how protein protein interaction networks and high throughput genomic data can be used to
prioritise disease genes. The introduction will conclude with an outline of the aims of the
thesis.
1.2 An overview of cancer biology
Cancer is characterised by uncontrolled cell growth and proliferation, invasion in to surrounding
tissue, and the eventual spread to multiple sites across the body. When human cells die, or
become damaged, other cells grow and divide to replace them. Cancer may occur if this
process is disrupted. Cancers are typically treated using surgery, chemotherapy, radiotherapy,
targeted therapy, immunotherapy, or hormone therapy. Chemotherapy involves using drugs,
often in combination, to kill cancer cells. Radiotherapy uses x-rays and other high-energy
radiation to kill cancer cells using a “beam” of radiation, or by introducing radioactive material
in to the body. Targeted therapy, using drugs, or monoclonal antibodies, that speciﬁcally
target cancer cells can have fewer side-eﬀects than other treatments. Hormone therapy can
be given to stop, or slow the growth of hormone sensitive cancers before surgery.
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Cancers are caused by genetic mutation, but many factors inﬂuence its occurrence.
Genetic, environmental, and epigenetic factors are all known to be important across the many
types of cancer. The well known environmental factors include smoking, which is associated
with a 10-fold increase in lung cancer mutation frequency in comparison to non-smokers
(Govindan et al., 2012). Epigenetic alterations, such as DNA methylation, are known to
be important for the progression of certain types of colorectal cancer where more than 10
percent of genes can be diﬀerentially methylated (Beggs et al., 2013).
For over 100 years cancer has been thought to be a disease of the genome (Boveri, 2008),
but only in the 1970s were researchers successful in showing this to be true (Stehelin et al.,
1976). There are heritable genetic factors that contribute to cancer (germ-line mutations)
and confer an increased risk of developing cancer at some point during a person’s lifetime
(Pomerantz & Freedman, 2011). Indeed, there is an increased rate of cancer among close
relatives of people with cancer (Pomerantz & Freedman, 2011).
All cancers arise due to somatic mutations that arise in the DNA of cancer cells. However,
not all somatic mutations will have contributed to the development of the cancer. The
mutations which have played some part in the development of the cancer are termed driver
mutations and there are corresponding driver genes in which the driver mutations most
commonly occur (Stratton et al., 2009). The somatic mutations that have played no part
in the development of the cancer are known as passenger mutations. The discrimination
between driver and passenger mutations is at the heart of cancer genomics.
The identiﬁcation of sequence-level variation in cancers was only possible due to the
completion of the human genome project (Lander et al., 2001; Venter et al., 2001). The
draft human reference sequence was instrumental to our understanding of cancer. However,
the development of next-generation sequencing (NGS) technologies, that could generate
gigabases of sequence information in a very short time, allowed cancer researchers to
characterise sequence-level variation in cancers at a scale that was not possible using classical
Sanger sequencing techniques (Sanger & Coulson, 1975). As the cost of next-generation
sequencing fell in the mid-2000s, the ﬁeld of cancer genomics appeared (Mardis, 2011).
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Cancer genomics involves the analysis of large datasets, of possibly millions of biomolecular
features and thousands of samples in an hypothesis free manner. Its introduction presented
a drastic change to the exclusively hypothesis driven approach used in cancer research up to
that point. The most high proﬁle whole-’omics approach in cancer research to date has been
The Cancer Genome Atlas (TCGA) project, whose aim it was, across 27 research centres, to
“accelerate our understanding of the molecular basis of cancer through the application of
genome analysis technologies, including large-scale genome sequencing”.
The Cancer Genome Atlas has so-far collected data on 34 diﬀerent cancer types, across six
diﬀerent genomic technologies including: full exome sequence, single nucleotide polymorphism
(SNP), methylation data, messenger RNA sequencing (mRNA-seq), messenger RNA (mRNA)
expression, and micro-RNA (miRNA) sequencing (Weinstein et al., 2013). In addition to the
genomic proﬁling, clinical features were also collected from samples, including cancer stage,
cancer grade, age at onset, gender, ﬁve-year survival data, and other cancer-type speciﬁc
clinical features.
The success of TCGA has lead to the establishment of the Genomics England project to
conduct whole-genome sequencing on 100 000 genomes, 50 000 of which will be focussed on
cancer. The main aim of Genomics England is to beneﬁt patients of rare genetic disorders
and cancers, to bring about new medical insights, and to establish robust infrastructure to
include NGS technology as part of routine clinical testing in the National Health Service
(NHS) (Caulﬁeld et al., 2015).
1.3 Discovering genes that contribute to cancer us-
ing exome sequence data.
1.3.1 Characteristic cancer mutations
Single nucleotide variants (SNVs) are the most common type of mutation discovered in
cancer exome sequencing. However, mutations much larger than SNVs occur in cancer.
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There are somatic copy number variants (SCNVs), where sections of DNA are repeated, or
truncated. In colorectal cancer, the ampliﬁcation of some SCNVs known as micro-satellites
is associated with prognosis and is indicative of a malfunction in the DNA mismatch-repair
pathway (Muzny et al., 2012). Translocations also occur, where sections of chromosomes
are re-ordered, or attached to other chromosomes. In some cases chromosomes are shattered
and DNA strand breaks are repaired among random segments of chromosomes in a process
known as chromothripsis (Stephens et al., 2011). Regions of local hypermutation where the
mean inter-mutation distance between six or more mutations is less than 1000 base-pairs
describe a phenomenon called Kataegis (Alexandrov et al., 2013; Nik-Zainal et al., 2012).
1.3.2 Heterogeneity in cancer
When searching for genes that contribute to cancer using NGS data, heterogeneity within
samples and across samples can cause some problems which are outlined below.
1.3.2.1 Inter-patient heterogeneity
Two patients may have cancer in the same tissue, but the aetiology and molecular causes of
their cancers may be completely diﬀerent. In most of The Cancer Genome Atlas comprehensive
molecular analyses to date very few genes are mutated across more than 10 percent of
samples in each cancer type (Vogelstein et al., 2013). Many of the genes mutated at
low frequencies in one cancer are often mutated at higher frequencies in another cancer
(Vogelstein et al., 2013). Genes that carry mutations in more than one sample, but still
relatively few samples are the norm in the large scale cancer studies (Wood et al., 2007;
Kandoth et al., 2013a).
The Cancer Genome Atlas studies have used methods to identify signiﬁcantly mutated
genes where the mutation frequency in particular genes is increased above a background
mutation rate across a group of samples (Lawrence et al., 2013; Dees et al., 2012). These
methods may be underpowered to detect mutated genes that contribute to cancer due to
inter-patient genetic heterogeneity (Leiserson et al., 2013b; Vogelstein et al., 2013), where
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each patient has slightly diﬀerent molecular alterations that lead to the same cancer outcome.
There may be suﬃcient power to detect the genes frequently mutated across cancer subtypes,
but not the causative genes that are speciﬁc to subtypes.
One way to address this problem may be to consider that cancer could be driven by a
mutation to any gene within a molecular pathway, any disruption to which causes a cancer
phenotype. Wood et al. (2007) suggested that the large number of infrequently mutated
genes in breast cancer, may in fact reﬂect a smaller number of cell-signalling pathways.
A pathway based approach may be key in identifying the genes that contribute to cancer
progression. Such an approach is explored in Chapter 5.1 on page 153.
1.3.2.2 Intra-tumour heterogeneity
The most popular methods to discover cancer driver genes in large scale sequencing studies
use data derived from tumour biopsies (Dees et al., 2012; Lawrence et al., 2013). However,
tumours exhibit histological and molecular heterogeneity. A tumour is not a homogeneous
population of malignant cells, it is a heterogeneous population of cells where the sub-clonal
populations best adapted to their environment gain a selective advantage and proliferate
(Stratton et al., 2009; Vogelstein et al., 2013). The evolutionary model of the tumour is well
established, but it is only recently that researchers have understood aspects of intra-tumour
heterogeneity.
Cytogenetic studies of solid tumours normally show multiple tumour cells with diﬀering
karyotypes (Höglund et al., 2002). Tannock (2014) found that when multiple regions of single
solid tumours were sequenced, between 63 percent and 69 percent of somatic mutations
were not detectable in all tumour regions. In addition to evidence for the divergent evolution
of tumours there is also evidence for the convergent evolution of subclones, and metastases
that independently acquire mutations in the same driver genes (Tannock, 2014). There were
also diﬀerences in prognostic gene expression signatures across regions of the same solid
tumour.
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1.4 The Cancer Genome Atlas
The Cancer Genome Atlas (TCGA) project began in 2006 (Garraway & Lander, 2013). Its
aim was to obtain the molecular proﬁle of three cancers (Hudson et al., 2010); glioblas-
toma multiforme (GBM), serous cystadenocarcinoma of the ovary, and lung squamous cell
carcinoma. Since then its scope has increased to include 34 distinct cancer types across
6 data modalities including exome sequence data. The Cancer Genome Atlas adopted the
same data standards as the International Cancer Genome Consortium (ICGC) to insure
comparability of data across cancer sequencing studies. Despite the precautions taken to
standardise the clinical features and molecular data, analysis across cancer types was not
trivial. In 2013 the ﬁrst twelve TCGA cancers were re-analysed using standardised analysis
pipelines as part of The Pan-Cancer analysis project (Weinstein et al., 2013). In Chapter 2 I
performed exploratory analysis on TCGA and Pan-Cancer colorectal cancer exome sequence
datasets to understand the technical eﬀects within the data.
1.5 The Pan-Cancer analysis project
The goal of the Pan-Cancer analysis project was to adopt a coordinated approach to
TCGA datasets across twelve tumour types and to apply standardised approaches to analyse
the molecular data (Weinstein et al., 2013). Even given the steps taken to standardise
the data across the cancer types, some challenges with unknown consequences remained.
Challenges to standardising the data included the use of improved array technologies for more
recently analysed cancers and multiple sequencing technologies used within each cancer type,
resulting in the potential for large batch eﬀects (Weinstein et al., 2013). Each cancer also
had a diﬀerent staging and grading strategy, which made cross-cancer analyses of the most
important prognostic indicators non-trivial. The Pan-Cancer analysis project was further
developed in 2014, when whole-genome sequencing of Pan-Cancer samples was conducted
to supplement the earlier TCGA exome sequencing (Hoadley et al., 2014).
Initial analysis by Kandoth et al. (2013a) found that TP53, mutated in 42 percent of
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samples, was the most frequently mutated gene across the Pan-Cancer dataset. PIK3CA was
the second most frequently mutated gene, and was never co-mutated with PIK3R1. However,
across cancer types there was signiﬁcant heterogeneity in both TP53 and PIK3CA mutation
frequencies. By using the whole-genome sequenced samples and unsupervised clustering
techniques, the cancers grouped according to their tissues of origin (Hoadley et al., 2014).
1.6 Cancer staging and tumour grading
The Pan-Cancer data contains cancer grade and stage clinical information. In Chapter 3 I
investigated whether there were mutated genes that were associated with cancer grade and
stage across cancers.
Cancer prognosis is primarily determined by two factors; the cancer stage, and the primary
tumour grade (Engers, 2007). Cancer staging is a relatively well standardised procedure,
agreed by the WHO (Edge & Compton, 2010). Staging consists of the measurement of
three features, the TNM status. T corresponds to the size of the primary tumour and extent
within the tissue, or organ of origin. N denotes the degree of spread to lymph nodes, either
local to the tissue of origin, or more distant. The M parameter indicates the presence of
distant pathological spread of the cancer where metastasis is either absent or present. By
using these three parameters, pathologists and clinical teams establish the clinical stage of a
cancer as one of four high level categories of stage I, II, III, or IV, with prognosis becoming
successively poorer going from stage I to stage IV. Tumours that have not spread beyond
the primary tissue of origin are categorised as stage I, or II. Tumours that have spread to
lymph nodes, but not to any other tissues, are categorised as stage III, and tumours that
have spread to other tissues are assigned the stage IV classiﬁcation.
In addition to cancer staging, tumour grading is the next most important prognostic
indicator of patient survival (Hammond et al., 2000), and is used by clinicians to inform
patient care (Engers, 2007). In contrast to cancer staging which is established using standard
guidelines across cancer types, there are no such guidelines to establish tumour grade across
tumours of diﬀerent tissue types. Each cancer has associated with it one, or more, grading
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systems which may be used; Prostate cancers use Gleason grading (Epstein, 2010), renal
cancers commonly use the Fuhrman system (Fuhrman, Susan A and Lasky, Larry C and
Limas, 1982), and ovarian cancers and endometrial cancers mainly use the FIGO grading
system (Shepherd, 1989).
Tumour grading is usually conducted by a pathologist (as part of a clinical team) who
inspects a slide preparation derived from a tissue biopsy, or tumour resection, using a
microscope. The pathologist assesses the degree to which the structure of the tumour is
well or poorly diﬀerentiated in comparison to the healthy tissue (Epstein, 2010).
Cancer grading systems usually use a three tier, or four tier system. Across all grading
systems the scale of tumour diﬀerentiation ranges from well diﬀerentiated as the lowest
number, to poorly diﬀerentiated as the highest number. Tumour grading is a subjective
process and inter-pathologist agreement for four tier systems is fair at best (Lang et al., 2005;
Han et al., 2013; Scholten et al., 2004). By using a two tier grading system (that combines
grade I and II in to low grade, and grade III and IV in to high grade) inter-pathologist
agreement is better (Kapucuoglu et al., 2008), and the two tier grading systems retain the
prognostic power of the four tier systems (Scholten et al., 2004; Kapucuoglu et al., 2008).
At present, the limiting factor to creating a standardised grading system across cancers
is the lack of known biological correlates of tumour grade across cancers. In Chapter 3 I
investigated whether there are mutational correlates of tumour grade across cancers, where
the grading outcome was based on a two tier system.
1.7 High-order cancer types in the Pan-Cancer dataset
The Cancer Genome Atlas and Pan-Cancer analysis projects have used genomic information
to discover signatures of various cancer types, with little attention paid to the diﬀerences
between high-order classes of cancer. The Pan-Cancer dataset is composed of ﬁve high-
order diﬀerentiation subtype classes; adenocarcinomas, squamous cell carcinomas, urothelial
carcinomas, blood cancers, and central nervous system cancers.
All carcinomas originate from the epithelial tissues such as the skin, or those which line
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organs such as the colon. There are various subclasses of carcinomas deﬁned by the specialised
functions of the epithelial cells. Adenocarcinomas originate from glandular epithelial cells.
Squamous cell carcinomas originate from the squamous epithelial cells on the surface of the
body, or tissue lumen. Urothelial carcinomas begin from a type of epithelium speciﬁc to
the urinary tract and bladder. The blood cancers, such as acute myeloid leukaemia (AML)
originate in the bone marrow tissue. Cancers of the central nervous system originate in the
spinal cord, or brain.
The cell types of each of these broad cancer categories perform specialised functions and
have diverse morphology. It is conceivable that the mutational processes that contribute to
cancer formation and progression diﬀer between each high-order subtype of cancer. Weinstein
et al. (2013) found that Pan-Cancer types generally clustered according to their tissue of
origin, and that the lung squamous cell, and head and neck squamous cell carcinomas were
grouped. By grouping the twelve Pan-Cancer cancer types into ﬁve high-order categories
the patterns of mutated genes that discriminate between the cancer types may be identiﬁed
and new disease mechanisms revealed. I investigate how the ﬁve categories diﬀer in their
patterns of somatic mutation in Chapter 4.1 on page 101.
1.7.1 Cancers of unknown primary origin
Around three percent of all diagnosed cancers are cancers of unknown primary (CUP) origin.
These are stage IV metastatic cancers that usually occur at multiple sites across the body.
Prognosis for these cancers is typically poor. A correct diagnosis of the primary tumour may
have implications for patient care. However, identiﬁcation of a primary tumour is diﬃcult,
and is most often possible post mortem. Gene expression tools have been developed to
predict the primary origin of CUP (Tothill et al., 2005; Ramaswamy et al., 2001; Su et al.,
2001) , but no tool has been developed to predict CUP origin based on whole exome sequence
data. Metastases are thought to inherit the mutations that occurred in the primary tumour.
Due to the successful discrimination of high order cancer types in Chapter 4.1 a Random
Forest approach was used in Chapter 4.2 to generate a model to assign the Pan-Cancer
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cancers to their tissue of origin based on exome sequence data. Genomics England will
conduct whole genome sequencing on CUPs, thereby generating the data to validate this
Random Forest approach.
1.8 An outline of exome sequencing
Within the last decade, a new generation of sequencing technologies have been developed
which allow the fast parallel sequencing of millions of reads of DNA. One of the most popular
NGS technologies is the Illumina sequencing by synthesis technology.
The human genome is composed of around 3 billion nucleotides, whereas the exome is
approximately one percent of that size (30 million nucleotides). The exome contains all of
the DNA sequence that is transcribed in to mRNA and eventually translated in to protein. As
proteins constitute the majority of the cellular machinery, mutations in proteins are expected
to be most likely to result in a disease. Whole exome sequencing was undertaken by TCGA
to study the DNA alterations that cause cancers.
In the case of exome sequencing the ﬁrst step is exon capture, using one of the exon
capture kits. The DNA library is then prepared on a ﬂow cell using solid-phase bridge
ampliﬁcation, a modiﬁed version of polymerase chain reaction (PCR), to create millions of
clusters of clonal reads of up to 150 base-pairs in length (Metzker, 2010; Berglund et al.,
2011). Sequencing-by synthesis (SBS) is then performed to characterise the sequence of
upwards of hundreds of millions of short sequences simultaneously (Figure 1.8.1). Each cluster
of template sequences should be identical and have incorporated the same dye modiﬁed
nucleotide during each round of SBS. The nucleotide incorporated at each step is inferred
from the colour of ﬂuorescent light emitted by the cluster upon excitation with a laser. In
this way, each round of SBS represents the addition of a single nucleotide, whose identity is
known by the colour of emitted light. For each cluster of templates, the nucleotide sequence
is inferred from the order of colours recorded from each successive round of SBS (Metzker,
2010).
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Figure 1.8.1: Sequencing by synthesis
DNA polymerase is bound to the primer templates and a single dye labelled nucleotide is incorporated in to
far end of the strand. The DNA polymerase reaction is halted because of an inhibitory group attached to
the incorporated nucleotide. All nucleotides are then washed oﬀ the ﬂow cell and imaging of the entire ﬂow
cell is performed. The dye group and polymerase inhibiting group are then removed from each template in
a cleavage step, and the next addition of dye modiﬁed nucleotides begins. The ﬁgure is reproduced from
Metzker (2010) with copyright permission (License Number 3707211251218).
1.8.1 Types of mutations uncovered by exome sequencing
Exome sequencing is used to identify mutations, such as single nucleotide variants (SNVs)
and small insertions and deletions (indels), that occur in the protein coding sections of genes
and 5’ and 3’ un-translated regions. Synonymous SNVs do not cause a change to the amino
acid sequence of the protein encoded by the gene. However, non-synonymous SNVs cause a
change in the amino-acid sequence that may aﬀect protein function. Non-synonymous SNVs
also include premature start and stop codon mutations, which change the positions in the
mRNA transcript at which mRNA is translated in to protein. Start and stop codon mutations
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can have catastrophic eﬀects on protein function by prematurely initiating translation of the
mRNA molecule, or truncating the translated peptide chain respectively. Both mutations
have potential to severely aﬀect the tertiary, three-dimensional, structure of the protein and
its function.
Indels are typically rarer than SNVs. Indels of single nucleotides result in frame-shift
mutations where the triplet amino acid code is disrupted, that is, all the amino acids following
the indel would be modiﬁed. The resulting protein may not function normally. Indel mutations
tend to occur in multiples of three, such that the post-indel amino acid sequence remains
intact.
Exome sequencing can also detect copy number variants (CNVs): sections of DNA that
are repeated a certain number of times. Chromosomal rearrangements may also be detected
using exome sequence data where two sections of the same sequence read map to diﬀerent
chromosomes.
1.8.2 Exome-sequencing in cancer studies
The reduction in the price of NGS technology has brought with it the ability to sequence the
genomes of thousands of individuals. Cancerous tumours harbour both the mutations that
are unique to the cancer (somatic mutations), and also the mutations that were inherited
from parents (germ-line mutations). Exome sequencing and variant annotation must be
conducted on the normal tissue and tumour tissue to identify the somatic mutations. The
germ-line mutations that occur in both the normal tissue and the tumour are discarded to
leave the somatic mutations.
Exome sequencing can give unparalleled characterisation of the mutation proﬁle of a
human tissue sample, but only in the coding regions of the genome. The exome comprises
around one percent of the human genome, leaving 99 percent completely uncharacterised.
Vogelstein et al. (2013) suggested that based on exome studies of monogenic diseases, we
can expect to uncover around 80 percent of the variants contributing to cancer by focusing
on coding regions. These regions are more likely to aﬀect function of the resultant protein
30
and contribute to cancer than a non-coding mutation (Vogelstein et al., 2013).
1.9 Clinical practice and next-generation sequencing
As the cost of next generation sequencing is decreasing, clinics and laboratories are considering
how to include NGS technology as part of their routine procedures (Meldrum et al., 2011;
Garraway & Lander, 2013). For cancers this may mean using the mutational proﬁle of a
tumour to make predictions about current clinical measures and outcomes. The task of
cancer bioinformaticians is to provide relevant information about mutations associated with
clinical features such as cancer sub-type classiﬁcations, or cancer grading and staging.
Recent studies have used exome-sequence panels to identify mutations that can guide
patient care, most notably in terms of targeted therapy (Frampton et al., 2013). Already, copy
number variants (CNVs), SNVs, and small indels can be genotyped using NGS technology and
used identify the genes which can guide targeted therapies for individual patients (Frampton
et al., 2013).
Cancer diagnostic tests based upon sequence mutations are currently in development.
In oesophageal cancer, a potential diagnostic test that uses a combination of Cytosponge
sample collection and whole-genome sequencing has discriminated between pre-malignant
adenomas and adenocarcinomas (Weaver et al., 2014). Tests that analyse circulating-tumour
DNA sequence show potential for real-time monitoring of the eﬀects of cancer treatment and
disease progression using blood plasma samples (Dawson et al., 2013; Newman et al., 2014;
Diaz & Bardelli, 2014). For colorectal cancer, a test that measures epigenetic modiﬁcation
in cells collected from fecal samples has had success (Ned et al., 2011).
As sequencing technology becomes cheaper, it will become viable for clinics to move most
cancer testing over to NGS methods because a single sequence run may be used to conduct
many tests (Rehm, 2013; Garraway & Lander, 2013). The Genomics England project is
focused on integrating NGS analysis into standard NHS practice by performing whole genome
sequencing on 100 000 genomes. The Genomics England Clinical Interpretation Partnership
(GeCIP) composed of NHS and academic researchers will collaborate with experts from
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private companies to “...accelerate the development of new diagnostics and treatments for
NHS patients...” (Genomics England, 2015). The GeCIP will also feedback ﬁndings for
individual patients to clinicians to inform treatment decisions (Caulﬁeld et al., 2015).
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1.10 An overview of machine learning
This thesis makes use of Random Forest and other machine learning methods. I will now
provide an overview of machine learning methods and Random Forest in particular.
The amount of genomic data available on the world wide web is increasing. In the case
of TCGA, upwards of 5000 whole exome sequence datasets are available to researchers.
There is a corresponding increase in information in the available genomic datasets, which
provides opportunities for bioinformatics research. Apart from classical statistical techniques,
algorithms can be used to extract the information within the data by pattern recognition.
The development of algorithms for learning these patterns is a branch of computer science
called machine learning.
In bioinformatics research machine learning methods can be used to develop patterns and
rules that describe a well characterised set of samples. The rules can be used to classify new,
unseen, samples. Complex interactions between multiple features may not be appropriately
described using classical statistical methods and may not be easily included in statistical
prediction models. However, machine learning methods oﬀer a solution to include complex
interactions between features in a prediction model.
1.10.1 Supervised and unsupervised methods
Supervised learning techniques use a set of samples for which the outcome class is known.
Rules are discovered that describe each class, and the rules are used to classify samples
whose class is unknown. Unsupervised learning techniques take a set of samples without
class labels and identify clusters of samples based upon the features. The clusters are then
described based on patterns in the features.
1.10.2 Evaluation of machine learning methods
Machine learning methods for classiﬁcation tasks are heavily reliant on the dataset being
an accurate representation of the population. Random noise in the dataset used for model
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building may lead to a classiﬁcation model that exploits attributes that discriminate only
between the samples of that speciﬁc dataset, resulting in an over-ﬁtted model that does not
perform well when applied to new data. There are numerous methods employed by machine
learning researchers to mitigate over-ﬁtting, and measure any over-ﬁtting which may be
present in a classiﬁcation model.
1.10.2.1 Independent test data
Machine learning classiﬁers are usually built using a subset of the whole dataset known as a
training set. Using a training set to measure the overall performance of a classiﬁer leads to
over-optimistic estimates of performance because of over-ﬁtting. The performance of the
model can then be measured in the part of the dataset that was not used for model building,
known as the test set. If a dataset is large, partitioning it in to a training set and test set is
desirable.
1.10.2.2 K-fold cross-validation
When using datasets that have been partitioned in to a training set and a test set, uninfor-
mative patterns among features in the training set can lead to an overﬁtted classiﬁcation
model. K-fold cross-validation (Stone, 1978) provides a way to further estimate the extent
of the over-ﬁtting. The entire dataset is ﬁrst randomly split in to k number of folds. Each
fold is treated as a test set in turn, the remaining k-1 folds are treated as the training set.
Classiﬁer performance is measured as the mean classiﬁcation accuracy across the k folds. In
order to maintain a similar class composition in each fold as the overall dataset, stratiﬁed
cross-validation can be used. In stratiﬁed cross-validation each fold is composed of a similar
proportion of each outcome class as the training set. A typical approach is to repeat the
cross validation procedure ﬁve times, each time having randomly selected samples for each
fold (Figure 1.10.1). The cross-validation steps can be repeated to mitigate bias in the way
the cross validation folds have been deﬁned.
34

































Combine training models 
0.94 0.93 0.84 0.82 0.90 Round 1 validation  accuracy 
A depiction of the cross validation process where a data set is ﬁrst split in to a training set for model
building and a validation dataset. The training set is split in to ﬁve folds. Each fold is used as the test set
in turn while the remaining sets are used to train the model. Each round of model building has associated
with it a classiﬁcation accuracy. The mean classiﬁcation accuracy across the ﬁve rounds of model building
provides an indication of the extent to which overﬁtting may be a problem with the dataset. The models
from the folds are usually combined in some way, trained on the entire training set, and then tested in the
validation set. The validation set accuracy can be expected to be achieved in unseen data.
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1.10.2.3 Validation datasets
If cross-validation techniques are applied to the entire dataset during model building, no test
set will be available to assess the classiﬁcation accuracy of the model. Each fold will have
been used for model construction and model testing. An independent validation dataset is
required to obtain an unbiased estimate of how the classiﬁer will perform on future datasets
(Figure 1.10.1).
1.10.2.4 Over-sampling and under-sampling techniques
When outcome classes are imbalanced, a binary classiﬁer can tend toward choosing the
majority classiﬁcation for all samples (Barandela & Sã, 2003). In order to balance outcome
classes two main techniques can be used: up-sampling, and down-sampling. Down-sampling
can be used to reduce the size of the majority class down to the size of the minority class,
and can be thought of as jack-knife (Efron & Gong, 1983) sampling the majority class.
However, this comes at the cost of removing information contained in the unused majority
class samples from the model building process. Up-sampling, or sampling with replacement,
can be used to increase the size of the minority class to equal that of the majority class.
Bootstrapping (Efron & Tibshirani, 1985) is commonly used to randomly duplicate samples
of the minority class. The synthetic minority over-sampling technique (SMOTE) (Chawla
et al., 2002) is more sophisticated. SMOTE nominates a seed sample, and creates new
synthetic samples by combining features from the seed sample’s k-nearest neighbours.The
SMOTE algorithm is used in Chapter 4.2 to increase the size of a small training set.
1.10.2.5 Classiﬁcation statistics and visualisation
The results of machine learning tasks are commonly presented as classiﬁcation statistics.
For binary classiﬁcation tasks the terms sensitivity or recall, and speciﬁcity or precision, are
typically used to measure the performance of classiﬁcation models (Table 1.10.1).
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Table 1.10.1: Binary classiﬁcation statistics
Condition
Condition positive (CP) Condition negative (CN)
Test Outcome Test outcome positive (TOP) True Positive (TP) False Positive (FP)Test outcome negative (TON) False Negative (FN) True Negative (TN)
Speciﬁcity = TN/CN Negative Predictive Value = TN/TON
Sensitivity = TP/CP Positive Predictive Value = TP/TOP
Accuracy = TP + TN/TP + FP + FN + TN Prevalence = CP/CP + CN
The calculation of classiﬁcation statistics are shown in relation to the contingency table for the
possible classiﬁcations during a binary classiﬁcation task.
Receiver Operator Characteristic (ROC) curves are commonly used to visualise how
the sensitivity (true positive rate) and speciﬁcity (1- false positive rate) change across
classiﬁcation model thresholds (Figure 38). A plot lying above the diagonal indicates that the
classiﬁer performed better than chance. ROC curves provide a way to compare classiﬁcation
models based on the integral of the ROC curves, or Area Under the Curve (AUC) statistic.
The AUC is a summary of how a classiﬁer performs at all possible classiﬁcation threshold
probabilities. Classiﬁcation models with higher AUC are generally preferable to those with a
comparatively lower AUC. ROC curves and the AUC statistic are used in two chapters in
this thesis (Chapters 3, and 4) to visualise classiﬁcation results.
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Figure 1.10.2: ROC curve example
Two ROC curves generated for models A and B. Model B has a higher AUC than model A and may be
considered a superior classiﬁcation model. The diagonal line indicates the plot that would be generated by a
non-informative classiﬁer.
1.10.3 Decision tree classiﬁers
Decision Trees are supervised classiﬁers composed of a set of decisions represented as a
tree. In a tree every decision is represented by a node, and each node that has daughter
nodes indicates a decision to be made on the values of a feature. The C4.5 algorithm
(Quinlan, 1993) is a popular single tree classiﬁcation method. It provides a good example for
the construction of single trees based upon a dataset consisting of N samples, M features,
and one binary outcome O. At each decision the information gain achieved by partitioning
samples based on each feature is measured. Information gain can be described as the increase
in enrichment of outcome classes among subclasses in comparison to the parent class. The
attribute mj with the highest information gain is used to partition the samples in to two
subsets. This process continues recursively until all subclasses consist of a single outcome
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class. These terminal classes can be described as leaves. Some decision tree algorithms
prune back leaves of each tree in order to mitigate over-ﬁtting.
1.10.4 Random Forest
In Chapter 4.1 I have used Random Forest to identify the features that discriminate between
ﬁve classes of cancer based upon the somatic exome mutation proﬁle of the cancers. A
Random Forest (Breiman, 2001) is a supervised ensemble classiﬁer based upon multiple
decision trees. Each decision tree in the group of trees, or forest, generates a class prediction
for each sample. For each sample the class prediction of the forest is the most common class
predicted across all trees in the forest.
Random Forest uses two techniques to avoid overﬁtting: bagging, and random feature
selection. In a Random Forest analysis a training set and test set can be used where model
building is conducted on the training set. The training set is divided in to a learning set and
an out-of-bag set. For each tree a bootstrap sample of the learning set is used. A tree is
learned by splitting the set of samples based on the feature that best partitions the samples.
This process continues until each subset of samples after a decision are of the same class.
The out-of-bag set is used to measure the classiﬁcation accuracy of the forest, and the
importance of each feature. The out-of-bag samples are run through each tree in the forest.
The importance of each feature is commonly measured as either the gini impurity (Kuhn
& Mori, 1995), or mean clariﬁcation accuracy (Breiman, 2001). These measures provide
a summary of the ability of each feature to correctly classify the out-of-bag set across the
forest.
In order to prevent over-ﬁtting due to out-of-bag and learning set deﬁnition, cross-
validation approaches can be used. In addition to the bagging approach, Random Forest also
randomises the set of features from which a decision can be made at each node of each tree.
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1.11 How protein interaction networks can be used
to identify new disease gene candidates.
Chapter 5 of this thesis uses protein interaction networks to prioritise candidate disease
genes by supplementing gene-level scores with protein interaction data. I will now provide an
overview of protein interaction networks, some background on graph theory, the network
properties of disease genes, and a summary of the methods used to prioritise candidate
disease genes using network data.
As mentioned in section 1.3.2.1 on page 22 genetic heterogeneity may prevent some of the
genes that contribute to cancer from being discovered using gene-level tests. Univariate tests
often assume independence between the features being tested. For genes, the assumption of
independence is not appropriate. Genes code for proteins, and the function of a protein may
be a single step in a larger pathway composed of a group of proteins. Across a sample of
individuals, disruption to the function of a diﬀerent protein from the same pathway in each
sample may cause the same disease. For each univariate test conducted, only a subset of
cases will carry disease variants in a gene, and other cases will carry mutations in other genes
in the same pathway (Leiserson et al., 2013b). Protein-Protein interaction (PPI) networks
contain information about which proteins physically interact and may be part of a pathway.
By combining the analysis of univariate data with the information within protein interaction
networks researchers may identify the pathways that are enriched for genes associated with
diseases and possibly untangle some of the genetic heterogeneity of a disease.
1.11.1 Protein-protein interaction networks
Two main high-throughput technologies have been important for the creation of PPI networks;
Yeast-2-Hybrid (Y2H) (Young, 1998), and tandem aﬃnity puriﬁcation and mass spectrometry
(TAP-MS) (Gavin et al., 2002). The Y2H system is used to test for binary protein interactions
across the proteome in a pairwise manner. The TAP-MS technique is able to identify protein
complexes consisting of more than two proteins, by ﬁrst ’pulling down’ the protein complex
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and then by characterising the constituent proteins using mass spectrometry techniques.
Various protein interaction databases have been created by searching the literature
for reports of protein interactions in small experiments. There are now many available
databases, including; the Human Protein Reference Database (HPRD) (Keshava Prasad
et al., 2009), the Molecular INTeractions database (MINT) (Licata et al., 2012), the
Biological General Repository for Interaction Datasets (BIOGRID) (Stark et al., 2006), the
Biomolecular Interaction Network Database (BIND) (Bader et al., 2003), and the IntAct
molecular interaction database (Hermjakob et al., 2004). Other databases have been created
by combining much of the information available in these public resources, including; the
irefweb (Turner et al., 2010) database, STRING (Franceschini et al., 2013), the protein
interaction network analysis platform (PINA) (Cowley et al., 2012), the Human Protein
Protein Interaction network (HuPPI) (Lehne & Schlitt, 2009), and the Consensus Pathway
Database (CPDB) (Kamburov et al., 2013). The HumanNet (Lee et al., 2011), and PrePPI
(Zhang et al., 2012) databases also provide predicted protein interactions.
1.11.2 An overview of graph theory
Networks can be represented as graphs to allow analysis. A PPI network can be represented
as a graph G = (V ,E ), where proteins are represented by vertices V , and interactions
between the proteins are represented by edges E (Figure 1.11.1). A directed graph describes
relationships of cause and eﬀect where information ﬂows from one vertex to another: each
edge being assigned a direction to indicate information ﬂow. Gene regulation networks
are examples of directed graphs. A graph that imposes no restriction on the direction of
information ﬂow across edges is called an undirected graph. PPI networks can be described
as undirected graphs. Throughout this thesis, only undirected graph representations of PPI
networks are used.
Graphs have many numeric properties which can be exploited for analysis and all can be
broadly categorised as either a local property, or a global property.
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The largest component of the HuPPI2 (Lehne & Schlitt, 2009) human protein protein interaction network.
The small blue circles are vertices that represent proteins, and the grey lines that connect the vertices are
the edges, or physical interactions between proteins.
1.11.2.1 Vertex measures
Vertex measures are local graph properties. Each vertex can be described by a number of
vertex properties, the most simple of which is vertex degree (Figure 1.11.2a). The vertex
degree is deﬁned as the number of edges that connect to a given vertex. Clustering coeﬃcient
(Figure 1.11.2b) indicates the density of edges among a vertex’s adjacent vertices as the
proportion of edges among the adjacent vertices in comparison to the total possible number
of edges. Assortativity (Figure 1.11.2c) describes the mean degree of the vertices adjacent
to a vertex. Other metrics describe each vertex in relation to the entire network, and not just
42
its local neighbourhood. The concept of a path, the series of edges between any two given
vertices, can be summarised as a path length. The shortest path length (Figure 1.11.2d)
is important for the calculation of other network properties. The betweenness centrality
(Figure 1.11.2e) of a vertex describes the importance of each vertex for eﬃcient information
ﬂow through the graph as the number of shortest paths that pass through the vertex.
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The importance of a vertex and its local structure in a graph can be characterised by several
measures. (a) The Degree (MK ) is the number of edges that vertex K shares with other vertices.
(b) The Clustering Coeﬃcient describes the interconnectivity between the neighbouring vertices
of K and is deﬁned as the number of edges between neighbouring vertices of K (nK ) divided by
the number of possible edges between neighbours of K . (c) The Assortativity NCK is deﬁned as
the average degree of the neighbours of K . (d) The Shortest Path SPEK between vertices E and
K is deﬁned as the smallest number of edges between the pair of vertices. (e) The Betweeness
BK of vertex K is the number of shortest paths in the graph which pass through vertex K . Figure
adapted from Yamada & Bork (2009).
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1.11.2.2 Global graph properties
A graph can be described using a number of global properties. The number of vertices and
edges can give an indication of the size and density of a graph. The diameter of a graph,
or the mean shortest path length, indicates the ease at which information can ﬂow across
it. Most biological and real world graphs, such as telecommunication networks and social
networks (Albert & Barabasi, 2002) have a diameter of ﬁve, showing that most vertices can
reach most other vertices by traversing no more than ﬁve edges.
Most biological networks exhibit a scale-free topology (Albert & Barabasi, 2002; Ravasz
et al., 2002). The degree distribution of a biological graph will typically follow a power-law
distribution, with many vertices having a small degree and very few vertices having a large
degree.
1.11.3 Network properties of disease genes
Proteins that have a high degree are highly connected and are known as hubs. Hubs
usually correspond to genes that perform essential functions in the cell (Jeong et al., 2001).
Mutations in hub genes tend to be lethal and evolution is more constrained in these genes
(Saeed & Deane, 2006). There is however limited consensus on the subject. Wachi et al.
(2005) found that disease genes tend to be hubs. However, Goh et al. (2007) found that
when disease genes that are also essential are removed from a PPI network, the remaining
disease genes are not more highly connected than other genes. Genes for monogenic disorders
are central to protein interaction networks, whereas genes contributing to complex diseases
are closer to the periphery, although they are closer to one another than expected (Barrenas
et al., 2009). Non-essential disease genes tend not to be hubs, but are more central to the
PPI network than expected. Proteins that are associated with the same disease are ten times
more likely to interact physically (Goh et al., 2007). Proteins that have a similar biological
function as deﬁned by Gene Ontology (GO) terms tend to be in close proximity in a PPI.
Similarly, proteins that are involved in the same or similar diseases tend to cluster in protein
interaction networks (Goh et al., 2007; Gandhi et al., 2006). These properties of disease
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proteins in general indicate that a disease can be associated with a community, or module,
of vertices in a PPI network. A community can be a group of highly interconnected group of
vertices.
There is heterogeneity across cancers in terms of the commonly mutated genes. Even
within cancers, there is no single gene which is mutated in all samples (Vogelstein et al., 2013).
The originating mutation of cancers of the same type can be heterogeneous. The apparent
heterogeneous driver mutations of cancers of the same type may be due to mutations in
functionally related genes which are close, or adjacent in a protein interaction network (Oliver,
2000). The proteins that have not been associated with the disease, but that interact closely
with disease causing genes would be potential candidate disease genes. This is an example of
guilt by association. The guilt by association hypothesis is central to many of the methods
that prioritise and predict new disease genes. Chapter 5.1 on page 153 of this thesis describes
the development of a network-based method for disease gene prioritisation based on the
guilt-by-association hypothesis.
1.11.4 Predicting disease genes using networks
Many approaches prioritise candidate genes based on the proximity of candidate genes to
disease genes. Candidate genes that are closer to disease genes are ranked more highly
(Leiserson et al., 2013b). The simplest methods employ neighbour counting (Oti et al.,
2006) to rank candidate genes according to the number of disease genes to which they are
adjacent in the PPI network. Two proteins can be involved in the same disease pathway
without interacting physically. There are methods that quantify the closeness of candidate
genes and known disease genes in terms of the shortest path metric. Krauthammer et al.
(2004) used a molecular triangulation method, which ranked candidate genes with small
shortest path distances to known diseases genes most highly as disease gene candidates. In
Alzheimer’s disease, their highly ranked candidates agreed with a manually curated gene set.
The CFinder algorithm (Palla et al., 2005, 2007) identiﬁes structures in the PPI network
known as cliques. In a PPI network a clique corresponds to set of proteins where each
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member of the set shares an edge with all other members of the set. CFinder then identiﬁes
the cliques which intersect by k members and treats the resultant communities as important.
In addition to local network properties, global network properties have been used to
prioritise candidate disease genes. The random walk with restart (Tong et al., 2008) can
successfully identify known disease genes in a network (Köhler et al., 2008). Random
walk methods typically perform better than local network property methods (Navlakha &
Kingsford, 2010). However, methods that combine the results of local and global network
approaches perform best (Navlakha & Kingsford, 2010).
The above methods use only the network structure to predict and prioritise candidate
disease genes. There are many de-novo pathway discovery methods that integrate protein
interaction network data and ’omic experiment data to discover perturbed pathways and
disease genes.
1.11.4.1 De-novo pathway discovery methods
The jActiveModules (Ideker et al., 2002) cytoscape (Shannon, 2003) plugin was the ﬁrst
algorithm to search for modules in a PPI network that was integrated with experimental
data. It used a greedy simulated annealing (Kirkpatrick, 1984) approach to identify the
subnetwork with the highest activity score.
Chuang et al. (2007) developed a method that uses gene expression data to discover
diﬀerentially expressed subnetworks in a PPI network. The method takes a gene-list of
diﬀerentially expressed genes and grows diﬀerentially expressed subnetworks that best
discriminate between cases and controls using a greedy algorithm. From a diﬀerentially
expressed seed protein, an additional neighbouring protein is added to the group. The mean
z-score of the proteins included in the subnetwork is computed for cases and controls, and the
additional protein is permanently included in the subnetwork if the discrimination between
cases and controls (the mutual information) is increased above a user-deﬁned threshold. The
HyperModules (Leung et al., 2014) cytoscape software takes a similar greedy approach. It
grows modules from mutated seed genes to uncover the subnetwork that best predicts a
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binary clinical outcome, or survival. The DEGAS (Ulitsky et al., 2010) algorithm aims to
ﬁnd a perturbed subnetwork by solving a minimum covering set problem. It uses a greedy
approach to identify the smallest subnetwork that covers all but n cases k times each. The
authors use the proteins which are diﬀerentially expressed in each individual as seeds for
the analysis, but any gene-based test for which each sample can be given a binary score at
each gene could be used. The NetBox (Cerami et al., 2010) algorithm identiﬁes modules of
mutated genes that are either adjacent in a PPI network, or are connected through a single
linking gene. KeyPathwayMiner (Alcaraz et al., 2011) identiﬁes the maximally connected
subnetworks in which the number of non-labelled (non-signiﬁcant) genes does not exceed a
user-deﬁned k by using an Ant Colony Optimisation (Dorigo et al., 1999) technique. The
Dapple algorithm (Rossin et al., 2011) uses a gene list, protein interaction network data,
and recombination hotspot data to test whether genes in the list are more closely connected
in the PPI network than would be expected. It has been used to provide candidate genes
for genome wide association studies (GWAS), where an associated locus may contain many
genes. These methods compute the statistical signiﬁcance of the resulting subnetworks, by
comparison to an empirical distribution of subnetwork scores, achieved in a variety of ways
including vertex label swapping, edge swapping, and case-control sample swapping where
appropriate.
Network methods are limited by the coverage and quality of the network used. It is
unlikely that any of the current human PPI databases are complete. PPI databases contain
false positives, which will introduce noise and aﬀect the results of network-based analyses.
Most networks are not tissue speciﬁc, and may be a result of the union of interactions across
many cell types and conditions (Leiserson et al., 2013b).
1.12 Study aims
This study aims to identify the mutated genes which are associated with clinical features
in cancer and to develop a method to prioritise candidate disease genes. Machine learning
methods are used to identify the genes which when mutated are indicative of cancer grade,
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cancer stage, and cancer types. A network-based method is developed to prioritise candidate
genes in cancer exome sequence data and a further network-based method is applied to
rheumatoid arthritis GWAS data.
1.12.1 Speciﬁc aims of the thesis
• Identify mutated genes associated with grade, and stage across cancers
To establish whether there are mutated genes that correlate with a high grade, or grade 3
and 4 classiﬁcation, across three types of adenocarcinoma. There is a lack of knowledge of
the mutations that indicate cancer grade as low, or high, across multiple cancers. I tested
whether there are mutated genes associated with cancer grade using logistic regression
analysis while adjusting for participant age, gender, and stage. The same method was used
to establish the mutated genes associated with cancer stage.
• Identify the mutated genes that discriminate ﬁve high-order cancer types (adenocarci-
nomas, squamous cell carcinomas, urothelial carcinomas, blood, and brain cancers)
from one another
To identify the mutated genes that discriminate ﬁve high-order cancer types (adenocarcinomas,
squamous cell carcinomas, urothelial carcinomas, blood, and brain cancers) from one another.
The Cancer Genome Atlas has focused most cross cancer investigations on identifying new
cancer subtypes. Relatively little attention has been paid to identifying the mutations
that discriminate between known high-order cancer types in the Pan-Cancer dataset. I
used ten 2-class Random Forest analyses to uncover the mutated genes that discriminated
between these ﬁve cancer types in a pairwise manner. I also created a multi-class classiﬁer
to discriminate cancers of diﬀerent tissue types. For cases of advanced cancer of unknown
primary origin this may be useful for pinpointing the primary cancer site in order to inform
treatment.
• Use prior biological information in the form of a protein interaction network to suggest
new complex disease gene candidates
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To use prior biological information in the form of a protein interaction network to suggest
new complex disease candidate genes. Using TCGA colorectal cancer exome sequence data
and the HuPPI2 (Lehne & Schlitt, 2009) protein interaction network I developed a method
called k-pseudo cliques analysis. I used the MutSigCV (Lawrence et al., 2013) test to identify
signiﬁcantly mutated protein coding genes in the TCGA colorectal cancer dataset. Then, I
used the HuPPI2 (Lehne & Schlitt, 2009) protein interaction network to identify communities
of proteins and establish if any of the communities were enriched for genes that were more
mutated than expected based on the gene-level test statistic. The utility of the network
method was established by comparing KEGG colorectal and cancer pathway enrichment
p-values to that of the univariate test.
In addition, Region Growing Analysis was used to analyse rheumatoid arthritis GWAS data
in order to prioritise candidate disease genes which did not reach genome-wide signiﬁcance.
50
Chapter 2
Exploratory analysis of The Cancer




This chapter describes exploratory analyses performed using The Cancer Genome Atlas
(TCGA) colorectal cancer exome sequence datasets from June 2012 (Muzny et al., 2012),
December 2012, and the Pan-Cancer 2013 analysis (Kandoth et al., 2013a). I demonstrate
how a potentially confounding sequencing technology eﬀect in interim TCGA data from the
December 2012 data release was identiﬁed, and describe its presence in the TCGA June 2012
data and Pan-Cancer 2013 data. I also investigated the potential to discriminate between
micro-satellite instability high samples from micro-satellite instability low samples.
It was common for TCGA studies to use diﬀerent exome sequence analysis pipelines
for each cancer type. The breast cancers (Koboldt et al., 2012), ovarian serous carcinoma
(Bell et al., 2011), renal clear cell carcinoma (Creighton et al., 2013), and colorectal cancer
(Muzny et al., 2012) used various exome sequence capture kits, and sequence analysis
pipelines. I applied a variety of exploratory data analysis techniques to TCGA June 2012,
TCGA December 2012 and the Pan-Cancer 2013 colorectal cancer exome sequence datasets
to arrive at my decision to use the Pan-Cancer 2013 dataset for all analyses of TCGA samples
throughout later chapters in this thesis.
2.1.1 Confounding factors
The exome sequencing process relies on a complex set of procedures, including, exon capture,
polymerase chain reaction ampliﬁcation of DNA, the sequencing step itself, and downstream
processing of the raw sequence data. When these conditions are varied within an experiment
the measured outcomes may vary according to technical factors. Technical eﬀects can often
account for a larger proportion of the variance in an experiment’s outcome measures than




The Cancer Genome Atlas (TCGA) exome sequence dataset for colon and rectal cancer was
collected using two diﬀerent Next Generation Sequencing (NGS) technologies and analysis
pipelines (Table 2.1.1): Illumina sequencing by synthesis technology (Bentley et al., 2008) and
ABI SOLiD sequencing by ligation technology (Valouev et al., 2008). The two technologies
are fundamentally diﬀerent and each has systematic errors. For both technologies substitution
errors are the most common error type (Metzker, 2010), along with an under-representation
of AT-rich and GC-rich regions. The Illumina technology was also known to show an
increase in SNV substitution frequency where the preceding base was guanine. In addition,
diﬀerent exome capture protocols, and sequence analysis pipelines were used across the
two sequencing technologies in TCGA June 2012, and TCGA December 2012 datasets.
(Table 2.1.1). Variant annotation was conducted using MuTect (Cibulskis et al., 2013)
for the Illumina sequenced samples, and using SAMTools (Li et al., 2009) for the SOLiD
samples (Table 2.1.1). Therefore, technical eﬀects due to sequencing technology cannot
be disentangled from a sequence analysis pipeline eﬀect. Throughout this chapter I use the
term sequencing technology eﬀect to refer to this combined sequencing machine and analysis
pipeline eﬀect. In contrast, the Pan-Cancer study used a single variant annotation step across
both sequencing technologies. They used the TGI Washington University VariantAnnotator,
and removed known false positive somatic mutations and germ-line SNPs present in the
dbSNP database (Sherry et al., 2001).
Table 2.1.1: Sequencing technology and analysis pipelines in TCGA and Pan-Cancer datasets
Exome sequencing steps and parameters Illumina ABI SOLiD Pan-Cancer Analysis
exome target capture NimbleGen SeqCap EZ Exome 2.0 Solution Probes NimbleGen CCDS Solution Probes As Illumina and SOLiD
VCRome 2.1 (HGSC design, NimbleGen)
post capture PCR 14 cycles 12 cycles As Illumina and SOLiD
Mapping reads BWA (bwa-0.5.9rcl) BFAST (version 0.6.4). As Illumina and SOLiD
HG reference HG18 BWA reference generated an BROAD and distributed to sequencing centres HG19
Mutation Detection MuTect (GATK) SAMTools Pileup and custom ﬁlters Variant Annotator
Each step going from sequence capture through to variant annotation for the TCGA June 2012, TCGA
December 2012, and Pan-Cancer analysis dataset is shown above. In the Pan-Cancer Analysis column, the
only modiﬁcation to the analysis of the Illumina and SOLiD data was the mutation annotation step.
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2.1.2 Micro-satellite instability
In colorectal cancer there are two important classes of tumours, the tumours which are
hypermutated, and those which are not. Hypermutated tumours carry many SNV mutations,
which are often accompanied by a micro-satellite instability high (MSI-H) phenotype. Micro-
satellite instability is measured using the Bethesda micro-satellite marker panel consisting of
ﬁve markers (Umar et al., 2004; Fidalgo et al., 1998; Boland et al., 1998) three of which
are dinucleotide markers (D2S123, D5S346, and D17S250), and two are mononucleotide
markers (BAT25, and BAT26) (Boland et al., 1998; Dietmaier et al., 1997; Bocker et al.,
1997).
Based on the Bethesda panel testing each tumour was classiﬁed as one of three types
by TCGA: micro-satellite instability stable (MSS), micro-satellite instability low (MSI-L),
and micro-satellite instability high (MSI-H) (Umar et al., 2004). A tumour was classiﬁed
as MSS when there was no diﬀerence in the copy number of any of the markers between
the normal tissue and tumour tissue. A tumour was classiﬁed as MSI-L if a single marker
diﬀered in copy number between the normal tissue and tumour tissue. When two or more
markers diﬀered in copy number between the normal tissue and tumour tissue, a tumour was
classiﬁed as MSI-H (Boland et al., 1998; de la Chapelle & Hampel, 2010).
MSI-H occurs in around 15% of colorectal tumours (Boland et al., 1998) when mismatch
repair (MMR) pathway genes malfunction. It can be caused by a recessive mechanism when a
heterozygote acquires inactivating mutations in the wild-type copy of MSH2, MLH1, MSH6,
or PMS2 (Parsons et al., 1993), or because of two mutations arising independently in both
working copies of an MMR gene in a wild-type homozygote (de la Chapelle & Hampel, 2010).
The MSS and MSI-H annotations imply fundamentally diﬀerent routes to cancer.
By using a selection of descriptive, inferential, and exploratory methods I analysed three
TCGA data sets (TCGA June 2012, TCGA December 2012, and Pan-Cancer). I investigated
potential technical eﬀects using over-representation analyses and principal component analysis
(Pearson, 1901), and used non-metric Multi Dimensional Scaling (nmMDS) (Kruskal, 1964)
to visualise potential technical eﬀects driving variation within each of the three datasets.
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2.2 Methods
I downloaded TCGA December 2012 mutation annotation format (MAF) ﬁles and clinical
data from TCGA data portal on December 17th 2012. The Pan-Cancer data was downloaded
from synapse (accession syn1710680) on October 3rd 2013. I obtained TCGA June 2012
mutation and clinical data from the supplementary data of Muzny et al. (2012) after personal
communication from the Pan-Cancer analysis author indicated that the Muzny et al. (2012)
colorectal cancer exome sequence data was the most reliable data release.
Figure 2.2.1 shows the pipeline I used to analyse each of the three TCGA datasets
(TCGA June 2012, TCGA December 2012, and Pan-Cancer). I retained the samples for
which mutation data and clinical data were available. The Pan-Cancer data and TCGA June
2012 data were composed of the same samples, but used a diﬀerent sequence annotation
step (Table 2.1.1), and there were changes to the clinical metadata. TCGA June 2012
metadata was used where missing from the Pan-Cancer dataset. For each of the three
datasets I measured the frequency of SNVs, indels, all mutations and functional mutations.
Hypermutated samples were deﬁned by an indel:SNV ratio greater than 10%.
For each dataset I conducted three exploratory analyses (Figure 2.2.1): I used non-
metric Multi-Dimensional Scaling (nmMDS) (Kruskal, 1964) to investigate and visualise
any phenotypic and technical eﬀects in the data; I combined principal component analysis
(Pearson, 1901) with various inferential analyses (kruskal-wallis test, spearman’s correlation,
and wilcoxon ranks sum test) to identify technical eﬀects driving the variation in the data;
and I used over-representation analyses to identify imbalances in the study design. The
results of the exploratory analyses informed my decision as to which dataset would be used
for all further analyses in this thesis.
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The analysis pipeline for each of the three cancer datasets; TCGA December 2012, Pan-Cancer October
2013, and TCGA June 2012. For each dataset the samples with sequence data and clinical features were
retained. The frequency of SNVs and indels were then calculated along with the most frequently mutated
genes. The exploratory analyses included: multi-dimensional scaling, to identify and understand clusters of
samples; non-parametric methods for class imbalance analyses including chi-square, Fisher’s exact test, and
Wilcoxon signed-rank test; and principal component analysis to understand the degreee to which variation
among samples was driven by latent variables, and to understand the features associated with those latent
variables.
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2.2.1 Binary mutation matrix
The MAF ﬁles contained somatic mutation data: the mutations that were found only in an
individual’s tumour and not in their normal tissue. ’Silent’ synonymous mutations which
do not lead to a change in the amino acid sequence in the translated protein were removed
from the MAF ﬁle. For each dataset I used the union of the functionally mutated proteins
across all samples to generate a matrix M of proteins P by samples S . Each element in M ,
M [p, s], was set to 0 if there was no protein coding mutation for protein p and sample s, or
set to 1 if at least one protein coding mutation was present for protein p and sample s. This
matrix represented the presence of protein coding mutations in each protein coding gene in
each sample.
2.2.2 Non-Metric Multi Dimensional Scaling
2.2.2.1 Creating the dissimilarity Matrix
Non-metric Multi Dimensional scaling (nmMDS) requires a pairwise sample dissimilarity
matrix to be created from the binary mutation matrix. For each dataset I calculated the
similarity between samples based upon the simple matching coeﬃcient: the proportion of
binary features in which two samples agree. I then subtracted each element of the simple
matching similarity matrix from 1 to give the dissimilarity matrix required for nmMDS
analysis.
2.2.2.2 nmMDS procedure
nmMDS uses a pairwise sample distance, or dissimilarity, matrix as its input to create a
representation of the pairwise distance between all samples in as many dimensions as required
by the researcher (up to the number of features used in the analysis). By representing
pairwise sample distances in two dimensions I can represent pairwise similarities on a plot. A
small distance between two points on the nmMDS plot indicated a high similarity between
two samples. A plot of the two nmMDS dimensions resulting from a two dimensional nmMDS
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procedure can be thought of as a close to optimal two-dimensional representation of the
pairwise similarity between samples. In comparison to a plot of principal components, which
are linear combinations of features in the data, nmMDS applies a mapping of samples to
k-dimensional space, where k is deﬁned by the user. This means two-dimensional nmMDS
plots, where k = 2, can represent pairwise diﬀerences between samples based upon all
features, which is not possible using two-dimensional plots of pairs of principal components.
I conducted nmMDS using the ISOMDS function from the R “MASS” package (Venables &
Ripley, 2003).
For all three datasets (TCGA June 2012, TCGA December 2012, and Pan-Cancer) I
created nmMDS plots and coloured the points (samples) according to the sequencer analysis
pipeline, and the micro-satellite instability status.
2.2.3 Identifying features correlated with the ﬁrst principal com-
ponent
Principal Component Analysis (PCA) was conducted on the binary mutation matrix for each
of the three datasets. I used correlation analysis to identify whether the sequence analysis
pipeline, age, gender, cancer type, and silent mutation frequency were correlated with the
ﬁrst principal component (PC1). If there was a technical eﬀect present in the data, this
analysis would identify that eﬀect as a signiﬁcant and large correlation with PC1.
2.2.4 Over-representation analyses to discover potential study
design problems
I used the Fisher’s Exact test, and Chi-square analysis to identify class imbalances across
pairs of categorical features. I tested to see whether sequence technology was imbalanced
across cancer anatomical site, cancer type, gender, age, and micro-satellite instability status.




The Cancer Genome Atlas December 2012 data contained clinical and exome sequence data
for 345 samples. The TCGA June 2012 and Pan-Cancer datasets contained the same 224
samples. There was an intersection of seventy-nine samples between the 224 Pan-Cancer
and TCGA June 2012 data, and TCGA December 2012 data. The TCGA December 2012
hypermutated samples were not present in the Pan-Cancer dataset.
There was an intersection of 79 samples between the TCGA June 2012 and December
2012 datasets. There was a signiﬁcant diﬀerence in the ranked number of silent mutations
per individual (Z = 45, p = 0.01) between these two datasets. However, the median
number of silent mutations was unchanged (Mdn= 17.0). The ranked number of mutations
per individual changed across the two TCGA 2012 datasets (Z = 253, p = 2.39× 10−5).
Although, the median remained unchanged (Mdn=64).
2.3.1 non-metric Multi-Dimensional Scaling
Figures 2.3.1a and 2.3.2a on page 61, shows a sequencing technology eﬀect in TCGA
December 2012 and TCGA June 2012 data respectively, which was not present in the
Pan-Cancer data (Figure 2.3.3a). In both the TCGA December 2012, and TCGA June
2012 data, the majority of the hypermutated samples formed a cluster in the centre of the
nmMDS plot (Figure 2.3.1a, and Figure 2.3.2a respectively). In TCGA December 2012 data
the 55 microsatellite instability (MSI-H) samples were concentrated in the centre of the
nmMDS plot (Figure 2.3.1b), as they were in the TCGA June 2012 data (Figure 2.3.2b).
MSI-H status was associated with hypermutation (p = 2.2 × 10−16) in the TCGA June
2012 data. None of the TCGA December 2012 SOLiD sequenced MSI-H samples were
hypermutated by my deﬁnition, although they seemed to be clustered at the centre of the
samples (Figure 2.3.1b). The Pan-Cancer dataset did not include any of the 55 TCGA
December 2012 hypermutated samples. As part of the Pan-Cancer quality control process
hypermutated samples which carried more than 500 mutations were removed from further
analysis. The hypermutated samples were expected to harbour many passenger mutations,
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which do not contribute to tumour diﬀerentiation or progression (Kandoth et al., 2013a).
These samples were removed by Kandoth et al. (2013a) to reduce noise when identifying
signiﬁcantly mutated genes and grouping samples based on common patterns of mutation.
The Pan-Cancer data included nine MSI-H samples which when labelled according to the
TCGA June 2012 metadata appeared to be clustered at the centre of the samples (Figure
2.3.3b).
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Figure 2.3.1: TCGA December 2012 colorectal nmMDS plots
(a) Sequencing technology eﬀect in TCGA De-
cember 2012 dataset using non-metric MDS
(b) Microsatellite instability-high central cluster in
TCGA December 2012 dataset using non-metric
MDS
Figure 2.3.2: TCGA June 2012 colorectal nmMDS plots
(a) Sequencing technology eﬀect in TCGA June
2012 dataset using non-metric MDS
(b) Microsatellite instability-high samples central
cluster in TCGA June 2012 dataset using non-
metric MDS
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Figure 2.3.3: Pan-Cancer colorectal nmMDS plots
(a) Sequencing technology eﬀect not seen in the
Pan Cancer dataset using non-metric MDS
(b) Microsatellite instability-high samples central
cluster in Pan-Cancer dataset using non-metric
MDS
2.3.2 Metadata correlations with the ﬁrst principal component.
In each of the datasets; TCGA December 2012, TCGA June 2012, and Pan-Cancer 2013; the
ﬁrst principal component of the variation in the binary mutation matrix was highly correlated
with the silent mutation rate (Table 2.3.1). In each dataset there was also a small, but
signiﬁcant correlation between sequencing technology and the ﬁrst principal component
(Table 2.3.1).
Table 2.3.1: First principal component correlations with metadata in each data set.
variance explained N samples silent mutation rate sequencing technology
rs p-value p-value
TCGA December 2012 7.08% (34.67) 345 0.96 2.2× 10−16 W = 17974 2.2× 10−16
TCGA June 2012 17.52% (51.40) 224 0.87 2.2× 10−16 X 2 (2) = 52.91 3.24× 10−12
Pan-Cancer analysis 16.68% (50.23) 224 0.86 2.2× 10−16 X 2 (2) = 9.46 0.01
age gender cancer type
TCGA December 2012 rs p-value W p-value W p-value
TCGA June 2012 0.03 0.77 15536 0.36 15521 1.19× 10
Pan-Cancer analysis 0.19 4.28× 10−3 6968 0.14 6780 1.39× 10−3
For each dataset, relationships between; silent mutation rate, sequencing technology, age, gender, and
cancer type; and PC1 were calculated. Wilcoxon’s rank sum test was used to compare PC1 scores across
cancer type and gender. Spearman’s rho correlation was used to assess the relationship between PC1 and:
silent mutation rate, and age. The kruskal wallis test was used to ﬁnd diﬀerences in PC1 scores across
sequencing technology for TCGA June 2012 and Pan-Cancer analysis data where there were three sample
classes (SOLiD, Illumina, and both or not available). Wilcoxon’s rank sum was used to ﬁnd diﬀerences in
PC1 scores across sequencing data for TCGA December 2012 data where there were two sequencing classes
(SOLiD, and Illumina). In each data set the silent mutation rate is most highly correlated with the ﬁrst
principal component.
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Across each of the three datasets PC1 scores diﬀered across sequencing technologies,
and cancer type (Table (2.3.1)). In The TCGA June 2012 and Pan-Cancer data there was a
weak, but signiﬁcant relationship between age and PC1 score.
2.3.3 Class imbalance analysis
The proportions of colon and rectum cancers processed using SOLiD, or Illumina technology
were not balanced in the TCGA June 2012 and Pan-Cancer datasets (χ2 (2, N = 224) =
12.60, p = 1.84× 10−3 ). The anatomical site, the section of colon or rectum from which
the tumour sample was collected, was not balanced across the sequencing technologies
(χ2 (8, N = 224) = 15.37, p = 0.05 ). However, age, gender and stage were balanced
across the sequencers. In the TCGA December 2012 data the samples sequenced using
Illumina technology were enriched for colon cancer samples (p = 0.01). The anatomical
site of the cancers was imbalanced across sequencing technology (χ2 (10, N = 345) =
29.87, p = 9.01× 10−4), but age, gender, and stage were not.
2.4 Discussion
According to the nmMDS plots (Figures 2.3.1a and 2.3.2a) there was a sequencing technology
eﬀect in the TCGA December 2012, and TCGA June 2012 data, which was reduced in the
Pan-Cancer 2013 data (Figure (2.3.3a)). The main driver of variation in the samples was
the mutation rate, not a technical eﬀect. PC1 and sequencer type were correlated in each of
the three datasets, but this may be confounded by the skewed distribution of cancer types
across the sequence technologies.
I expected to see identical number of mutations for the 79 samples that intersected
between the TCGA June 2012 and TCGA December 2012 datasets. However, the number
of mutations per sample changed across the two datasets, and indicated undocumented
changes to the analysis pipeline.
The imbalance of colon and rectum cancers across sequencing technology may have
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arisen because the study used an opportunity sample, rather than deﬁning quotas at the
study outset. Hypermutation was an important feature in the TCGA December 2012 and
TCGA June datasets, and it was highly associated with the MSI-H phenotype A classiﬁer
could be developed to classify samples as MSI-H or non-MSI-H using exome sequence data
and our sample similarity measure. However, there are already existing tools to predict MSI
status using exome sequence data without using the established Bethesda marker panel test
(RepeatSeq (Highnam et al., 2013), lobster (Gymrek et al., 2012)).
2.5 Conclusion
In each of the three datasets (TCGA December 2012, TCGA June 2012, and Pan-Cancer)
the feature most highly correlated with PC1 of the binary mutation matrix was the frequency
of mutations. Based on nmMDS plots there was a sequencing technology eﬀect in the TCGA
December 2012 dataset, and June 2012 TCGA data, which was reduced in the Pan-Cancer
data set.
Future large scale sequencing studies should be aware of potential technical eﬀects, and
take appropriate precautions during the study design phase. Features which are known to
exhibit variation across classes, should, as much as is possible, be balanced appropriately
across diﬀerent experimental conditions. I advise other researchers to use a single sequencing
technology and pipeline to process all samples in a study.
Based on this exploratory investigation in to the TCGA and Pan-Cancer colorectal cancer




Predicting cancer grade and stage





The stage and grade of a tumour are deemed the strongest indicators of cancer prognosis
(Engers, 2007). Cancer staging is conducted using the World Health Organisation (WHO)
TNM system (Edge & Compton, 2010). It measures three standardised features of the
cancer: the size of the primary tumour (T), the presence or absence of tumours in regional
lymph nodes (N) and the presence or absence of distant metastases (M). There are four
broad cancer stages, ranging from stage I to stage IV. The tumour size and cancer spread
increases along with the cancer stage category.
Tumour grading is based solely on morphological criteria following histological assessment
and, as such, is considerably more subjective than staging. Tumour grading measures the
degree of diﬀerentiation of the neoplastic cells compared with the cells of the surrounding
healthy tissue (Epstein, 2010). The degree of diﬀerentiation is a continuum from near
normal to totally undiﬀerentiated. Tumours with near normal diﬀerentiation are assigned a
low-grade annotation (usually grade 1, or 2), and poorly diﬀerentiated tumours are assigned
a high-grade annotation (usually grade 3, or 4). The cut-oﬀ points between the levels of
diﬀerentiation are not well deﬁned. Consequently, the deﬁnition for what is deemed well
diﬀerentiated for one pathologist may well be diﬀerent from another (Engers, 2007). Indeed,
inter pathologist grading agreement is fair at best across multiple studies (Engers, 2007;
Lang et al., 2005; Han et al., 2013; Scholten et al., 2004). In addition, multiple grading
systems are used across and within cancer types. Prostate cancers use the Gleason grading
system (Epstein, 2010), ovarian, and endometrial cancers use the FIGO grading system
(Shepherd, 1989), and renal clear cell carcinomas use the Fuhrman grading system (Fuhrman,
Susan A and Lasky, Larry C and Limas, 1982). A more standardised and objective measure
may improve diagnostic accuracy and aid decision making regarding treatment. In order to
achieve this, I must establish molecular correlates of cancer grade across multiple cancers.
The reduction in sequencing cost in the last decade has made possible the collection of
large numbers of exome sequenced cancer samples. The Pan-Cancer Initiative (Weinstein
et al., 2013) was established to enable the comparison of the ﬁrst 12 Cancer Genome Atlas
66
cancer types across multiple omics data types. New cancer subtype classiﬁcations have
resulted from the analysis of this dataset (Ciriello et al., 2013; Hofree et al., 2013). In this
study I used data from the Pan-Cancer Initiative (Weinstein et al., 2013) to identify clinical
and exome sequence-based features that are associated with cancer grade and stage across
and within multiple types of adenocarcinomas, the most frequent epithelial subtype of cancer.
Identiﬁcation of exome-sequence based features that are correlated with cancer grade may
help with the future development of a grading system that could be used across cancers, or
at least help with our understanding of the genes involved in cancer grade.
There is limited literature on the sequence-based correlates of tumour grading within and
across tumour tumour types in contrast to the well studied area of sequence-based correlates
of tumour types. The existing literature use candidate gene approaches (Garcia-Dios et al.,
2013). I could not ﬁnd any previous work that attempted to predict cancer grade across
multiple cancer types using clinical features and whole exome sequence derived features.
Lee et al. (2013) created models to predict advanced clinical stage in TCGA colorectal
cancer data. They used an elastic net (Zou & Hastie, 2005) approach to integrate mutation,
gene expression, copy number alteration and methylation data and found that a set of 158
features corresponding to 143 genes gave the best model of association. However, they
did not validate their models in an independent test set, nor did they attempt to identify
the common correlates of cancer stage across multiple cancers. Greater understanding of
the genes involved in cancer grade could help lead to the creation of an objective tumour
grading system across cancers that would be useful to pathologists when performing tumour
grading, and may be applicable to tumours which currently do not have grading systems
such as adrenocortical tumours.
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3.2 Methods
I used patient age (A; at initial onset), gender (G), cancer stage (S), tumour type (T), and
features derived from the exome somatic mutation proﬁle of each patient’s primary tumour
to predict whether the tumour was low-grade (1,2) or high-grade (3,4). Logistic regression
and AIC (Akaike, 1974) backwards model selection were used to create the models in the
presence or absence of relevant clinical data such as tumour staging. The analyses were
repeated using stage as the outcome of interest.
Adenocarcinoma grade predictive models were built by combining data from the three
tumour types (endometrial carcinoma, renal cell carcinoma and ovarian carcinoma) and then
in each individual tumour type separately. A summary of the model building steps is provided
in Figure 3.2.1 on page 72. Four ’baseline’ models were built comprising the clinical features
(A,G,S,T; Table 3.2.1). Models were re-run with the inclusion of exome-derived features,
namely protein mutational information (P) and variant frequency features (V). By including
the exome sequence derived features in addition to the clinical features I could measure any
additional predictive power captured by the exome sequence derived features. For ovarian
carcinoma and endometrial carcinoma models were built without inclusion of gender.
Table 3.2.1: Grade and stage classiﬁcation model abbreviations
Across cancer models Model name + proteins + variant frequency + proteins & variant frequency
age gender AG AGP AGV AGPV
age gender stage AGS AGSP AGSV AGSPV
age gender tumour type AGT AGTP AGTV AGTPV
age gender stage tumour type AGST AGSTP AGSTV AGSTPV
Within cancer models Model name + proteins + variant frequency + proteins & variant frequency
age WA WAP WAV WAPV
age (gender) WAG WAGP WAGV WAGPV
age (gender) stage WA(G)S WA(G)SP WA(G)SV WA(G)SPV
A summary of the logistic regression models combining clinically derived features with exome derived
mutation features. Model name = models composed of clinical features are baseline models. + proteins
= baseline clinical and protein feature models. + variant frequency = baseline clinical and variant
frequency feature models. + proteins & variant frequency = baseline clinical , protein and variant
frequency models.For stage prediction models the stage covariate (S) in the above models was replaced with
the grade covariate (Gr).
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3.2.1 The data set
Mutation Annotation Format (MAF) ﬁles and clinical data ﬁles for each of the 12 Pan-
Cancer project data sets (accession syn1710680) were downloaded from Sage Synapse on 3rd
October 2013. For each individual exome, sequencing had been performed on paired normal
and tumour tissue in order to identify the mutations speciﬁc to the tumour tissue (somatic
mutations). I retained 970 samples for which exome-sequence data and age, gender, tumour
stage and tumour grade data were available.
3.2.2 Data pre-processing
3.2.2.1 Phenotype deﬁnition: Tumour grade and stage grading dichotomisa-
tion
Eight tumour grading categories were used to deﬁne grade in the Pan-Cancer data (G1, G2,
G3, G4, Grade 1, Grade 2, Grade 3, High-Grade). The tumours with a grading equivalent to
grades 1 or 2 were assigned to the low-grade category. The high-grade tumours had grade
classiﬁcations of G3, G4, Grade 3 and High-grade. In renal clear cell carcinoma studies, this
approach yielded improved inter-pathologist grading agreement (Lang et al., 2005; Al-Aynati
et al., 2003). The distribution of grade annotations across tumour type and stage (low/high)
is shown in Table 3.6.4. Twenty two cancer stage categories were used to describe the
cancer stage of the 970 tumour samples. I grouped the 22 classes into two classes, low-stage
(stages I and II) and high-stage (stages III and IV). Low-stage samples represented the
cancers limited to the organ of origin without evidence of metastasis, and high-stage samples
represented locally advanced and metastatic cancers. The distribution of stage annotations
across tumour type and grade (low/high) is shown in Table 3.6.3.
3.2.2.2 Predictors: Creating the protein binary mutation matrix
I removed ’silent’ mutations, which did not change the amino acid sequence in the translated
protein, from the MAF ﬁle. I used the union of the functionally mutated proteins across
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all samples to generate a matrix M of proteins P by samples S . Each element in M [p, s],
was set to 0 if there was no protein coding mutation for protein p, and sample s, or set
to 1 if at least one protein coding mutation was present for protein p, and sample s. This
matrix represented the presence of any protein coding mutations in each protein coding gene
in each sample. Similar approaches have been taken in other studies (Hofree et al., 2013;
Leiserson et al., 2013a).
3.2.2.3 Predictors: Variant frequency features
I recorded the frequency of each of the six transition and transversion SNV substitutions
across the exome to test for their ability to discriminate low-grade from high-grade tumours.
Transition and Transversion frequencies have been shown to discriminate between cancer types
(Kandoth et al., 2013a; Lawrence et al., 2013). I also recorded, and tested the discriminatory
potential of the frequency of ten types of sequence variant; frame shift deletions, frame
shift insertions, in-frame deletions, in-frame insertions, missense, nonsense, RNA, silent, and
splice site mutations. The variant frequency features were not normally distributed across
samples (Figure 3.6.1) therefore, I tested whether median variant frequencies varied across
grade using the Wilcoxon rank sum test, and across stage using the Kruskal-Wallis test.
3.2.2.4 Deﬁning the training set and test set
For each of the analyses, I randomly assigned samples without replacement to a 2/3 training
set and a 1/3 test set. I balanced the high-grade and low-grade outcomes in the training
sets to prevent a binary classiﬁer from favouring the majority class (Barandela & Sã, 2003).
I down-sampled the majority class to be of equal size to the minority class. Any surplus
majority class training samples were assigned to the test set.
3.2.3 Mutated protein and variant frequency feature selection
I reduced the number of proteins used as predictors in the training sets using a simple
heuristic; a protein feature was retained if it carried at least one protein coding mutation in
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more than 5% of training samples in any one of the tumour types, similar to the approach
used by Kandoth et al. (2013a). The number of proteins retained for each analysis is shown
in Table 3.2.2. I then built single exome feature logistic regression models for each of the
remaining proteins and each variant frequency feature separately including clinical features
age, gender, stage, grade and tumour type (for the cross tumour models) as covariates.
Table 3.2.2: Number of proteins retained after frequency ﬁlter
grade classiﬁcation
All 3 cancers renal cell ovarian carcinoma endometrial carcinoma
training set size 474 236 38 130
N genes passing ﬁlters 562 12 16 1788
stage classiﬁcation
All 3 cancers renal cell ovarian carcinoma endometrial carcinoma
training set size 580 238 18 84
N genes passing ﬁlters 919 14 47 2360
Across the adenocarcinomas and within each adenocarcinoma, the size of the training set used to build each
logistic regression models are shown above. The N genes passing ﬁlters shows the number of genes which
carry functional mutations in at least 5% of the training set.
3.2.4 Final model building
All features passing a threshold for signiﬁcance in the single exome feature logistic regression
(FDR<0.1 (Benjamini & Hochberg, 1995)) were taken forward for a range of multi-exome
feature logistic analyses. I used stepwise backward model selection (using Akaike’s information
criterion (Akaike, 1974)) to reﬁne the multi-exome feature models further for each of the
sets of features. Stepwise backwards model selection removed each feature from the logistic
regression model and re-computed Akaike’s Information Criterion (AIC), if the AIC was
lower in the new model, the new model was adopted as the ’new best’ model. This process
continued until the AIC could not be lowered by removing any features from the ’new best’
model. At that point the model was considered optimal. It must be remembered that here
’new best’ refers to a local optima and not the optimal global solution to the regression
problem.
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3.2.4.1 Model performance and comparisons
I used model sensitivity, speciﬁcity, accuracy, and the area under the curve (AUC) to measure
and compare the performance of each classiﬁcation model along with model sensitivity,
speciﬁcity and accuracy. I tested whether any improvement in classiﬁcation performance was
achieved by including exome derived sequence features over clinically derived features alone
using the roc.test function within the pROC R package (Robin et al., 2011). I used the
bootstrap permutation method originally described in Hanley & McNeil (1983). A p-value
below 0.05 indicated an improvement in classiﬁcation performance by adding exome sequence
derived information to the clinical variables in the ’baseline’ models AGS, AGT, and AGST.
3.2.4.2 Tumour stage classiﬁcation methods
I used the same model building process as described above (sections 2.1-2.4.2) to predict
cancer stage, this time including tumour grade (low-grade / high-grade) as a predictor.
The analysis scripts used in this chapter can be found at
https://github.com/SutherlandRuss/RS_PhD_scripts.
















Sample mutation frequency filter 
Retain proteins mutated in 5% of any 
included cancer type. 
Univariate protein selection  using 
logistic regression. Proteins 






Logistic Regression and AIC- based 
model selection. Predictive Model 
Measure model 
performance 
The analysis pipeline shows how I ﬁrst split the samples in to a two thirds training set and one third test set.
The majority class was downsampled to the minority class size. If the model was to include protein features
then all proteins with mutations in ≥5% of the training set were retained. Individual proteins which were
signiﬁcantly associated with the outcome were retained for ﬁnal multi-protein model building. If proteins
were not to be included in the model, the 5% mutation frequency and logistic regression feature selection
steps were skipped. The ﬁnal multivariate model building step resulted in AIC reﬁned model which was then
tested using the test set.
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3.3 Results
I used 970 samples (247 endometrial carcinoma, 416 renal cell carcinoma and 307 ovarian
carcinoma) from the Pan-Cancer data set for which exome sequence data, age, gender,
tumour stage and tumour grade information was available from the 3908 Pan-Cancer data
set samples. Three hundred and ﬁfty ﬁve samples were annotated as low-grade, and 615 as
high-grade across the three tumour types (150 low, 97 high for endometrial carcinoma; 177
low, 239 high for renal cell carcinoma; 28 low, 279 high for ovarian carcinoma). There were
435 low-stage (stage 1 and stage 2) and 535 high-stage (stage 3 and stage 4) samples across
the 3 tumour types (184 low, 63 high endometrial carcinoma; 237 low 179 high renal cell
carcinoma; 14 low 290 high for ovarian carcinoma). The sample demographics and summary
statistics for endometrial carcinoma, renal cell carcinoma and ovarian carcinoma combined
and stratiﬁed according to cancer stage, high-grade / low-grade categorisation are shown in
Table 3.6.1. The distribution of grade classes across cancer types and stages (low/high) is
shown in Table 3.6.3 along with the grade class mapping. The distribution of stage classes
across cancer types and grades (low/high) is shown in Table 3.6.4 along with stage class
mapping. Across adenocarcinomas frame-shift deletions, frame-shift insertions, in-frame
deletions and splice site mutations showed signiﬁcant diﬀerences in frequency between low
and high-grade tumours. Wilcoxon rank sum tests are available in Table 3.6.2. However,
none were predictive of grade when adjusted for age, stage, tumour type and proteins in the
regression models. For the endometrial cancers, C>G/G>C transversion mutation frequency
was higher in the low-grade tumours in comparison to high-grade tumours after Bonferroni
correction (0.05/64, α = 7.8× 10−4), W (n1 = 150, n2 = 97) = 4918.5, p = 2×10−5. None
of the variant frequency features showed a signiﬁcant diﬀerence across grade, or stage in the
renal or ovarian carcinomas.
3.3.1 Cross-adenocarcinoma grade classiﬁcation
When predicting grade across adenocarcinomas, the presence of at least one TP53 coding mu-
tation was predictive of high tumour grade (OR = 7.62, CI [4.35, 13.64], p = 2.91×10−14)
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when adjusting for patient age (at initial onset), gender (OR = 2.89, CI [1.74, 4.84], p =
4.76×10−5), and stage (OR = 4.89, CI [3.08, 7.84], p = 2.61×10−11) in the best per-
forming model AGSTP. This model performed signiﬁcantly better than the clinical features
alone. (D = 3.25, p = 6.0 × 10−4). ROC curves are shown in Figure3.3.1. Across
adenocarcinomas in model AGTP, TP53 protein coding mutations were predictive of
cancer grade (OR = 7.40, CI [3.60, 15.73], p = 8.84×10−08) when adjusted for pa-
tient gender (OR = 2.56, CI [1.38, 4.86], p = 3.29×10−03), and tumour type (ovar-
ian tumour type [OR = 2.46, CI{0.95, 6.36}, p = 0.06], endometrial tumour type
[OR = 0.62, CI{0.31, 1.25}, p = 0.18]). Model AGTP performed better than the
AGT model (D = 3.45, p = 3.0 × 10−4). In the AGV model C>G/G>C transversions
were predictive of cancer grade (OR = 1.06, CI [1.03, 1.10, p = 8.21×10−03]), as were
frame shift deletions (OR = 0.88, CI [0.83, 0.93], p = 6.13×10−06). When proteins
were included with age, and gender (model AGP), the variant frequency features were
replaced in the model by TP53 (OR = 12.24, CI [6.89, 22.46], p = 2.0×10−16), ARID1A
(OR = 2.13, CI [0.97, 4.70], p = 0.06) , CTCF (OR = 0.36, CI [0.08, 1.18], p =
0.13), CTNNB1 (OR = 0.09, CI [0.01, 0.33], p = 1.69×10−03) and PIK3R1 (OR =
0.41, CI [0.15, 1.04], p = 0.69). I found diﬀerences when comparing the variant frequency
features across cancer grade at the univariate level, but when included in the regression and
adjusted for all covariates they were not predictive of cancer grade (Table3.6.2). Cross-cancer
grade classiﬁcation statistics can be found in Table 3.3.1.
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Figure 3.3.1: Across cancer grade classiﬁcation ROC curves.
A= age, G= gender, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant
frequency. Across cancer models to predict cancer grade based upon clinical features perform well with
model AGST performing best (AUC = 0.822). When the clinical models are supplemented with protein
information classiﬁcation performance improves slightly and the best performing model is AGSTP (AUC =
0.851).
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Table 3.3.1: Across cancer grade classiﬁcation statistics
Sensitivity Speciﬁcity Accuracy Positive predictive value (PPV) Area Under the Curve (AUC)
model AG 0.50 0.50 0.50 NA 0.50
model AGP 0.53 0.90 0.62 0.94 0.78
model AGV 0.68 0.61 0.66 0.85 0.66
model AGPV 0.53 0.90 0.62 0.94 0.78
model AGS 0.74 0.82 0.76 0.93 0.79
model AGSP 0.78 0.78 0.78 0.92 0.84
model AGSV 0.74 0.82 0.76 0.76 0.79
model AGSPV 0.78 0.78 0.78 0.92 0.84
model AGT 0.59 0.81 0.64 0.91 0.74
model AGTP 0.53 0.91 0.62 0.95 0.80
model AGTV 0.59 0.81 0.64 0.91 0.74
model AGTPV 0.53 0.91 0.62 0.95 0.80
model AGST 0.66 0.82 0.70 0.92 0.82
model AGSTP 0.68 0.84 0.72 0.93 0.85
model AGSTV 0.66 0.82 0.70 0.92 0.82
model AGSTPV 0.68 0.84 0.72 0.93 0.85
A= age, G= gender, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant
frequency.
Model performance metrics for all models created to predict cancer grade across endometrial carcinoma,
ovarian carcinoma and renal cell carcinoma. Classiﬁcation sensitivity was highest for those models that
included cancer stage. Model AGTP achieved a high-grade classiﬁcation speciﬁcity of 0.907 in the test set,
indicating that any unseen tumour classiﬁed as high-grade is likely to be a high-grade tumour. For models
with identical classiﬁcation statistics, such as AGSTP and AGSTPV, the more complex model (AGSTPV)
has been reﬁned to the simpler model (AGSTP) though the AIC model selection process.
I investigated the positions of TP53 mutations by mapping mutations to the 11 TP53
exons (Figure3.3.2). At each TP53 exon a larger percentage of high-grade samples carried
mutations than low-grade samples. Clinical sequencing of TP53 has typically focused on
exons 5-8. In addition to mutations in exons 5-8, 31.6% of TP53 mutations in high-grade
samples mapped outside exons 5-8. Among the low-grade samples 20% of TP53 mutations
mapped outside of exons 5-8. The vast majority of samples carried a single protein coding
mutation in TP53. There were 16 mutations among high grade samples and a single mutation
among low-grade samples that did not map to the canonical TP53 exons.
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Figure 3.3.2: Percentage of low-grade and high-grade samples carrying protein coding
mutations in each TP53 exon.





































The TP53 gene has eleven canonical exons based upon the ensembl release 76 (Flicek et al., 2014) transcript
ENST00000269305 represented on the x-axis. In high-grade samples TP53 mutations are more prevalent
than in low-grade samples across most exons. TP53 mutations are found outside of exons 5-8 which are
typically sequenced in the clinic. ’NA’ mutation frequency represent those mutations that did not map to
any TP53 exon.
3.3.1.1 Grade classiﬁcation within adenocarcinomas
When predicting endometrial carcinoma grade the best performing model included age,
stage, and protein features (model WASP) (Table 3.6.9 on page 94) with AUC of 0.879
(Figure3.3.3). TP53 functional mutations were associated with high cancer grade (OR =
11.78, CI [3.91, 44.28], P = 4.64 × 10−05) when adjusted for cancer stage (OR =
2.06, CI [0.77, 5.57], p = 0.15) (Table 3.6.7 on page 92). PTEN functional mutations
predicted low cancer grade (OR = 0.38, CI [0.15, 0.94], p = 0.04). The WAP model
outperformed the baseline model WA (D = 3.42, p = 3.0× 10−4), as did model WAGSP
(D = 2.5, p = 0.01) (Figure 3.3.3 on page 79, and Table 3.6.9 on page 94). The WASP
model outperformed the WAP model (D = 2.17, p = 0.02).
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Histological type was not included in the logistic analysis because of the distribution of
grade across histological type. After I removed 17 samples of indeterminate histological type
with “serous and endometrioid features”, there remained 150 low-grade and 49 high-grade
endometrioid adenocarcinomas. For serous tumours there were 44 high-grade tumours
and no low-grade tumours. I could not reliably measure the eﬀect of TP53 and PTEN
mutations. I found that samples with functionally mutated copies of TP53 , and PTEN were
imbalanced across histological type using Fisher’s exact test (TP53 p = 3.8× 10−8, PTEN
p = 5.55×10−10). I investigated whether TP53 and PTEN sample mutation frequency
changed across stage for high-grade and low-grade tumours (Figure3.3.4), and found a
negative association between PTEN functional mutation and increasing cancer stage in
high-grade endometrial carcinomas (OR = 0.61, CI [0.41, 0.90], P = 0.02). A trend that
was reﬂected across other genes in the high-grade samples (Figure 3.3.4). For the ovarian
and renal adenocarcinomas, neither proteins, nor variant frequency features were included
in cancer grade prediction models after AIC backwards model selection (Figures 3.6.3a,
and 3.6.4a on page 97; Table 3.6.7 on page 92, Table 3.6.10 on page 95, and Table 3.6.11
on page 98)
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Figure 3.3.3: Endometrial carci-
noma grade classiﬁcation ROC
curves
W= within cancers, A= age S=
Stage, P= proteins. Model WAP
performs comparably to the WASP
model, despite not including stage
information.













high grade all genes
stage1 stage2 stage3 stage4
Circle sizes indicate sample sizes. Larger circles
indicate a larger sample for that particular group.
The low-grade stage four group was composed
of a single sample, which carried functional
mutations in both TP53 and PTEN.
3.3.2 Stage classiﬁcation
Across adenocarcinomas the age, gender, grade, tumour type and proteins model (model
AGGrTP ) performed with the highest AUC of 0.874 (Figure 3.3.5b). The signiﬁcantly
contributing features were tumour grade (OR = 4.50, CI [2.89, 7.11], p = 5.14×10−11),
ovarian tumour type (OR = 20.50, CI [10.6, 43.87], p = 2.0×10−16) and endometrial
tumour type (OR = 5.10, CI [0.30, 0.84], p = 8.91×10−03). Model AGGrP performed
with an AUC of 0.847 (Figure 3.3.5b). The predictive features were high-grade (OR =
4.72, CI [3.00, 7.52], p = 3.33×10−11), male gender (OR = 0.59, CI [0.35, 0.98], P =
0.04), TP53 (OR = 5.40, CI [3.12, 9.48], p = 2.67×10−09), FNDC1 (OR = 0.16, CI [0.03, 0.69], p =
0.02), PIK3CA (OR = 0.21, CI [0.10, 0.42], p = 1.88×10−05) and PIK3R1 (OR =
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0.24, CI [0.09, 0.57], p = 2.06×10−03). Model AGGrV achieved an AUC of 0.843 (Figure
3.3.5b) and the contributing features were; high-grade (OR = 8.30, CI [5.53, 12.68], p =
2.0×10−16), male gender (OR = 0.39, CI [0.25, 0.60], p = 1.59×10−05) and frame-
shift deletion frequency (OR = 0.92, CI [0.85, 0.98], p = 0.01). When proteins were
included instead of cancer grade, model AGPV performed with an AUC of 0.803 (Fig-
ure 3.3.5b) and the predictive features were; TP53 (OR = 8.94, CI [5.71, 14.36], p =
2.0×10−16), PIK3CA (OR = 0.24, CI [0.12, 0.45], p = 1.72×10−03), and PIK3R1
(OR = 0.24, CI [0.09, 0.56], pp = 1.72×10−03).
Figure 3.3.5: Stage classiﬁcation across cancers ROC curves
(a) clinical feature baseline models (b) clinical feature plus exome information models
A= age, G= gender, Gr= grade, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant
frequency. Across cancers the best performing model was AGGrT (AUC = 0.874). No additional predictive
power was gained by including protein information in model AGGrTP.
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Table 3.3.2: Across cancer stage classiﬁcation statistics
Sensitivity Speciﬁcity Accuracy Positive predictive value (PPV) Area Under the Curve (AUC)
model AG 0.79 0.35 0.62 0.67 0.57
model AGP 0.58 0.88 0.70 0.89 0.78
model AGV 0.71 0.54 0.65 0.72 0.70
model AGPV 0.58 0.88 0.69 0.89 0.80
model AGGr 0.87 0.66 0.79 0.81 0.79
model AGGrP 0.85 0.72 0.80 0.84 0.85
model AGGrV 0.82 0.75 0.80 0.85 0.84
model AGGrPV 0.82 0.73 0.79 0.84 0.84
model AGT 0.54 0.97 0.70 0.97 0.81
model AGTP 0.54 0.97 0.70 0.97 0.81
model AGTV 0.54 0.97 0.70 0.97 0.81
model AGTPV 0.54 0.97 0.70 0.97 0.81
model AGGrT 0.73 0.84 0.77 0.88 0.87
model AGGrTP 0.73 0.84 0.77 0.88 0.87
model AGGrTV 0.73 0.84 0.77 0.88 0.87
model AGGrTPV 0.73 0.84 0.77 0.88 0.87
A= age, G= gender, Gr= grade, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant
frequency. Model performance metrics for all models created to predict cancer stage across endometrial
carcinoma, ovarian carcinoma and renal cell carcinoma. Classiﬁcation performance as measured by AUC was
highest for the age, gender, grade and tumour type model at 0.874. The AGPV model showed high-grade
classiﬁcation speciﬁcity of 0.874. For any unseen sample I would be conﬁdent that a high-grade
classiﬁcation was correct. For models with identical classiﬁcation statistics, such as AGGrT and AGGrTPV,
the more complex model (AGGrTPV) has been reﬁned to the simpler model (AGGrT) though the AIC
model selection process.
3.3.2.1 Stage classiﬁcation within adenocarcinomas
No exome sequence features were predictive of cancer stage when adenocarcinoma types were
analysed individually. In endometrial carcinoma age, and grade (model WAGr) (Table 3.6.9
on page 94, and Table 3.6.8 on page 93) was the best performing model, and had an AUC
of 0.625 (Figure 3.6.2 on page 96). The WAGr model was also the best performer in ovarian
carcinoma (Table 3.6.11 on page 98, and Table 3.6.8 on page 93) with an AUC of 0.661
(Figure 3.6.3b on page 96). The age, gender, and grade model (model WAGGr) (Table 3.6.10
on page 95, and Table 3.6.8 on page 93) performed best in renal carcinoma with an AUC of
0.716 (Figure 3.6.4b on page 97).
The complete set of cross cancer grade and stage prediction model summaries are shown
in Tables 3.6.7 on page 92 and 3.6.8 on page 93 respectively. Cross cancer grade and stage
model classiﬁcation statistics are shown in Table 3.3.1 on page 76 and Table 3.3.2.
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3.4 Discussion
This is the ﬁrst study to attempt to use whole exome sequence derived features to identify
the mutated genes associated with tumour grade across adenocarcinomas. I show potential
for a model combining age, gender, tumour type and a protein mutation feature in the
absence of tumour stage. When adding the protein feature (mutation of TP53) to the model,
high speciﬁcity was achieved (0.907). The predictive accuracy of model AGSTP including
TP53 mutation status outperformed model AGST which was composed of clinical features.
This conﬁrms the previously known association between TP53 mutations and cancer
grade in ovarian carcinoma and endometrial carcinoma. Across three types of adenocarcinoma
(endometrial, kidney, and ovarian) I have shown that the presence of one or more protein
coding mutations in TP53 is associated with of high-grade cancer when adjusted for age,
stage, gender and tumour type.
TP53 functional mutations were associated with high-grade status in endometrial carci-
noma, and PTEN functional mutations were associated with low-grade cancer. However, the
serous and endometrioid histological subtypes may confound this result: I could not adjust
for histological type in the regression models because all except one serous endometrial
carcinoma tumour was high-grade, leading to a breakdown of the logistic regression model. In
endometrial carcinoma, the high-grade serous tumour type is characterised by near ubiquitous
mutation of TP53 , whereas mutation of PTEN is indicative of the endometrioid tumour
type, these mutations being almost mutually exclusive (Kandoth et al., 2013a). However,
TP53 mutation incidence is greater in high-grade endometrioid tumours than in low-grade
endometrioid tumours (Lax et al., 2000). The trend for PTEN mutation frequency to de-
crease across cancer stage when stratiﬁed by grade (Figure 3.3.4) may reﬂect an association
between PTEN mutations and micro-satellite instability-high tumours, which are typically
low-stage (Samarnthai et al., 2010; Kandoth et al., 2013b).
I discovered a set of proteins which when mutated were associated with high cancer stage,
where low-stage indicated at worst a locally advanced tumour, and high-stage indicated
tumour extension beyond the organ of origin. Using model AGPV, the sensitivity was 0.584,
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but the high speciﬁcity of 0.876 shows that using a model comprising frame-shift deletions,
TP53, ARID1A, PIK3CA and PIK3R1 it may be possible to predict cancer stage using a
simple statistical model that does not require surgery or a Magnetic Resonance Imaging
(MRI) scan. Perhaps, further developed, this model could be used to prioritise patients
with clinical feature and exome feature proﬁles that do not give a clear stage prediction for
more extensive stage characterisation. TP53 mutations are known to be associated with
high cancer stage. PIK3CA and PIK3R1 mutations predicted low tumour stage, which is
consistent with the ﬁndings of showing co-occurrence of mutation in these genes if PTEN
was also mutated (Kandoth et al., 2013b).
Even though I am the ﬁrst to take a whole exome approach to identify mutated genes
associated with cancer grade across adenocarcinomas I found no additional genes associated
with cancer grade. I conﬁrmed the association between TP53 mutation and high-grade
status in endometrial carcinoma, and the association of PTEN mutation with endometrioid
histological type found in a candidate gene analysis (Garcia-Dios et al., 2013).
There was no pathologist ID attached to each tumour’s grading in TCGA Pan-Cancer
data, putting a limitation on this analysis. Some variation and noise should be expected from
this fact. However, I expect that the most prognostic mutated genes should be common
across pathologists. Up until recently, the original tissue histology reports were available, and
it may have been possible to create a pathologist ID for the Pan-Cancer dataset based on
the histology reports. However, in recent months the pathology report clinician signatures
have been censored, and it is not possible to accurately assign each pathology report to a
pathologist. For large scale cancer sequencing studies, such as Genomics England, it would
be beneﬁcial to record the pathologist ID so that the variation among pathologists can
be modeled. It is entirely possible in this study that issues with inter pathologist grading
reliability contributed to heterogeneity in the high-grade and low-grade classes. This may
explain why TP53 was the only protein I found to be associated with cancer grade. I
attempted to account for this issue by reducing the number of grading classes from three and
four class systems to a two class system which has been shown to improve inter pathologist
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There is potential for an across cancer grading system using exome sequence data and clinical
features. Using age, gender, tumour type and exome sequence protein features (model
AGTP) to predict cancer grade performs almost as well as using age, gender, stage and
tumour type information (model AGST). This system could be used to aid tumour grading
when cancer stage information is not available, for example when an MRI has not yet been
conducted.
Across adenocarcinomas TP53 functional mutation was predictive of high-grade tumour
status once adjusted for age, gender, stage and tumour type. Although across adenocar-
cinomas the exome sequence information did not add much predictive information above
the clinical covariates in model AGST, tumour stage information is not typically available
to pathologists when conducting tumour grading. There may also be potential to use the
tumour stage prediction model AGPV to predict cancer stage across adenocarcinomas based
on frame-shift deletion frequency and TP53 , ARID1A, PIK3CA and PIK3R1 features.
In endometrial carcinoma TP53 and PTEN functional mutation was associated with
cancer grade, although this was not independent of histological type. Across ovarian and
renal carcinomas there were no proteins associated with cancer grade.
I would urge future large-scale cancer sequencing projects, such as Genomics England to
record a pathologist ID variable along with tumour grade. This would allow scientists to
create more robust tumour grade prediction models adjusted for pathologist eﬀects. The
reported genes and variant frequency features may reﬂect diﬀering proportions of each cancer
of high-grade and low-grade status included in the training set.
This study is being further developed. The TCGA pathology slides are being re-graded
by a single expert pathologist (Dr Salvador Diaz-Cano) . These annotations will be used
as the outcome in further regression models and will be free of inter-pathologist variation.
Further work could involve a tumour grading validated by multiple pathologists, to create a
consensus grading for each tumour type at which point machine learning methods would
predict the consensus grade.
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3.6 Supplementary materials
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Beeswarm scatterplots show that the frequency of mutations across samples is non-normally distributed for
all variant types in low-grade and high-grade cancers. The median muteation frequency, and lower and
upper quartile values are indicated thick and thin black lines respectively.
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Table 3.6.1: Grade and stage demographics table
Total dataset low grade high grade stage 1 stage 2 stage 3 stage 4
total sample
N 970 355 615 361 74 405 130
median age (IQR) 61.05 (11.65) 60.57 (12.01) 61.33 (11.43) 60.76 (12.33) 61.42 (11.77) 61.63 (11.15) 59.86 (11.13)
gender N (f/m) 699/271 254/101 445/170 239/122 43/31 334/71 83/47
endometrial
N 247 150 97 164 20 50 13
median age (IQR) 63.04 (11.09) 61.51 (11.04) 65.42 (10.79) 62.69 (11.17) 66.2 (10.97) 62.5 (9.70) 64.77 (15.12)
gender N (f/m) 247/0 150/0 97/0 164/0 20/0 50/0 13/0
renal
N 416 177 239 197 40 112 67
median age (IQR) 60.66 (12.09) 59.84 (12.67) 61.28 (11.64) 59.16 (13.03) 59.08 (11.33) 63.96 (11.46) 60.51 (9.58)
gender N (f/m) 145/271 76/101 69/170 75/122 09/31 41/71 20/47
ovarian
N 307 28 279 0 14 243 50
median age (IQR) 59.98 (11.30) 60.14 (12.75) 59.96 (11.17) N/A 61.29 (12.82) 60.37 (11.14) 57.72 (11.61)
gender N (f/m) 307/0 28/0 279/0 0/0 14/0 243/0 50/0
The number of samples, the number of each gender, and the sample age median and interquartile range
(IQR) for the total dataset, and the total dataset when stratiﬁed by cancer grade (low-grade / high grade)
and cancer stage (stage 1 / stage 2 / stage 3 / stage 4).
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Table 3.6.2: Descriptive statistics and class imbalance tests across and within cancers
Total sample low/high Wilcoxon rank sum test stages I / II / III / IV Kruskal-Wallis test




frame shift del 2 (3) 3/2 (4/4) W= 134143.5, p=1.79× 10−9 3/3/1/1 (5/5/3/3) χ2(3) = 86.96, p = 9.87× 10−19
Frame_Shift_Ins 1 (2) 1/1 (2/2) W= 131070.5, p=4.3× 10−8 1/1/0/1 (3/2/1/1) χ2(3) = 67.56, p = 1.42× 10−14
in-frame del 1 (2) 1/0 (2/1) W= 128290, p=1.23× 10−6 1/1/0/0 (2/2/1/1) χ2(3) = 74.86, p = 3.89× 10−16
In_Frame_Ins 0 (0) 0/0 (1/0) W= 119427, p=1.1× 10−3 0/0/0/0 (1/0/0/0) χ2(3) = 18.28, p = 3.9× 10−4
Missense_Mutation 38 (27) 38/38 (28/27) W= 112397.5, p= 0.44 39/43/36/36 (32/25.25/23/28.5) χ2(3) = 15.08, p = 1.0× 10−3
Nonsense_Mutation 3 (3.75) 3/3 (3/3) W= 120459.5, p= 6.63× 10−3 3/3/3/3 (4/3/3/2) χ2(3) = 26.65, p = 2.0× 10−5
nonstop mutation 0 (0) 0/0 (0/0) W= 110266, p= 0.68 0/0/0/0 (0/0/0/0) χ2(3) = 20.67, p = 1.20× 10−4
RNA 1 (5) 2/1 (5/4) W= 134588, p= 0 3/2.5/0/1 (5/6.75/2/4) χ2(3) = 111.09, p = 6.40× 10−24
Silent 12 (10) 13/11 (11/9) W= 122058, p= 2.13× 10−3 13/12.5/11/11 (11/11.75/9/9.75) χ2(3) = 30.06, p = 1.34× 10−6




A>C/T>G 4 (4) 3/4 (4/4) W= 106307, p= 0.49 4/5/3/4 (5/4/4/4) χ2(3) = 1.76, p = 5.30× 10−4
A>G/T>C 8 (8) 8/8 (10/7) W= 118105.5, p= 0.03 9/8/7/8 (11/9.75/7/7.75) χ2(3) = 3.40, p = 1.98× 10−7
A>T/T>A 4 (6) 4/4 (5/6) W= 104993, p= 0.32 5/5/4/4.5 (6/5.75/5/6) χ2(3) = 4.67, p = 0.20
C>A/G>T 10 (9) 10/10 (9/9) W= 112263.5, p= 0.46 10/12/9/10 (11/9.75/9/8) χ2(3) = 1.08, p = 0.01
C>G/G>C 7 (6) 6/7 (4.5/8) W= 90722, p= 1.0× 10−5 6/8/7/7 (6/7/7/7) χ2(3) = 1.39, p = 3.12× 10−3
C>T/G>A 21 (14) 22/20 (19/13) W= 127045.5, p= 2.0× 10−5 24/22.5/20/18.5 (19/13.5/12/13.75) χ2(3) = 4.06, p = 7.76× 10−9
Total sample low/high Wilcoxon rank sum test stages I / II / III / IV Kruskal-Wallis test




frame shift del 3 (3) 3/3 (4/5) W= 6971.5, p= 0.58 3/3/3/2 (5/5.5/2/2) χ2(3) = 3.26, p = 0.35
Frame_Shift_Ins 1 (2) 1/1 (2/2) W= 7402.5, p= 0.81 1/1/1/1 (2/2/2/2) χ2(3) = 0.62, p = 0.89
in-frame del 1 (2) 1/2 (2/3) W= 6608.5, p= 0.22 2/1.5/1.5/1 (3/4/2.75/4) χ2(3) = 0.63, p = 0.89
In_Frame_Ins 0 (0) 0/0 (1/1) W= 6808.5, p= 0.33 0/0/0.5/0 (1/1/1/1) χ2(3) = 1.821, p = 0.61
Missense_Mutation 45 (27) 41/52 (164.25/235) W= 6470, p= 0.14 47/58.5/40/40 (218.25/144.75/162.5/150) χ2(3) = 1.68, p = 0.64
Nonsense_Mutation 4 (3.75) 4/5 (12/17) W= 7016, p= 0.64 4/7.5/4/3 (15.25/13.5/10/9) χ2(3) = 4.41, p = 0.22
nonstop mutation 0 (0) 0/0 (0/1) W= 6346.5, p= 0.02 0/0/0/0 (0/0/0/0) χ2(3) = 2.07, p = 0.56
RNA 1 (5) 1/2 (4/4) W= 7054, p= 0.68 2/2/1/1 (4/3.5/3/2) χ2(3) = 3.63, p = 0.30
Silent 14 (10) 14/16 (65.25/95) W= 6652, p= 0.26 15/19/12.5/12 (82.25/58.5/72.75/47) χ2(3) = 1.74, p = 0.63




A>C/T>G 2 (5) 2/3 (4/5) W= 6171.5, p= 0.04 2/3.5/3/2 (5.25/3.25/4.75/5) χ2(3) = 1.22, p = 0.75
A>G/T>C 7 (41) 6/8 (35.5/49) W= 6387, p= 0.10 6/8/7/5 (47.75/35.75/35.5/11) χ2(3) = 2.88, p = 0.41
A>T/T>A 3 (7) 2/4 (6/8) W= 6054, p= 0.02 3/2/3.5/2 (7/7/4.75/3) χ2(3) = 0.63, p = 0.89
C>A/G>T 10 (33) 9/12 (32/42) W= 6337, p= 0.09 10/16.5/8.5/12 (36/24.75/26.5/26) χ2(3) = 0.63, p = 0.89
C>G/G>C 6 (6.5) 5/8 (5/10) W= 4918.5, p= 2.0× 10−5 5/7/6/6 (5/11.25/5.75/11) χ2(3) = 5.91, p = 0.12
C>T/G>A 36 (190.5) 38/35 (176.25/230) W= 7270.5, p= 0.99 39/37.5/32/33 (221.75/157.5/169.25/101) χ2(3) = 3.19, p = 0.36
Total sample low/high Wilcoxon rank sum test stages I / II / III / IV Kruskal-Wallis test




frame shift del 3 (3) 3/3 (5/4) W= 22394, p= 0.30 3/4/3/2 (5/4/4/2) χ2(3) = 8.02, p = 0.5
Frame_Shift_Ins 1 (2) 1/1 (2/3) W= 21767.5, p= 0.60 1/2/1/1 (3/2/3/2) χ2(3) = 3.95, p = 0.267
in-frame del 1 (2) 1/1 (2/2) W= 22110.5, p= 0.40 1/1/1/0 (2/2/2/1) χ2(3) = 8.07, p = 0.04
In_Frame_Ins 0 (0) 0/0 (1/1) W= 21515, p= 0.70 0/0/0/0 (1/0/1/0) χ2(3) = 2.23, p = 0.53
Missense_Mutation 38 (27) 36/39 (18/22.5) W= 18502.5, p= 0.03 36/40/39/35 (18/21.75/17/24) χ2(3) = 4.61, p = 0.20
Nonsense_Mutation 3 (3.75) 3/3 (3/2) W= 19769.5, p= 0.25 3/2/3/2 (2/2.25/2/2) χ2(3) = 0.52, p = 0.92
nonstop mutation 0 (0) 0/0 (0/0) W= 20616.5, p= 0.47 0/0/0/0 (0/0/0/0) χ2(3) = 0.90, p = 0.83
RNA 4 (5) 4/4 (5/6) W= 22598, p= 0.23 4/6/4/3 (5/5.25/6/5) χ2(3) = 4.57, p = 0.21
Silent 12 (10) 12/12 (9/8) W= 20614, p= 0.66 12/11/13/12 (8/8/7.25/8.5) χ2(3) = 2.94, p = 0.40




A>C/T>G 5 (4.25) 4/5 (4/5) W= 18928, p= 0.07 5/5/5/5 (4/5/5/4) χ2(3) = 1.84, p = 0.61
A>G/T>C 10 (7) 9/10 (7/7) W= 20345, p= 0.51 10/9.5/10/10 (7/8.5/7.25/6) χ2(3) = 0.25, p = 0.97
A>T/T>A 6 (4) 5/6 (3/6) W= 19989.5, p= 0.34 6/6/6/6 (4/5.25/4.25/6.5) χ2(3) = 1.40, p = 0.71
C>A/G>T 11 (8) 10/11 (7/7) W= 19242, p= 0.11 9/11/13/11 (7/7/6/7) χ2(3) = 10.37, p = 0.02
C>G/G>C 7 (5) 6/7 (4/6) W= 20045.5, p= 0.36 7/7/7/5 (5/6/5/6) χ2(3) = 2.20, p = 0.53
C>T/G>A 19 (11) 18/20 (9/12) W= 19302.5, p= 0.13 19/19.5/20/18 (10/8.5/10.25/12.5) χ2(3) = 0.91, p = 0.82
Total sample low/high Wilcoxon rank sum test stages I / II / III / IV Kruskal-Wallis test




frame shift del 1 (3) 1/1 (2/2) W= 4293, p= 0.37 NA/1/1/1 (NA/2.5/2/1) χ2(3) = 3.1, p = 0.2
Frame_Shift_Ins 0 (2) 0/0 (1/1) W= 4091.5, p= 0.61 NA/0/0/0 (NA/1/1/0) χ2(3) = 2.32, p = 0.31
in-frame del 0 (2) 0/0 (1/1) W= 3786, p= 0.75 NA/1/0/0 (NA/1/1/1) χ2(3) = 4.37, p = 0.11
In_Frame_Ins 0 (0) 0/0 (0/0) W= 3831.5, p= 0.74 NA/0/0/0 (NA/0/0/0) χ2(3) = 0.644, p = 0.72
Missense_Mutation 33 (27) 34.5/33 (12.75/25.5) W= 4147.5, p= 0.59 NA/41.5/32/36 (NA/19/24/28.5) χ2(3) = 7.42, p = 0.02
Nonsense_Mutation 2 (3.75) 2.5/2 (3/3) W= 4042.5, p= 0.76 NA/3/2/2.5 (NA/3.5/3/3) χ2(3) = 0.98, p = 0.61
nonstop mutation 0 (0) 0/0 (0/0) W= 3710, p= 0.23 NA/0/0/0 (NA/0/0/0) χ2(3) = 3.85, p = 0.15
RNA 0 (5) 0/0 (1/1) W= 3828, p= 0.83 NA/0/0/0 (NA/0/1/1) χ2(3) = 3.54, p = 0.17
Silent 10 (10) 12/9 (6.75/8) W= 4314.5, p= 0.36 NA/14.5/9/10 (NA/10.5/8/10) χ2(3) = 8.54, p = 0.01




A>C/T>G 3 (4) 3/3 (2.25/4) W= 3959, p= 0.91 NA/5.5/3/3 (NA/3.75/4/4) χ2(3) = 8.71, p = 0.01
A>G/T>C 6 (5) 6.5/6 (6/5) W= 4088, p= 0.68 NA/7/6/7 (NA/9/4.5/6) χ2(3) = 4.88, p = 0.09
A>T/T>A 4 (4) 3.5/4 (5.5/4) W= 3863.5, p= 0.92 NA/5/3/3.5 (NA/3.75/4/5.75) χ2(3) = 4.03, p = 0.13
C>A/G>T 8 (8) 8.5/8 (8.25/8) W= 4276, p= 0.41 NA/12/8/8.5 (NA/8/8/6.75) χ2(3) = 7.25, p = 0.03
C>G/G>C 8 (9) 8/7 (7/9.5) W= 4020.5, p= 0.80 NA/12/7/9 (NA/3.5/8.5/9.5) χ2(3) = 8.58, p = 0.01
C>T/G>A 18 (11) 19/18 (12.25/11) W= 4084, p= 0.69 NA/20/18/18 (NA/13/11/13.75) χ2(3) = 1.19, p = 0.55
The descriptive statistics, and inferential statistics for each variant classiﬁcation, and transition and
transversion variant type across all three cancers and within each cancer.
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Table 3.6.3: Stage assignment frequencies stratiﬁed by grade
Total renal cell carcinoma ovarian carcinoma endometrial carcinoma
Total High grade Low grade Total High grade Low grade Total High grade Low grade Total High grade Low grade
IIA 2 1 1 0 0 0 2 1 1 0 0 0
IIB 4 4 0 0 0 0 4 0 4 0 0 0
IIC 8 3 5 0 0 0 8 5 3 0 0 0
IIIA 3 2 1 0 0 0 3 1 2 0 0 0
IIIB 14 13 1 0 0 0 14 1 13 0 0 0
IIIC 226 213 13 0 0 0 226 13 213 0 0 0
IV 50 43 7 0 0 0 50 7 43 0 0 0
StageI 198 74 124 197 123 74 0 0 0 1 1 0
StageIA 83 20 63 0 0 0 0 0 0 83 63 20
StageIB 70 20 50 0 0 0 0 0 0 70 50 20
StageIC 10 4 6 0 0 0 0 0 0 10 6 4
StageII 51 30 21 40 16 24 0 0 0 11 5 6
StageIIA 4 3 1 0 0 0 0 0 0 4 1 3
StageIIB 5 1 4 0 0 0 0 0 0 5 4 1
StageIII 112 83 29 112 29 83 0 0 0 0 0 0
StageIIIA 17 4 13 0 0 0 0 0 0 17 13 4
StageIIIC 14 10 4 0 0 0 0 0 0 14 4 10
StageIIIC1 8 7 1 0 0 0 0 0 0 8 1 7
StageIIIC2 11 10 1 0 0 0 0 0 0 11 1 10
StageIV 69 59 10 67 9 58 0 0 0 2 1 1
StageIVA 1 1 0 0 0 0 0 0 0 1 0 1
StageIVB 10 10 0 0 0 0 0 0 0 10 0 10
The rows denote the stage classiﬁcations in the Pan-Cancer clinical data across endometrial carcinoma,
ovarian carcinoma and renal cell carcinoma. The columns indicate the frequency of each of the cancer
stages in total, and stratiﬁed by broad cancer grade, and cancer type.
Table 3.6.4: Grade assignment stratiﬁed by tumour stage (low/high)
Total renal cell carcinoma ovarian carcinoma endometrial carcinoma
Total High-stage Low-stage Total High-stage Low-stage Total High-stage Low-stage Total High-stage Low-stage
G1 7 0 7 7 7 0 0 0 0 0 0 0
G2 198 60 138 170 132 38 28 6 22 0 0 0
G3 450 354 96 172 88 84 278 8 270 0 0 0
G4 68 58 10 67 10 57 1 0 1 0 0 0
Grade1 76 10 66 0 0 0 0 0 0 76 66 10
Grade2 74 10 64 0 0 0 0 0 0 74 64 10
Grade3 92 40 52 0 0 0 0 0 0 92 52 40
HighGrade 5 3 2 0 0 0 0 0 0 5 2 3
The rows denote the cancer grade classiﬁcations in the Pan-Cancer clinical data across endometrial
carcinoma, ovarian carcinoma and renal cell carcinoma. The columns indicate the frequency of each of the
cancer grades in total, and stratiﬁed by broad cancer stage, and cancer type.
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Table 3.6.5: Complete across cancer grade classiﬁcation models
Odds Ratio (OR) CI (2.5%, 97.5%) p-value
model AG (Intercept) 1.00 (0.84,1.20) 1
model AGP (Intercept) 0.43 (0.27, 0.65) 8.68× 10−5
model AGPV gender (male) 2.22 (1.29, 3.87) 4.43× 10−3
TP53 12.25 (6.90, 22.47) 2.0× 10−16
ARID1A 2.13 (0.97, 4.70) 0.06
CTCF 0.36 (0.08, 1.18) 0.13
CTNNB1 0.09 (0.01, 0.33) 1.69× 10−3
PIK3R1 0.41 (0.15, 1.04) 0.069
model AGV (Intercept) 0.98 (0.70,1.36) 0.88
‘C>G/G>C‘ 1.06 (1.03,1.10) 8.21× 10−4
frame shift del 0.88 (0.83,0.93) 6.13× 10−6
model AGS (Intercept) 0.30 (0.21,0.42) 2.79× 10−12
model AGSV stage (high) 9.38 (6.18,14.48) 2.0× 16
gender (male) 1.45 (0.90,2.34) 0.13
model AGSP (Intercept) 0.24 (0.15,0.35) 1.34× 10−11
model AGSPV stage (high) 4.60 (2.88,7.43) 2.64× 10−10
gender (male) 2.23 (1.33,3.78) 2.52× 10−3
TP53 6.32 (3.56,11.44) 5.35× 10−10
CTNNB1 0.10 (0.02,0.38) 3.45× 10−3
model AGT (Intercept) 0.15 (0.04,0.52) 2.88× 10−3
model AGTV age 1.02 (0.1,1.03) 0.11
gender (male) 2.73 (1.47,5.19) 1.72× 10−3
tumour type (OV) 14.86 (7.53,30.66) 4.19× 10−14
tumour type (UCEC) 0.98 (0.52,1.88) 0.95
model AGTP (Intercept) 0.37 (0.22,0.62) 1.95× 10−4
model AGTPV gender (male) 2.56 (1.38,4.86) 3.29× 10−3
tumour type (OV) 2.46 (0.95,6.36) 0.06
tumour type (UCEC) 0.62 (0.31,1.25) 0.18
TP53 7.40 (3.60,15.73) 8.84× 10−08
model AGST (Intercept) 0.12 (0.03,0.42) 1.25× 10−3
model AGSTV age 1.01 (0.99,1.03) 0.33
stage (high) 4.55 (2.78,7.52) 2.27× 10−09
gender (male) 2.75 (1.43,5.47) 3.03× 10−3
tumour type (OV) 6.36 (2.99,13.92) 2.22× 10−6
tumour type (UCEC) 1.24 (0.63,2.48) 0.54
model AGSTP (Intercept) 0.18 (0.11,0.26) 2.0× 10−16
model AGSTPV stage (high) 4.89 (3.08,7.84) 2.61× 10−11
gender (male) 2.89 (1.74,4.84) 4.76× 10−05
TP53 7.61 (4.35,13.64) 2.91× 10−12
A= age, G= gender, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Table 3.6.6: Complete across cancer stage classiﬁcation models
Odds Ratio (OR) CI (2.5%, 97.5%) p-value
model AG (Intercept) 1.2 (0.99,1.46) 0.07
gender (male) 0.54 (0.37,0.77) 7.80× 10−4
model AGP (Intercept) 0.68 (0.54,0.87) 1.74× 10−3
TP53 10.05 (6.45,16.13) 2.0× 10−16
ARID1A 0.52 (0.20,1.23) 0.15
CHD3 0.27 (0.04,1.19) 0.12
PIK3CA 0.26 (0.12,0.51) 1.5× 10−4
PIK3R1 0.24 (0.09,0.55) 1.58× 10−3
model AGV (Intercept) 2.12 (1.63,2.77) 2.56× 10−8
gender (male) 0.50 (0.34,0.73) 4.37× 10−4
frame shift del 0.91 (0.85,0.97) 4.32× 10−3
in-frame del 0.85 (0.75,0.94) 4.41× 10−3
nonstop mutation 0.86 (0.68,1.01) 0.10
model AGPV (Intercept) 0.84 (0.61,1.14) 0.25
frame shift del 0.95 (0.89,1.00) 0.06
TP53 8.94 (5.71,14.36) 2.0× 10−16
ARID1A 0.52 (0.20,1.23) 0.15
PIK3CA 0.24 (0.12,0.47) 4.75× 10−5
PIK3R1 0.24 (0.09,0.56) 1.72× 10−3
model AGGr (Intercept) 0.33 (0.23,0.45) 2.67× 10−11
grade (high) 9.16 (6.16,13.85) 2.0× 10−16
gender (male) 0.40 (0.26,0.60) 1.35× 10−5
model AGGrP (Intercept) 0.37 (0.24,0.57) 5.15× 10−6
grade (high) 4.72 (3.00,7.52) 3.33× 10−11
gender (male) 0.59 (0.35,0.98) 4.39× 10−2
TP53 5.40 (3.12,9.48) 2.67× 10−9
FNDC1 0.16 (0.03,0.69) 1.97× 10−2
PIK3CA 0.21 (0.10,0.42) 1.88× 10−5
PIK3R1 0.24 (0.09,0.57) 2.06× 10−3
model AGGrV (Intercept) 0.56 (0.38,0.82) 3.08× 10−3
model AGGrPV grade (high) 8.30 (5.53,12.68) 2.0× 10−16
gender (male) 0.39 (0.25,0.60) 1.59× 10−5
frame shift del 0.92 (0.854,0.982) 0.01
in-frame del 0.90 (0.79,1.01) 0.09
nonstop mutation 0.85 (0.68,1.018) 0.11
model AGT (Intercept) 0.20 (0.07,0.59) 3.44× 10−3
model AGTP age 1.02 (1.00,1.04) 0.04
model AGTV tumour type (OV) 27.31 (14.37,57.72) 2.0× 10−16
model AGTPV tumour type (UCEC) 0.41 (0.25,0.65) 2.02× 10−4
model AGGrT (Intercept) 0.10 (0.03,0.32) 9.8× 10−5
model AGGrTP age 1.01 (0.10,1.03) 0.12
model AGGrTV grade (high) 4.50 (2.89,7.11) 5.14× 10−11
model AGGrTPV tumour type (OV) 20.50 (10.6,43.87) 2.0× 10−16
tumour type (UCEC) 0.51 (0.30,0.84) 8.91× 10−3
A= age, G= gender, Gr= grade, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Table 3.6.7: Cancer grade prediction models within cancers
Odds Ratio (OR) CI (2.5%, 97.5%) p-value
model WA (Intercept) 0.07 (0.01,0.58) 0.017
model WAV age 1.04 (1.01,1.08) 0.016
model WAP (Intercept) 0.92 (0.43,1.97) 0.84
model WAPV PTEN 0.37 (0.15,0.90) 0.03
TP53 13.05 (4.39,48.71) 1.87× 10−5
endometrial
carcinoma model WAGS (Intercept) 0.05 (0.00,0.42) 8.05× 10−3
model WAGSV age 1.05 (1.01,1.08) 0.02
stage (high) 3.37 (1.49,8.04) 4.39× 10−3
model WAGSP (Intercept) 0.77 (0.34,1.71) 0.52
model WAGSPV stage (high) 2.06 (0.77,5.57) 0.15
PTEN 0.38 (0.15,0.94) 0.04
TP53 11.78 (3.91,44.28) 4.64× 10−5
Odds Ratio (OR) CI (2.5%, 97.5%) p-value
renal cell








model WAGS (Intercept) 0.40 (0.23,0.66) 5.42× 10−4
model WAGSP stage (high) 5.05 (2.89,9.06) 2.69× 10−8
model WAGSV gender (male) 1.53 (0.87,2.73) 0.15
model WAGSPV
Odds Ratio (OR) CI (2.5%, 97.5%) p-value





carcinoma model WAGS (Intercept) 0.00 (NA,7.76× 1090) 0.99
model WAGSP stage (high) 53890100.00 (0,NA) 0.99
model WAGSV
model WAGSPV
W= within cancer, A= age, G= gender, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Table 3.6.8: Cancer stage prediction models
within cancers
Odds Ratio (OR) CI (2.5%, 97.5%) p-value





carcinoma model WAGGr (Intercept) 0.37 -2.68 7.29× 10−3
model WAGGrP grade (high) 5.76 3.61 3.04× 10−4
model WAGGrV
model WAGGrPV
Odds Ratio (OR) CI (2.5%, 97.5%) p-value
model WA (Intercept) 0.35 (0.09,1.25) 0.11
model WAP age 1.02 (1.0,1.04) 0.10
model WAV
model WAPV
model WAG (Intercept) 0.35 (0.09,1.25) 0.11
renal model WAGP age 1.02 (1.00,1.04) 0.10
cell model WAGV
model WAGPV
model WAGGr (Intercept) 0.12 (0.03,0.49) 4.23× 10−3
model WAGGrP age 1.02 (0.99,1.04) 0.17
model WAGGrV grade (high) 5.98 (3.34,11.06) 4.41× 10−9
model WAGGrPV
Odds Ratio (OR) CI (2.5%, 97.5%) p-value





carcinoma model WAGGr (Intercept) 0.00 (NA,2.33× 10154) 1.00
model WAGGrP grade (high) 208167800.000 (0,NA) 1.00
model WAGGrV
model WAGGrPV
W= within cancers, A= age, G= gender, Gr= grade, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Table 3.6.9: Endometrial carcinoma grade and
stage classiﬁcation statistics
Sensitivity Speciﬁcity Accuracy Positive predictive value (PPV) Area Under the Curve (AUC)
Grade
model WA 0.59 0.62 0.62 0.37 0.61
model WAP 0.69 0.92 0.86 0.76 0.83
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.69 0.92 0.86 0.76 0.83
model WAGS 0.66 0.68 0.68 0.44 0.75
model WAGSP 0.75 0.91 0.86 0.75 0.88
model WAGSV 0.66 0.68 0.68 0.44 0.75
model WAGSPV 0.75 0.91 0.86 0.27 0.88
Stage
model WA 0.50 0.50 0.50 NA 0.50
model WAP 0.50 0.50 0.50 NA 0.50
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.50 0.50 0.50 NA 0.50
model WAGGr 0.52 0.73 0.70 0.22 0.63
model WAGGrP 0.52 0.73 0.70 0.22 0.63
model WAGGrV 0.52 0.73 0.70 0.22 0.63
model WAGGrPV 0.52 0.73 0.70 0.22 0.63
W= within cancers, A= age, G= gender, Gr= grade, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Table 3.6.10: Renal cell carcinoma grade and
stage classiﬁcation statistics
Sensitivity Speciﬁcity Accuracy Positive predictive value (PPV) Area Under the Curve (AUC)
Grade
model WA 0.50 0.50 0.50 NA 0.50
model WAP 0.50 0.50 0.50 NA 0.50
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.50 0.50 0.50 NA 0.50
model WAG 0.50 0.50 0.50 NA 0.50
model WAGP 0.50 0.50 0.50 NA 0.50
model WAGV 0.50 0.50 0.50 NA 0.50
model WAGPV 0.50 0.50 0.50 NA 0.50
model WAGS 0.59 0.81 0.66 0.87 0.75
model WAGSP 0.59 0.81 0.66 0.87 0.75
model WAGSV 0.59 0.81 0.66 0.87 0.75
model WAGSPV 0.59 0.81 0.66 0.87 0.75
Stage
model WA 0.55 0.63 0.60 0.43 0.60
model WAP 0.50 0.50 0.50 NA 0.50
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.50 0.50 0.50 NA 0.50
model WAG 0.55 0.63 0.60 0.43 0.60
model WAGP 0.55 0.63 0.60 0.43 0.60
model WAGV 0.55 0.63 0.60 0.43 0.60
model WAGPV 0.55 0.63 0.60 0.43 0.60
model WAGGr 0.72 0.61 0.65 0.48 0.72
model WAGGrP 0.72 0.61 0.65 0.48 0.72
model WAGGrV 0.72 0.61 0.65 0.48 0.72
model WAGGrPV 0.72 0.61 0.65 0.48 0.72
W= within cancers, A= age, G= gender, Gr= grade, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
95
Figure 3.6.2: Endometrial carcinoma stage classiﬁcation ROC
W= within cancers, A= age, Gr= grade, P= proteins. Both the WA, and WAP models were uninformative.
By including grading information, stage prediction was improved in model WAGr.
Figure 3.6.3: Ovarian carcinoma ROC curves
(a) ovarian carcinoma grade classiﬁca-
tion baseline plus protein features
(b) ovarian carcinoma stage classiﬁcation
plus protein features
W= within cancers, A= age, Gr= grade, S= Stage, P= proteins. Models WA, and WAP were
non-informative when predicting grade, and stage. By adding stage and grade features the prediction of
cancer stage and grade respectively was improved. Where protein features were added to the analysis
(models WAP, WASP, and WAGrP) no protein features were included in ﬁnal models after AIC-based model
selection.
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Figure 3.6.4: Renal carcinoma stage classiﬁcation ROC curves
(a) renal carcinoma grade classiﬁcation
baseline plus protein features
(b) renal carcinoma stage classiﬁcation
baseline plus protein features
W= within cancers, A= age, G= gender, Gr= grade, S= Stage, P= proteins. Models WA, WAG, WAP,
and WAGP were non-informative when predicting grade, and stage. By adding stage and grade features the
prediction of cancer stage and grade respectively was improved. Where protein features were added to the
analysis (models WAP, WAGP, WAGSP, WASP, and WAGGrP) no protein features were included in ﬁnal
models after AIC-based model selection.
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Table 3.6.11: Ovarian carcinoma grade and
stage classiﬁcation statistics
Sensitivity Speciﬁcity Accuracy Positive predictive value (PPV) Area Under the Curve (AUC)
Grade
model WA 0.50 0.50 0.50 NA 0.50
model WAP 0.50 0.50 0.50 NA 0.50
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.50 0.50 0.50 NA 0.50
model WAGS 0.97 0.22 0.94 0.97 0.60
model WAGSP 0.97 0.22 0.94 0.97 0.60
model WAGSV 0.97 0.22 0.94 0.97 0.60
model WAGSPV 0.97 0.22 0.94 0.97 0.60
Stage
model WA 0.50 0.50 0.50 NA 0.50
model WAP 0.50 0.50 0.50 NA 0.50
model WAV 0.50 0.50 0.50 NA 0.50
model WAPV 0.50 0.50 0.50 NA 0.50
model WAGGr 0.92 0.40 0.91 0.99 0.66
model WAGGrP 0.92 0.40 0.91 0.99 0.66
model WAGGrV 0.92 0.40 0.91 0.99 0.66
model WAGGrPV 0.92 0.40 0.91 0.99 0.66
W= within cancers, A= age, G= gender, Gr= grade, S= Stage, T= tumour type (endometrial, ovarian, renal), P= proteins, V= variant frequency
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Chapter 4
Predicting cancer types using
TCGA exome sequence data and
Random Forest analysis.
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The PanCancer analyses have focused mainly on ﬁnding novel subgroups of cancers
(Hofree et al., 2013; Ciriello et al., 2013). I decided to discriminate between known ’high-
order’ cancer classes corresponding to ﬁve tissue types in the PanCancer exome sequence
dataset (adenocarcinoma, squamous cell carcinoma, urothelial carcinoma, a blood cancer,
and brain cancer).
In chapter 4.1 I use a Random Forest (Breiman, 2001) to identify the mutated genes
that discriminate between the ﬁve cancer types based exome sequence data. Based upon
this work I adopted a similar Random Forest approach in chapter 4.2 to build a classiﬁer to
predict the tissue of origin of samples in the PanCancer dataset. This approach could be
used to create a tool to assign a cancer of unknown primary origin (CUP) a putative tissue
of origin. In the future it may aid clinicians decide between treatment options for patients
with CUP. Stage IV CUPs represent 3-5 percent of cancer diagnoses, and patient outcomes
are typically poor (Pavlidis & Pentheroudakis, 2012). Although gene-expression models have
been developed to predict the origin of CUPs (Tothill et al., 2005), there is no model based
on whole exome sequence data.
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Chapter 4.1
Using exome sequence data and
Random Forest analysis to identify
the functional mutation patterns of
ﬁve high-order cancer types
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4.1.1 Introduction
The Pan-Cancer Analysis of the Cancer Genome Atlas (TCGA) data was an important
milestone for the analysis of genomic cancer data. Across twelve cancer types six diﬀerent data
types were collected, including tumour/normal exome sequence, gene expression microarray
data, DNA methylation array data, microRNA data, copy number variant data, protein
expression array data, and more than one hundred clinical variables. Standardising analysis
pipelines across the 12 cancer types has allowed researchers to discover new cancer subtypes
deﬁned across cancers. Most of the cross-cancer analyses have focused on the deﬁnition
of new cancer subtypes by grouping samples according to common molecular alterations
including somatic single nucleotide variants (SNVs), epigenetic modiﬁcations, copy number
variants and gene expression changes (Ciriello et al., 2013; Lawrence et al., 2014; Hofree
et al., 2013).
Multiple approaches have been used to analyse this rich data set, often employing the
integration of diﬀerent data types. The Dendrix algorithm (Leiserson et al., 2013a), was
applied to the exome sequence data to identify the genes that were mutually exclusively
mutated across the 12 cancer types. The ENCAPP framework (Das et al., 2015) used
an elastic net approach to integrate the molecular data for breast, ovarian and colorectal
cancers and uncover prognostic biomarkers. Ciriello et al. (2013) used hierarchical clustering
of selected functional events from somatic mutations, copy-number variants, and DNA
methylation events to discover that the twelve Pan-Cancer cancer types could be assigned to
two groups, characterised by either high numbers of SNVs, or high numbers of copy number
alterations. Network-based stratiﬁcation (Hofree et al., 2013) of the Pan-Cancer tumour
types identiﬁed new subclasses of ovarian, uterine, and lung adenocarcinoma cancers that
showed diﬀerent survival patterns based upon somatic mutation proﬁles that had undergone
a network smoothing step.
Relatively little attention has been paid to the diﬀerences between high-order cancer
types, which may share mutations that discriminate them from other cancer types. The
multitude of human cancers can be divided in to classes based on the tissue type in which
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they originate. In the Pan-Cancer dataset the twelve cancers can be divided in to ﬁve classes;
adenocarcinomas, squamous cell carcinomas, urothelial carcinomas, haematological cancers
and cancers of the central nervous system.
Adenocarcinomas originate from secretory cells in epithelial glandular tissue. Due to the
ubiquitous nature of secretory cells in humans these tumours are very diverse.
Squamous cell carcinomas also arise from epithelial cells, but unlike adenocarcinomas
these tumours do not originate from secretory cells. They are also diverse in terms of
histology, prognosis, aggression, and response to treatment.
Urothelial carcinomas arise in the complex transitional epithelial membranes encapsulating
the lumen of organs of the urinary system.
Haematological cancers are found in the blood bone marrow and include Acute Myeloid
Leukemia (AML).
Cancers of the central nervous system (CNS) include glioblastoma multiforme (GBM),
which is typically highly aggressive. It is diﬃcult to conduct histopathological analysis
on this class of tumours due to their location.
The cancers that arise from similar tissue types may share somatic mutations that contribute
to cancer progression and discriminate them from cancers originating from other tissue types.
In this study I have taken a high-order view of the 12 cancers of the Pan-Cancer analysis. I
used somatic mutation data derived from paired tumour / normal whole exome sequencing
to identify the proteins carrying functional mutations that can discriminate between the ﬁve
tissue types (adenocarcinomas, squamous cell carcinomas, urothelial malignancies, blood
cancers, and cancers of the central nervous system).
I conducted 10 pairwise comparisons to discriminate between the ﬁve cancer types. For
each comparison I split the sample with two thirds becoming a training set and one third
becoming a test set. I created Random Forest (Breiman, 2001) classiﬁcation models using
protein features and the clinical features; age, gender and cancer stage (where available). I
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tested the ability of the models derived from each comparison to discriminate between the
two cancer types in the test set. In addition, I identiﬁed the protein sets that discriminated
between the each of the cancer types.
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4.1.2 Methods
4.1.2.1 The data set
The Mutation Annotation Files (MAFs), containing the somatic mutation information for
all 12 Pan-Cancer cancers were downloaded from Sage Synapse (accession syn1710680) on
October third 2013 along with the clinical data ﬁles. I retained 3079 samples for which exome-
sequence, age, gender, and (where appropriate) tumour stage data were available. After I
removed the gender speciﬁc adenocarcinomas (ovarian carcinoma, endometrial carcinoma,
and breast invasive ductal carcinoma) from further analysis, 1739 samples remained.
Twenty three cancer stage categories were used to describe the cancer stage of the
samples. I collapsed the 23 categories in to 4 stages (I, II, III and IV). Cancer stage was not
available for glioblastoma, or AML, and was not included in any comparison for either of
those cancers.
4.1.2.2 Deﬁnition of the ﬁve cancer high-order cancer types
The 12 cancers were assigned to ﬁve classes according to their tissue type of origin, which
represented functionally similar cancers. In this study adenocarcinomas consisted of breast
adenocarcinoma (BRCA), kidney renal clear-cell carcinoma (KIRC), colon and rectum
adenocarcinoma (COADREAD), lung adenocarcinoma (LUAD), and ovarian carcinoma (OV).
The squamous cell carcinoma group consisted of head and neck squamous cell carcinoma
(HNSC), and lung squamous cell carcinoma (LUSC). Bladder urothelial carcinoma (BLCA)
represented the urothelial carcinomas, Acute myeloid leukaemia (AML) represented the
haematological malignancies, and glioblastoma (GBM) represented the tumours of the CNS.
The numbers of samples assigned to each of the ﬁve cancer classes are shown in Table
4.1.2.1. The urothelial cancer type contained 89 samples and was considerably smaller than
the other classes.
The assignment of the twelve Pan-Cancer tumour types to the ﬁve high-order classes,
and the availability of cancer stage information is shown in supplementary table 4.1.6.1.
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Table 4.1.2.1: High-order cancer type assignment
tissue type cancer type N
adenocarcinoma
colorectal adenocarcinoma 219
renal clear cell carcinoma 417
lung adenocarcinoma 155
squamous cell carcinoma head and neck squamous cell carcinoma 260lung squamous cell carcinoma 172
urothelial carcinoma bladder urothelial carcinoma 89
haematological malignancy acute myeloid leukemia 152
central nervous system glioblastoma 275
The cancer types are assigned to the tissue type with which they share a row. The frequency of samples for
each cancer type is shown in column N.
4.1.2.3 Creating the binary mutation matrix
I removed ‘silent’ mutations from the MAF ﬁle. I used the union of the lists of functionally
mutated proteins across all samples to generate a binary matrix M of proteins P by samples
S . Each element in M , M [p, s], was set to 0 if there was no protein coding mutation for
protein p and sample s, or set to 1 if at least one protein coding mutation was present for
protein p and sample s.
4.1.2.3.1 Mutated protein feature selection
I used a simple heuristic to reduce the number of proteins used as features in the Random
Forest models. I retained a protein feature if it carried at least one protein coding mutation
in ﬁve percent or more of any cancer class in the training set. The numbers of proteins taken
forward for model building across all Random Forest models are shown in Table 4.1.2.2.
4.1.2.4 Training set and test set deﬁnition.
When creating classiﬁcation models it is important that the model can be tested in an
independent set of samples that were not used to create the model. This allows researchers
to gain insight in to how the models perform on new data. For each of the ten pairwise
comparisons two thirds of the samples were assigned to the training set, which I used for
model building, and one third were assigned to the test set. I down-sampled the majority
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cancer class to be of equal size as the minority cancer class. The majority cancer class
samples removed during down-sampling were re-assigned to the test set. Table 4.1.2.2 shows
the number of samples in the training and test sets across the ten Random Forest models.
Table 4.1.2.2: Number of proteins used for model building, and training and test set sizes.
Comparison N proteins after ﬁlter Training set size Test set size
adenocarcinoma, squamous 1351 576 647
adenocarcinoma, urothelial 741 118 762
squamous, urothelial 910 118 403
adenocarcinoma, GBM 1236 366 700
squamous, GBM 621 366 341
urothelial, GBM 476 118 246
adenocarcinoma, leukemia 646 204 739
squamous, leukemia 824 204 380
urothelial, leukemia 462 118 123
GBM, leukemia 32 204 223
N proteins after ﬁlter: The number of proteins which were functionally mutated in ﬁve percent of the
training set samples of either class and taken forward for model building.
Training set size: The number of samples used for model building. Two thirds of the minority class samples
were assigned to the training set with an equal number of majority class samples.
Test set size: The number of samples assigned to the test set. No samples were used for model building
and model evaluation.
4.1.2.5 Random Forest prediction models
4.1.2.5.1 Random Forest model building
The Random Forest algorithm builds an ensemble classiﬁer using a collection, or forest, of
decision trees. Each decision tree provides a class prediction, or vote, for each sample. For
each sample, the class prediction of the Random Forest model is the modal class across all
votes in the forest.
For each comparison the training samples were divided in to a learning set and an out of
bag set. The learning set and out of bag set can be considered as an internal training set and
test set. To build each tree, a bootstrapped (Efron & Gong, 1983) sample of the learning
set is used. A tree is learned by splitting the set of samples based on the feature, from a
set of randomly selected features, that best partitions the samples in to their respective
classes. This process continues until each subset of samples after a decision are of the same
class and is repeated T times to create a forest of T trees. The out of bag set is used to
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measure the classiﬁcation accuracy of the forest, and the importance of each feature. The
out of bag samples are run through each tree in the forest. The feature importance is the
mean classiﬁcation accuracy of all decisions where the feature was used, and provides a
summary of the ability of each feature to correctly classify the out of bag samples across
the forest. Many diﬀerent measures of feature importance are available including the Gini
index (Breiman, 2001) and F-measure. However, I used classiﬁcation accuracy to indicate
feature importance because the the Gini index overestimates the importance of correlated,
but uninformative features (Nicodemus & Malley, 2009).
4.1.2.5.2 Cross Validation
The success of a Random Forest model is partly dependent on the deﬁnition of the training
set and test set. If suﬃcient noise exists in the training data, the Random Forest algorithm
will model that noise. While the model will perform well when the training set is re-classiﬁed,
the classiﬁcation performance in new data will not reach that of the training set. The
Random Forest model will be over-ﬁtted to the training set. I have tried to measure, and
alleviate any over-ﬁtting of the Random Forest models by using k-fold cross-validation.
The training set was divided in to k equally sized sub-samples called folds. A single fold
is used as an out-of-bag set in order to measure the performance of the model constructed
using the remaining folds. This process is performed k times in total, where each fold is
treated as the out-of-bag set once, and all remaining folds are treated as the learning set;
In this study k = 10. After using a k-fold cross-validation method, random noise resulting
from the deﬁnition of each fold may still cause some over-ﬁtting of the ﬁnal model. Any
remaining bias in the ﬁnal classiﬁcation models may be alleviated by repeating the ten-fold
cross-validation using alternative folds. I repeated the ten-fold cross validation ﬁve times.
By randomly assigning samples to ten folds for each cross validation iteration, the result
was a 5 x ten-fold cross validation process. The performance of the Random Forest model
building process was measured as the average classiﬁcation accuracy across the resultant 50
classiﬁcation models.
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4.1.2.5.3 Recursive Feature Elimination
By using a recursive feature elimination step I was able to identify the number of features
that lead to the best performing Random Forest model, and which were the best performing
features. The recursive feature elimination step worked by assigning a number of features
f ∈{1, 2, 3, · · · , 100, 200} to be used for model building in each cross-validation run. Within
each cross-validation run, the top f performing features were used to create a Random Forest
model, the classiﬁcation accuracy of which was used to select best performing f across all
50 cross-validation runs as measured by mean classiﬁcation accuracy.
The best performing f may not provide the most parsimonious model. A classiﬁcation
accuracy similar to that of the best performing model might be achieved by using smaller
number of features. In this investigation I chose to use the model composed of the smallest
set of fm features that performed with a mean classiﬁcation accuracy within two percent of
the best performing set of f features.
4.1.2.5.4 Summary of Random Forest model building
In brief I used a ﬁve x 10-fold cross-validation design using recursive feature elimination to
identify the top f features to be used in a ﬁnal Random Forest Model. Across each of the 50
(5 x 10) cross validation runs I created Random Forest models that ranked features in order
of their classiﬁcation accuracy and then created additional Random Forest models using
subsets of those features of sizes f ∈{1, 2, 3, · · · , 100, 200}. The number of features to be
used in the ﬁnal Random Forest model was the fm that performed with a mean classiﬁcation
accuracy within two percent of the best performing f across 50 cross validation runs.
The ﬁnal Random Forest model for each comparison was built using the entire training
set using the top fm features and was tested in the test set. For each comparison I built
Random Forests consisting of 500 trees, the number of features sampled at each decision
point was equal to the square root of the number of features submitted to the Random
Forest algorithm. I used mean classiﬁcation accuracy as the measure of feature importance.
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For each of the 10 pairwise comparisons among the 5 cancer classes the above analysis pipeline was used.
First, the dataset was split into a two thirds training set and one third validation set. The majority class was
down-sampled to equal the minority class size. 5 x 10 fold cross validation was then used to determine the
number of features S and the list of features P to be used to build the ﬁnal Random Forest model
according to mean classiﬁcation accuracy across the 50 folds. A ﬁnal Random Forest classiﬁer was
constructed using the list of features P using the entire training set. The ﬁnal classiﬁer was used to predict
the classes of the validation set in order to assess the real-world performance of the classiﬁer.
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4.1.2.5.5 Measuring model performance
I used the area under the curve (AUC) statistic to measure and compare the performance of
each classiﬁcation model along with model sensitivity, speciﬁcity and classiﬁcation accuracy
in the test set. The sensitivity was the proportion of correct positive class classiﬁcations
and the speciﬁcity was the proportion of correct negative class classiﬁcations. The positive
predictive value (PPV) and negative predictive value (NPV) were not appropriate to measure
the discriminative ability of the classiﬁcation models. The PPV and NPV are inﬂuenced by
the prevalence of the positive class. As positive class prevalence increases in the test set,
PPV increases and NPV decreases. Sensitivity, speciﬁcity and accuracy are not inﬂuenced
by positive class prevalence and were used to measure the discriminative power of the
classiﬁcation models.
4.1.2.5.6 Interpretation of the Random Forest models
The Random Forest algorithm outputs a classiﬁcation model that consists of a forest of T
(500 in this case) trees. The complete description of the forest, is not suitable for human
interpretation: Random Forest is a black box technique for sample classiﬁcation. Following
Renner et al. (2013) I used a heat map to broadly summarise the Random Forest models.
The randomForest implementation in R provides summary information about the similarity
of the samples using the proximity measure. The proximity is a metric measure of the
pairwise distance between samples according to the number of times each sample pair is
classiﬁed by identical decisions across the forest. The localImp measure stores information
that represents the similarity of the features in the forest according to the importance of
each feature for the classiﬁcation of each sample. I created heat maps of the training set
data for each comparison using these two pieces of information. The samples were ordered
based on hierarchical clustering of the proximity measure using the Ward method (Ward,
1963). The features were also ordered using hierarchical clustering of the localImp measure
using the Ward (Ward, 1963) method. The heat maps were intended to provide some insight
in to the construction of the Random Forest models (Figures 4.1.6.2 to 4.1.6.11).
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4.1.2.5.7 Gene set analysis of the discriminating features
The Random Forest output included a measure of the importance of each model feature. For
each Random Forest model containing more than 10 protein features I investigated which
disease pathways, if any, were enriched for the protein features included in the model. I
used the WebGestalt (Wang et al., 2013) platform to test for the enrichment of the KEGG
Disease Pathways (Kanehisa & Goto, 2000; Kanehisa et al., 2014) with the Random Forest
model protein features using Fisher’s Exact Test, a False Discovery Rate (FDR) (Benjamini
& Hochberg, 1995) q-value <0.1, and using the Entrez gene (Maglott, 2004) protein coding
gene set as the background. Pathway gene sets in which more than two genes were covered
by the Random Forest model gene list were considered.





The age of individuals diﬀered across the ﬁve cancer classes (F (4, 3044) = 15.22, p = 2.49×
10−12) (Table 4.1.3.1). Using t-tests AML samples were found to be signiﬁcantly younger
than samples from all other classes (adenocarcinoma (t(184.45) = −5.75, p = 3.66× 10−8),
glioblastoma (t(250.02) = −3.42, p = 7.34× 10−4), squamous (t(204.12) = −5.47, p =
1.3× 10−7), and urothelial (t(231.8) = −5.94, p = 1.03× 10−8)). The gender distribution
was unbalanced across the cancer types (χ2(71) = 35.97, p = 2.94× 10−7) (Table 4.1.3.1).
All sixteen mutation type frequencies and transition and transversion frequencies diﬀered
across the ﬁve cancer classes as measured using the Kruskal-Wallis test (Table 4.1.3.2) at the
Bonferroni adjusted signiﬁcance threshold (p<0.0016 : 0.05 / 32 tests stratiﬁed by cancer
type and stage). When stratiﬁed by cancer stages (I,II,III, and IV) there were no diﬀerences
across the ten mutation type frequencies at the Bonferroni signiﬁcance threshold (p<0.0016)
(Table 4.1.3.2). However, the A>G and T>C transition frequency diﬀered across the cancer
stages (χ2(3) = 46.12, p = 5.34× 10−10), as did the A>T and T>A transversion frequency
(χ2(3) = 16.18, p = 1.04× 10−3) (Table 4.1.3.2).
Table 4.1.3.1: High-order cancer type demographics
Total sample adenocarcinoma GBM leukaemia squamous urothelial statistical tests
N 1739 791 275 152 432 89
mean age (sd) 62.96 (12.67) 64.02 (12.2) 61.21 (12.54) 55.98 (16.39) 63.84 (11.34) 66.66 (11.42) F (4, 3044) = 15.22, p = 2.49× 10−12
gender N (f/m) 655/1084 337 / 454 101 / 174 72 / 80 119 / 313 26 / 63 χ2(71) = 35.97, p = 2.94× 10−7
The age and gender of samples is biased across the cancer classes, as shown by the anova and chisquare
results in the statistical tests column.
4.1.3.2 Random Forest prediction models
I used exome sequence derived protein features and clinical features (age, gender and stage
where available) using Random Forest with recursive feature elimination and ﬁve x 10-fold
cross validation to identify sets of proteins that discriminate between 5 cancer classes across
10 pairwise comparisons.

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1.3.1) except for that of the comparison between squamous cell carcinomas and urothelial
cell carcinomas (Table 4.1.3.3, and Figure 4.1.3.1). For all classiﬁcation models, except for
the comparison between squamous cell carcinomas and urothelial carcinomas, and between
adenocarcinomas and squamous cell carcinomas the classiﬁcation speciﬁcity exceeded the
sensitivity. In most models when a sample was classiﬁed as the positive class, I could be
conﬁdent the sample indeed belonged to the positive class.
The model that discriminated between adenocarcinomas and urothelial carcinomas was
composed of three features ( the genes APC, VHL, and cancer stage), and performed with
a high sensitivity of 0.967 (Table 4.1.3.3). The squamous cell carcinoma and urothelial
carcinoma classes were the most diﬃcult to distinguish as shown by the AUC of 0.771 (Table
4.1.3.3, and Figure 4.1.3.1). One hundred features were included in the model comparing
the squamous cell carcinomas and urothelial carcinomas: together with the lowest AUC, this
may indicate that overﬁtting had occurred. In addition, mean classiﬁcation accuracies that
were negative were recorded for the six least important features CHD7, MLL3, DNAH17,
OR6T1, MTMR2, and PLCE1.
For each comparison the model features ranked according to their mean classiﬁcation
accuracy in the training set are shown in Table 4.1.3.4. APC, and VHL were part of all models
that included adenocarcinomas. TP53 was part of all models that compared squamous cell
carcinomas. PTEN, and EGFR were included in all glioblastoma models, and TTN was part
of every AML model. There were no proteins that distinguished urothelial carcinomas from
all other cancer types.
By inspecting the heatmaps generated from the Random Forest training data, some
insight can be gained in to how the features in the models separated the classes in each
comparison. When comparing adenocarcinomas and squamous cell carcinomas, VHL and
APC were mutated only in adenocarcinomas, and KRAS mutations appeared to be only
in the squamous cell carcinomas (Figure 4.1.6.2 on page 128). Among the other features
included in the model, more complex interactions may explain their classiﬁcation. For the
adenocarcinoma and urothelial carcinoma comparison again VHL and APC were mutated
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only among adenocarcinomas, and the stage I cancers were all adenocarcinomas (Figure
129). When comparing urothelial carcinomas and glioblastomas ATM, and MLL2, were
mutated only in urothelial carcinomas, and TTN, ARID1A, and MLL3 mutations were most
common among the urothelial carcinomas. However, EGFR mutations were exclusive to
glioblastomas, and PTEN mutations were almost exclusive to glioblastoma (Figure 4.1.6.7
on page 133). For the comparison between squamous cell carcinomas and AML all of the
genes were most frequently mutated in the squamous cell carcinomas, with AML mutations
only occurring in TTN, TP53, and CDKN2A (Figure 4.1.6.9 on page 135). Across all of the
AML comparisons it appeared that the mutated genes that best characterised AML were
RUNX1, DNMT3A, NPM1, and FLT3 .
Table 4.1.3.3: Random Forest classiﬁcation model statistics
Positive class Negative class Sensitivity Speciﬁcity Accuracy AUC
adenocarcinoma squamous 0.85 0.83 0.84 0.88
adenocarcinoma urothelial 0.71 0.97 0.72 0.86
squamous urothelial 0.79 0.53 0.77 0.77
adenocarcinoma GBM 0.78 0.94 0.80 0.92
squamous GBM 0.78 0.95 0.83 0.94
urothelial GBM 0.80 0.83 0.83 0.85
adenocarcinoma leukemia 0.81 0.96 0.82 0.96
squamous leukemia 0.76 0.90 0.78 0.93
urothelial leukemia 0.77 0.97 0.92 0.96
GBM leukemia 0.86 0.86 0.86 0.94
The classiﬁcation statistics for each pairwise Random Forest comparison are shown in each row. Positive
class = the cancer type that was considered a true positive when successfully classiﬁed for the purpose of
calculating the classiﬁcation statistics. Negative class = the cancer type that was considered a true
negative when successfully classiﬁed for the purpose of calculating the classiﬁcation statistics.
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The ROC curves for all pairwise Random Forest comparisons show that an area under the curve (AUC) of at
least 0.80 was achieved in all comparisons except for that between squamous cell carcinomas and urothelial
carcinomas.
117
4.1.3.2.1 Random Forest with recursive feature elimination
For each of the comparisons I aimed to identify the model that best discriminated between
the two cancer classes and simultaneously the set of features used in the model. Classiﬁcation
performance in the training set can increase even if uninformative features are added to the
model; the classiﬁer can begin to model the noise in the training set, leading to over-ﬁtting. I
attempted to avoid over-ﬁtting by choosing the models with the smallest number of features
and a mean classiﬁcation accuracy within two percent of the best performing model. The
extent of model reﬁnement using this accuracy tolerance is visualised in supplementary
ﬁgures 4.1.6.1 on page 126. In most cases the best performing models may be over-trained,
containing more features than models of close to equal mean classiﬁcation accuracy (Figure
4.1.6.1). For three of the pairwise comparisons, ([adenocarcinoma, squamous], [squamous,
GBM], and [squamous, AML]) the best performing Random Forest model contained the
complete set of features that were input to the model.
4.1.3.3 KEGG disease pathway enrichment
KEGG disease pathway enrichment analysis was conducted for the models discriminating
squamous cell carcinomas from urothelial cell carcinomas, adenocarcinomas from glioblastoma,
squamous cell carcinoma from glioblastoma, adenocarcinomas from AML, urothelial cell
carcinomas from AML and glioblastoma from AML. These models were all composed of more
than 10 features. For the squamous cell carcinoma and glioblastoma comparison, enrichment
analysis using KEGG disease pathways (Kanehisa & Goto, 2000; Kanehisa et al., 2014)
identiﬁed 14 disease pathways enriched for the 53 proteins. The top 10 enriched pathways
were all cancers, or cancer related, with the most highly enriched pathway being the ‘p53
signalling pathway’ (adjusted p=3.00× 10−4). However, none of the enriched pathways were
squamous cell carcinomas. For the Adenocarcinoma and AML comparison, the KEGG disease
pathway enrichment analysis identiﬁed six cancer pathways enriched for genes in the model,
AML being the most highly enriched pathway (FDR adjusted p= 2.00 × 10−4). For the

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































enriched pathways including Acute Myeloid Leukaemia (FDR adjusted p=3.67× 10−8) and
Glioma (adjusted p=2.23× 10−9). The Random Forest models that discriminated between
the cancer types were enriched in gene sets that either directly correspond to the appropriate
cancers, or to cancer related processes.
4.1.4 Discussion
I have identiﬁed sets of protein features that discriminate between each of the ﬁve high-order
cancer types present in the Pan-Cancer data set. I found that many of the features included
in the models were already known to be either signiﬁcantly mutated in a subset of the
Pan-Cancer cancers, or exclusively mutated in one Pan-Cancer cancer type (e.g. VHL in
KIRC, APC in COADREAD, and DNMT3A in AML). This indicated that the features that
were most important for discriminating between the cancer types were those which were
signiﬁcantly diﬀerentially mutated across the cancer types at the univariate level.
I found that CASP8 was important for discrimination between adenocarcinomas and
squamous cell carcinomas, and squamous cell carcinomas and glioblastoma. This relationship
was not identiﬁed in early Pan-Cancer analysis papers, nor was CASP8 found to be signiﬁcantly
mutated (Kandoth et al., 2013a), but it has subsequently been associated with head and
neck squamous cell carcinoma (Hoadley et al., 2014; Lawrence et al., 2015). FRG1B was also
implicated in head and neck squamous cell carcinoma by Hoadley et al. (2014) and Lawrence
et al. (2015), in contrast to this analysis where it was important for the discrimination of
urothelial carcinomas and AML. NOTCH1 was not signiﬁcantly mutated in adenocarcinomas
(Kandoth et al., 2013a). However, Lawrence et al. (2015) found NOTCH1 inactivating
mutations in 19 percent of head and neck squamous cell carcinomas, validating the inclusion
of NOTCH1 in the model to discriminate between adenocarcinomas and squamous cell
carcinomas.
For the adenocarcinoma and glioblastoma comparison PBRM1 mutations were known to
be speciﬁc to kidney renal clear cell carcinoma (Kandoth et al., 2013a). PTEN and EGFR
were found to be most frequently mutated in glioblastoma samples (Kandoth et al., 2013a),
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and appeared in every model that included glioblastoma.
For the urothelial and glioblastoma comparison, MLL2 was more frequently mutated in
bladder urothelial cancer than in glioblastoma (Kandoth et al., 2013a; Hoadley et al., 2014).
PTEN and EGFR, frequently mutated in glioblastoma (Kandoth et al., 2013a) were also
included in the model. ARID1A, and ATM were signiﬁcantly mutated in TCGA bladder
urothelial carcinoma data (Weinstein et al., 2014).
For the squamous cell and urothelial carcinoma comparison CDKN2A was more frequently
mutated in head and neck squamous cell carcinoma and lung squamous cell carcinoma in
comparison to bladder urothelial carcinoma (Kandoth et al., 2013a; Lawrence et al., 2015).
When comparing bladder urothelial carcinoma and AML the genes MLL3, and MLL2 were
included in the model, both of which were mutated at higher frequency in bladder urothelial
carcinoma than in AML (Kandoth et al., 2013a; Hoadley et al., 2014).
For the comparison between glioblastoma and leukaemia, DNMT3A has been found to be
mutated in a higher percentage of leukaemia samples than glioblastoma samples (Kandoth
et al., 2013a). Mutations in the genes DNMT3A, RUNX1, NPM1, and FLT3 that best
discriminated AML from other cancer types also deﬁne three AML subtypes (Kandoth et al.,
2013a).
The Random Forest models include genes that in other cancer genome analyses have
potentially been spuriously called as signiﬁcantly functionally mutated, most notably CSMD3,
CSMD1, LRP1B, RYR2, RYR1 and PCLO (Lawrence et al., 2013). Those genes may have
been incorrectly labelled as signiﬁcantly mutated in other analyses because of the incorrect
assumptions of the background mutation rate of these genes by tools that assume a uniform
genome-wide background mutation rate. Many of the genes are late replicating, they have
a high local background mutation rate, and are expressed at low levels (Lawrence et al.,
2013). It is possible that diﬀerences in the overall mutation frequency of each cancer have
caused these spurious genes to be included in the models as being biologically discriminative
because they indicate a diﬀerence between the local background mutation rate across the
cancer types. In a further analysis it may be useful to use MutSigCV (Lawrence et al., 2013)
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gene scores for mutation signiﬁcance to weight the binary mutation matrix. In this way the
eﬀect of a local increase in background mutation rate at these genes may be accounted for
and biologically discriminative genes may be included in the models.
Further evidence for background mutation eﬀects may come from AML comparisons. The
gene TTN was the only gene included in models for all AML comparisons. TTN is the longest
human gene, and AML had the lowest mutation frequency of all of the Pan-Cancer cancers
(Kandoth et al., 2013a). TTN was rarely mutated in AML, and higher background mutation
rates among other cancers may be indicated as a mutation in the largest gene, TTN, which is
likely to accumulate passenger mutations. Indeed, using the Wilcoxon rank sum test samples
carrying TTN functional mutations had a higher overall SNV mutation frequency (Mdn=174)
than samples in which TTN was not mutated (Mdn=63) (W = 123350, p < 2.2× 10−16).
The set of cancers compared in this analysis is not comprehensive. It is reasonable
to assume that the entire set of genes that discriminates between each of the ﬁve cancer
classes in the Pan-Cancer dataset has not been identiﬁed. For example, PTEN mutations
were important for discriminating glioblastoma from the other cancer types. However, if
endometrial carcinoma had been included in the analysis PTEN may not have been included
in the model discriminating glioblastoma from adenocarcinoma, because PTEN mutations
occur in endometrioid endometrial adenocarcinomas (Kandoth et al., 2013b).
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4.1.5 Conclusions
By using Random Forest analysis I created models that showed good ability to discriminate
between the ﬁve high-order types in a pairwise manner. For most of the pairwise comparisons
the proteins that were found to be most important for cancer type discrimination were those
which either, were exclusively mutated in a single cancer type, or were more commonly
mutated in a single cancer type. For example VHL and APC were always included in models to
discriminate adenocarcinomas from other cancer types because they were exclusively mutated
in kidney renal clear cell carcinoma (Kandoth et al., 2013a) and colorectal adenocarcinoma
respectively.
The discriminative models included proteins which in other studies have been found to
be spuriously labelled as signiﬁcantly mutated, including: CSMD3 in ovarian carcinoma
(Lawrence et al., 2013); and LRP1B, MUC16, MUC4, CSMD1, PCLO, and RYR2 in
lung squamous cell carcinoma (Lawrence et al., 2013). These features should be treated
with caution. The reason they discriminate between cancer types may not be because
they are discriminative driver genes that are important for cancer progression, but because
they are susceptible to the accumulation of passenger mutations associated with late
replication time (in the case of CSMD3 ) and low levels of expression (Lawrence et al., 2013;
Stamatoyannopoulos et al., 2009; Pleasance et al., 2010).
The Random Forest approach to identifying features that discriminate between cancer
types may be useful to create tools to classify cancers of unknown primary origin. By
providing a prediction of the tissue of origin for a metastatic cancer of unknown primary
origin, clinicians may use the information to guide patient treatment; an idea which is
developed in the next section of this chapter.
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4.1.6 Supplementary Materials
Table 4.1.6.1: cancer stage distribution across cancers
Stage BLCA BRCA COAD GBM HNSC KIRC LAML LUAD LUSC OV READ UCEC
Not recorded 0 0 0 275 0 0 152 0 0 0 0 0
1 1 126 30 0 17 197 0 80 95 0 18 164
2 21 436 57 0 46 40 0 31 36 14 25 20
3 35 172 44 0 42 113 0 35 38 247 16 50
4 32 15 21 0 155 67 0 9 3 53 8 13
The contingency table shows the counts of cancers by stage (rows) and cancer type (columns). BLCA =
bladder, BRCA = breast, COAD = colon adenocarcinoma, GBM, = glioblastoma, HNSC = head and
neck squamous cell carcinoma, KIRC = kidney, LAML = acute myeloid leukaemia, LUAD = lung
adenocarcinoma, LUSC = lung squamous cell carcinoma, OV = ovarian cystadenocarcinoma, READ =
rectum adenocarcinoma, UCEC = endometrial carcinoma.
Table 4.1.6.2: cancer stage distribution across high-order cancer types
Stage adenocarcinoma glioblastoma AML squamous urothelial
Not recorded 0 275 152 0 0
1 615 0 0 112 1
2 623 0 0 82 21
3 677 0 0 80 35
4 186 0 0 158 32
The contingency table shows the counts of cancers by stage (rows) and high-order cancer type (columns).
Adenocarcinoma = breast, colon, rectum, ovarian, kidney, lung adenocarcinoma; AML = acute myeloid
leukaemia; squamous = lung squamous cell, head and neck squamous cell; urothelial = bladder urothelial
carcinoma.
125
Figure 4.1.6.1: Pairwise Random Forest classiﬁcation accuracy plots









































































































































































































































































































































































































For each comparison the mean classiﬁcation accuracy achieved (x-axis), by Random Forest models of
feature set sizes ranging from 1-100, 200. The ‘selected models’, contained the smallest number of features
that performed with classiﬁcation accuracy that was at most 2% lower than the model with maximum
accuracy. For ﬁgures (4.1.6.1b, and 4.1.6.1f), the models built to compare adenocarcinomas with urothelial
carcinomas, and urothelial carcinomas with glioblastoma were overﬁtting the training data when using more
than around 20 features. The model selection process selected models that used small numbers of features
and performed with high accuracy.
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Figure 4.1.6.1: classiﬁcation accuracy plots continued.
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For each comparison the mean classiﬁcation accuracy achieved (x-axis), by Random Forest models of feature
set sizes ranging from 1-100, 200. The ‘selected models’, contained the smallest number of features that
performed with classiﬁcation accuracy that was at most 2% lower than the model with maximum accuracy.
The squamous cell carcinoma and AML comparison (Figure 4.1.6.1h) demonstrates how the model selection
process has moved from a model containing 200 features that performed with a mean accuracy of 0.93, to a
more parsimonious model of 6 features that performed with a mean accuracy of 0.91.
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The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.3: Adenocarcinoma / urothelial carcinoma heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation. The brown scaled column indicates cancer stage, progressing
from stage 1 (grey) to stage 4 (dark brown)
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The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation. The brown scaled column indicates cancer stage, progressing
from stage 1 (grey) to stage 4 (dark brown). The green column indicates sample age ranging from grey to
dark green with increasing age.
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Figure 4.1.6.5: Adenocarcinoma / glioblastoma heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.6: Squamous cell carcinoma / glioblastoma heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.7: Urothelial / glioblastoma heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.8: Adenocarcinoma / leukemia heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.The green column indicates sample age ranging from grey to dark
green with increasing age.
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Figure 4.1.6.9: Squamous cell carcinoma / leukemia heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.10: Urothelial / leukemia heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation.
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Figure 4.1.6.11: Glioblastoma / leukemia heat map
The rows represent samples and columns represent genes in this heatmap. The coloured column to the left
of the heatmap indicates the class to which each sample belongs. The grey markers indicate in which gene
each sample carried a functional mutation. The green column indicates sample age ranging from grey to
dark green with increasing age.
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Chapter 4.2
Working towards predicting the
origin of cancers of unknown




Cancers of unknown primary origin (CUP) make up around ﬁve percent of all diagnosed
cancers and are the fourth leading cause of death from cancer (Pavlidis & Pentheroudakis,
2012). These cancers are typically aggressive metastases and patients can present with
tumours at multiple locations with complex histology, making the diagnosis of the primary
cancer type non-trivial. However, post mortem examinations can usually identify a primary
tumour, suggesting that the current clinical practice is failing (Pentheroudakis et al., 2007).
Recent work shows gene expression signatures of tumours of unknown primary origin can
supply a likely tissue of origin classiﬁcation (Tothill et al., 2005; Van Laar et al., 2009;
Ramaswamy et al., 2001; Su et al., 2001).
Recent work on the Pan-Cancer dataset showed that cancers clustered according to their
tissue of origin (Hoadley et al., 2014; Weinstein et al., 2013). The Pan-Cancer analysis
also identiﬁed mutations which were almost exclusive to certain cancers; such as APC in
colorectal cancer, and VHL mutations in kidney renal clear cell carcinoma (Kandoth et al.,
2013a); a result which was conﬁrmed in Chapter 4.1. A current theory is that the deﬁning
characteristics of CUP may be inherited from the tissue of primary origin (Dennis & Oien,
2005; Rosenfeld et al., 2008). Therefore, CUP that harbour APC mutations may be most
likely originate from a colorectal adenocarcinoma. Whereas CUP that carry VHL mutations
may be most likely to originate from a kidney renal clear cell carcinoma. Treatments known
to be successful for certain cancers may also be successful for treating their metastases.
When diagnosing the origin of CUP clinicians should have available to them as much
pathological, histological, and other molecular data as possible. In addition to gene expression
classiﬁcation tools for CUP (Tothill et al., 2005; Van Laar et al., 2009; Su et al., 2001),
tools which could provide a putative origin for CUP, based on exome or genome sequencing,
would be a useful aid to treatment choice. Tothill et al. (2013) used an exome sequence
gene panel to classify CUP in a small dataset. Whole-exome sequence data has not yet been
used to classify CUP.
Exome sequencing, and whole genome sequencing of CUP may also uncover mutations
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for which there are known pharmacogenetics associations. Indeed there are now studies
which have leveraged clinical exome sequencing of primary tumor biopsies to make decisions
about which targeted treatments are most appropriate for a patient (Frampton et al., 2013).
As sequencing costs continue to decrease, such sequence-based tests become economically
viable because the high cost of a single sequencing run can be oﬀset by the multitude of
tests which can be completed using whole exome, or whole genome sequence data (Garraway
& Lander, 2013).
In this thesis, I investigated the utility of a multi-class Random Forest classiﬁcation tool
to predict a primary site for CUP using whole exome sequence data comprising gene level
features, variant type frequencies and transition and transversion variant frequencies. The
tool was created and tested using a training and test set derived from the Pan-Cancer dataset.
The Pan-Cancer dataset is not a comprehensive set of all cancers and so we cannot make
accurate predictions for all cancers. As additional cancer exome sequence datasets become
available through the cancer genome atlas we can use them to create CUP prediction tools
that are more comprehensive. In the future this approach may also be adopted to predict the




I created an eleven class Random Forest classiﬁcation model to classify cancers according to
their tissue type. There is currently no suitable validation set in which to test the real world
performance of this classiﬁer. However, the Genomics England project plans to obtain the
whole genome sequence of carcinomas of unknown primary origin. This will allow me to test
how well the model agrees with the putative tissue of origin predicted by clinicians.
4.2.2.1 The Pan-Cancer dataset
I used the same Pan-Cancer dataset as in section 4.1.2.1 on page 105. I downloaded the
Mutation Annotation Format (MAF) ﬁles from Sage Synapse on October 10th 2013. I
removed mutations from the MAF ﬁle that were classiﬁed as ’silent’. Silent mutations are
synonymous mutations, which do not lead to a change in the amino acid in the translated
protein. I used the union of the lists of functionally mutated proteins across all samples to
generate a matrix M of proteins P by samples S . Each element in M [p, s], was set to 0 if
there was no protein coding mutation for protein p, and sample s, or set to 1 if at least one
protein coding mutation was present for protein p, and sample s.
I also computed the frequency of variant types and the six transition and transversion
(TV/TS) SNV types. I extracted samples with available exome sequence and clinical data for
age, gender and cancer stage. The Pan-Cancer dataset included Amyloid Myeloid Leukemia
(AML) which is not suitable as an origin of a solid metastasis, and so AML samples were
not included in the model building procedure.
4.2.2.2 Training set sampling
For each Pan-Cancer cancer type, two thirds of the samples were assigned to the training
set for model building and one third to the test set. I then used two sampling strategies.
The ﬁrst strategy used a downsampling procedure to down-sample all classes to be of equal
size to the smallest class in order to minimise the tendency of a classiﬁer to defer to the
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majority class (Barandela & Sã, 2003). The second strategy used both downsampling and
the synthetic minority over-sampling technique (SMOTE) (Chawla et al., 2002), and is
outlined below.
4.2.2.2.1 SMOTE up-sampling
A combination of down-sampling, and the SMOTE (Chawla et al., 2002) up-sampling
procedure was used to set the training set size of each of the ten cancer classes to be a
multiple of the minimum training class size.
The two thirds training set size for each cancer class m was computed as the set of
training set sizes M . The minimum training set size Mmin was recorded. The up-sampling
parameter u indicated the proportional increase in minority class training set size to be
achieved through SMOTE over-sampling. Where u = 2, the minimum class size was to
be doubled, and the balanced training set size to be achieved for each cancer class S was
derived by S = Mmin × u. The set of cancer classes where the two thirds sample size was
larger than the balanced training set size G was deﬁned by G = {m |m∈M and m>S}. For
the G classes, a balanced training set size of S was achieved through random selection of S
samples. The set of cancer classes with a two third sample size smaller than the balanced
training set size L was deﬁned by L = {m |m∈M and m<S}. For each class l∈L the number
of samples to be generated by the SMOTE (Chawla et al., 2002) procedure n∈N was found
by subtracting the two thirds training set size for class l , Ml , from the balanced training
set size S (n = S −Ml). For each class l∈L, the SMOTE procedure was used to create n
additional samples, so that the training set size for all classes were equal to S .
The SMOTE Chawla et al. (2002) procedure works by generating new synthetic training
set samples from a training set by using features drawn from a collection of P training
samples. The similarity between the training set samples is represented in ’sample space’
where the distance between the samples is inversely related to their similarity. The SMOTE
procedure creates a new sample by picking two training samples, and uses combinations of
the features of the two training samples to create a new, synthetic, training sample.
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Table 4.2.2.1: Two third training set sizes for each cancer type used to build the CUP
classiﬁers
BLCA BRCA COADREAD GBM HNSC KIRC LUAD LUSC OV UCEC
N samples 61 511 149 183 204 278 105 116 210 164
The two thirds training test class sizes of each cancer type were imbalanced
(χ2(9,N = 1981) = 719.20, p = 2.2× 10−16).
BLCA = bladder, BRCA = breast, COAD = colon adenocarcinoma, GBM, = glioblastoma, HNSC =
head and neck squamous cell carcinoma, KIRC = kidney, LUAD = lung adenocarcinoma, LUSC = lung
squamous cell carcinoma, OV = ovarian cystadenocarcinoma, READ = rectum adenocarcinoma, UCEC =
endometrial carcinoma.
This process results in a training set where classes either have been under-sampled
without replacement, or up-sampled without replacement, in order to create a set of size S .
4.2.2.2.2 Mutated protein feature selection
Protein features were retained if they carried at least one protein coding mutation in ﬁve
percent or more of any cancer class in the training set. By doing this I aimed to remove
genes likely to contain passenger mutations from the protein features, and only use those
features that were more likely to contain information that reﬂected biological characteristics
of the tumour (Kandoth et al., 2013a).
4.2.2.3 Random Forest model building
The model building pipeline is shown in Figure 4.2.2.1. All Random Forest models were
built using the Caret (Kuhn, 2008) package wrapper for randomForest in R. Models were
built using recursive feature elimination with 5 x 10 fold cross validation in order to select
the features for models composed of feature set sizes from 1-200 using feature set sizes of
(1-50, 60, 70, 80, 90, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200). Mean classiﬁcation
accuracy was used to select the feature subset size, N, that resulted in the best performing
models to use in ﬁnal model building. The ﬁnal model was built using the entire training set,
and the top N ranked protein features. In an attempt to reduce the eﬀect of over-ﬁtting
the classiﬁcation models I chose to use the model with the smallest feature set size that
performed within one percent of the best performing model.
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4.2.2.4 Classiﬁer performance measures
For each cancer class, a true positive in the test data was deﬁned as a correct classiﬁcation
of the cancer class label and a true negative was deﬁned as a classiﬁcation of any other
class label as any other class label except the positive class. For example when considering
colorectal adenocarcinomas, a true positive would be a colorectal adenocarcinoma being
classiﬁed as a colorectal adenocarcinoma, and a true negative could be a lung adenocarcinoma
classiﬁed as any other cancer class except colorectal adenocarcinoma. I used the area under
the ROC curve (AUC) statistic for each class to measure classiﬁer performance.




4.2.3.1 The down-sampled classiﬁer
The classiﬁer which balanced the classes to be of equal size to the smallest training set of
the 10 cancer classes performed with a mean accuracy of 72.5 percent (SD= 1.8) in the
test dataset (Table 4.2.3.1). Across all classes, the mean classiﬁcation sensitivity was 73.7
percent (SD= 15.7), and the mean classiﬁcation speciﬁcity was 96.9 percent (SD=2.0). The
selected model consisted of 23 features including all six of the transition and transversion
frequency features, and seven of the variant type features excluding ’In-frame insertions’,
and ’non-stop mutations’. There were nine proteins in the model: TP53, APC, PTEN, VHL,
KRAS, PIK3CA, CTNNB1, CDKN2A, and PBRM1 (Table 4.2.3.2) presented in order of
descending mean classiﬁcation accuracy.
Each cancer class was predicted with at least 71.3 percent accuracy (Table 4.2.3.1), the
lowest being found for head and neck squamous cell carcinoma and the highest for lung
squamous cell carcinoma at 95 percent. By inspecting the receiver operating characteristic
curve I observed that at all probabilities for being assigned to each class, the classiﬁer
performed well. Each class had an area under the curve (AUC) of at least 90 percent (Figure
4.2.3.2a).
4.2.3.2 The up-sampled classiﬁer
The performance of the up-sampled classiﬁer was similar to the down-sampled classiﬁer
(Table 4.2.3.1, and Figure 4.2.3.2b). The Smote up-sampled model included 30 features and
performed with an accuracy of 74.1 percent (SE= 1.99). All six transition and transversion
features were included in the model and seven of the variant type features excluding ‘In-frame
insertions’, and ‘non-stop mutations’ (Table 4.2.3.2). Age and gender features were included
in the model along with 15 protein features; TP53, APC, KRAS, VHL, PTEN, PIK3CA,
EGFR, PIK3R1, PBRM1, ARID1A, CTNNB1, CSMD3, ZFHX4, MUC16 and FRG1B.
There was no diﬀerence in classiﬁer performance when AUC scores (Figure 4.2.3.1 and
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Table 4.2.3.1: Test set performance statistics for the down-sampled and up-sampled CUP
classiﬁers
Down-sampled classiﬁer
BLCA BRCA COADREAD GBM HNSC KIRC LUAD LUSC OV UCEC
Sensitivity 0.61 0.61 0.90 0.79 0.45 0.91 0.58 0.91 0.87 0.75
Speciﬁcity 0.96 0.95 0.99 0.96 0.98 0.98 0.99 0.99 0.92 0.98
Positive Predictive Value 0.15 0.84 0.87 0.67 0.69 0.89 0.62 0.79 0.58 0.75
Negative Predictive Value 1.00 0.85 0.99 0.98 0.94 0.98 0.98 1.00 0.98 0.98
Prevalence 0.01 0.30 0.07 0.09 0.10 0.15 0.04 0.05 0.11 0.08
Detection Rate 0.01 0.18 0.06 0.07 0.05 0.14 0.02 0.04 0.09 0.06
Detection Prevalence 0.05 0.22 0.07 0.11 0.07 0.15 0.04 0.06 0.16 0.08
Accuracy 0.78 0.78 0.95 0.88 0.71 0.94 0.78 0.95 0.89 0.86
AUC 0.93 0.92 0.99 0.96 0.93 0.99 0.92 0.99 0.96 0.95
Smote up-sampled classiﬁer
BLCA BRCA COADREAD GBM HNSC KIRC LUAD LUSC OV UCEC
Sensitivity 0.50 0.63 0.91 0.87 0.48 0.92 0.63 0.93 0.89 0.75
Speciﬁcity 0.97 0.96 1.00 0.95 0.97 0.98 0.99 0.99 0.92 0.98
Positive Predictive Value 0.20 0.90 0.92 0.63 0.65 0.89 0.65 0.80 0.55 0.77
Negative Predictive Value 0.99 0.83 1.00 0.99 0.94 0.99 0.99 1.00 0.99 0.98
Prevalence 0.02 0.35 0.06 0.08 0.10 0.16 0.030 0.03 0.11 0.07
Detection Rate 0.01 0.22 0.05 0.07 0.05 0.15 0.02 0.03 0.09 0.05
Detection Prevalence 0.04 0.25 0.06 0.11 0.07 0.17 0.03 0.04 0.17 0.07
Accuracy 0.73 0.80 0.95 0.91 0.73 0.95 0.81 0.96 0.90 0.87
AUC 0.93 0.93 1.00 0.97 0.94 1.00 0.95 1.00 0.97 0.97
The classiﬁer that used down-sampling to balance classes in the training set (Down-sampled classiﬁer)
performed comparably to the classiﬁer that used a combination of down-sampling and smote up-sampling
(smote up-sampled classiﬁer).
BLCA = bladder, BRCA = breast, COAD = colon adenocarcinoma, GBM, = glioblastoma, HNSC =
head and neck squamous cell carcinoma, KIRC = kidney, LUAD = lung adenocarcinoma, LUSC = lung
squamous cell carcinoma, OV = ovarian cystadenocarcinoma, READ = rectum adenocarcinoma, UCEC =
endometrial carcinoma.
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(b) Smote up-sampled training set
The up-sampled classiﬁcation model showed equal, or marginally larger AUC values in comparison to the
down-sampled model.
Table 4.2.3.1) for each cancer class were compared between the down-sampled models and the
smote up-sampled models using a bootstrap permutation method (Hanley & McNeil, 1983)
and adjusted for multiple testing (BLCA [D = 0.20, p = 0.84], BRCA= [D = −2.44, p =
0.15], COADREAD= [D = −1.22, p = 0.22], GBM= [D = −0.77, p = 0.44], HNSC= [D =
−1.11, p = 0.26], KIRC= [D = −0.87, p = 0.38], LUAD= [D = −1.52, p = 0.13], LUSC=
[D = −0.45, p = 0.65], OV= [D = −0.57, p = 0.56], and UCEC= [D = −1.99, p = 0.05]).
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Table 4.2.3.2: Random Forest classiﬁer feature importance
Down-sampled classiﬁer
Features Importance Features Importance Features Importance
1 C>T_G>A 43.73 11 Missense_Mutation 22.39 21 CDKN2A 13.67
2 TP53 36.59 12 A>T_T>A 21.34 22 A>C_T>G 11.90
3 APC 34.10 13 Frame_Shift_Ins 21.26 23 PBRM1 8.21
4 C>A_G>T 33.36 14 Frame_Shift_Del 21.03
5 gender 31.29 15 KRAS 20.93
6 RNA 29.13 16 PIK3CA 19.44
7 C>G_G>C 27.92 17 Nonsense_Mutation 18.93
8 PTEN 24.74 18 CTNNB1 18.60
9 A>G_T>C 24.03 19 Splice_Site 17.79
10 VHL 23.89 20 In_Frame_Del 16.58
SMOTE up-sampled classiﬁer
Features Importance Features Importance Features Importance
1 TP53 49.80 11 PTEN 28.92 21 CTNNB1 19.07
2 C>T_G>A 47.27 12 A>T_T>A 28.89 22 EGFR 17.42
3 gender 47.00 13 PIK3CA 26.88 23 age 16.29
4 C>A_G>T 41.90 14 In_Frame_Del 26.53 24 ARID1A 14.55
5 APC 41.14 15 Missense_Mutation 26.17 25 CSMD3 13.51
6 RNA 39.70 16 VHL 25.83 26 FRG1B 13.41
7 C>G_G>C 37.75 17 A>C_T>G 24.14 27 PBRM1 12.75
8 A>G_T>C 34.38 18 KRAS 23.01 28 PIK3R1 12.66
9 Frame_Shift_Ins 31.18 19 Nonsense_Mutation 20.50 29 ZFHX4 9.69
10 Frame_Shift_Del 29.12 20 Splice_Site 19.97 30 MUC16 9.64
The variables included in each Random Forest model are ranked according to their mean classiﬁcation
accuracy in the training set.
4.2.4 Discussion
The classiﬁcation models contained proteins which are exclusively mutated in certain Pan-
Cancer cancer types. PBRM1 and VHL mutations are speciﬁc to renal cell carcinoma
(Kandoth et al., 2013a). APC mutations are mostly speciﬁc to colorectal cancer in this
dataset (Kandoth et al., 2013a). CDNK2A is most commonly mutated in the squamous cell
carcinomas; head and neck squamous cell carcinoma, and lung squamous cell carcinoma
(Kandoth et al., 2013a). Mutations in PTEN, and PIK3CA are most common in endometrial
carcinoma. KRAS mutations are most common in colorectal cancer and lung adenocarcinoma.
The CUP Random Forest model built on down-sampled data performed equally to the
classiﬁers built using the SMOTE up-sampling procedure. The features included in the model
built using the SMOTE up-sampled data included two genes; CSMD3, and MUC16, which
have been found to be signiﬁcantly mutated in some TCGA studies, but are thought to be
false positives (Lawrence et al., 2013). The down-sampled model is preferred because the
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protein features are more biologically plausible than those included in the up-sampled model.
The Random Forest method is limited by the number of cancer classes included in the
training set. I cannot make predictions about the origin of a cancer, if the tissue of its
true origin was not included in training set. In addition, a sample is always assigned to the
class with the highest classiﬁcation probability. This may increase the false positive rate
and reduce classiﬁcation speciﬁcity. An alternative would be to include an unknown class
category. By setting a threshold for the probability at which any sample can be assigned
to a class, the speciﬁcity of the classiﬁer may increase, because samples which have a low
probability of belonging to any of the 10 cancer type categories would be assigned to the
unknown category. In addition, the R implementation of Random Forest is limited to 32
categories, allowing for only 32 outcome classes. It may be preferable to use a k-nearest
neighbour, or k-medoids approach to build a classiﬁer which will have no limitation on the
number of outcome classes to which an unknown sample may be assigned.
4.2.5 Conclusion
By providing clinicians with a predicted tissue of origin based upon exome sequence mutations,
patient treatment decisions could be aided. The numbers of CUP that have been exome
sequenced is too small at present to draw strong conclusions about this approach. However,
within the next two years Genomics England plan to whole genome sequence many stage four
CUP. This will enable researchers to develop tools to predict the primary origin of late stage
metastatic cancers based on NGS data and provide some guidance to clinicians regarding
patient care.
There is further utility of this approach for tumour cells that circulate in blood, along
with cell free tumour DNA. A machine learning classiﬁcation approach, such as I have taken
here, may be able to assign a tissue of primary origin where circulating tumour cells are





prioritisation for complex diseases
using network-based methods
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Univariate tests to identify signiﬁcantly mutated genes in cancer, or to identify variants
associated with complex traits have been successful in identifying some of the genetic causes
of cancer and complex diseases. However, not all of the genes that explain cancer or the
heritable component of other complex diseases have been discovered. One reason for this
may be that these diseases are heterogeneous in terms of disease subtypes, where each
subtype has distinct genetic causes. Another reason may be that complex diseases are
genetically heterogeneous, with causal variants distributed among genes that operate as part
of a pathway. Univariate tests, may be underpowered to detect these associations (Leiserson
et al., 2013b).
Network-based tests may be able to detect disease associations at the pathway level
and suggest additional candidate disease genes. This chapter presents two investigations
in to integrating genomic data with protein interaction network data to provide additional
candidate disease genes. In Chapter 5.1 I developed the ‘k-pseudo cliques analysis’ and
analysed the PanCancer colorectal cancer exome sequence data (Kandoth et al., 2013a). In
Chapter 5.2 I used the Region Growing Analysis method developed by Lehne (2011) and
Christopher Tebbe to analyse rheumatoid arthritis single nucleotide polymorphism data from









Cancer is a complex and heterogeneous disease in which DNA mutation is the initial
cause of cancer and it is also part of the cancer phenotype. The mutations that initiate
cancer progression are known as driver mutations, and occur at a high frequency in exome
sequence tumour data (Ding et al., 2014). Genes carrying driver mutations, sometimes
called cancer genes, are mutated more frequently across samples (Kandoth et al., 2013a) and
many algorithms exploit this property to measure the degree to which genes are signiﬁcantly
mutated (Lawrence et al., 2013; Dees et al., 2012). In some cancers, such as colorectal cancer,
signiﬁcantly mutated gene products also physically interact with one another (Leiserson
et al., 2013a; Ciriello et al., 2012; Miller et al., 2011). This suggests that, at least for some
cancers, multiple genes can contribute to the cancer, and they can be part of the same
functional pathway.
Cancer, as well as other complex diseases, may arise due to the perturbation of pathways.
A perturbation to an important pathway, through knockout or gain of function mutation, of
a subset of any pathway members may cause the same disease phenotype. The example
of Acne Inversa shows this eﬀect in a monogenic disease where a mutation in any one of
three proteins adjacent in a protein protein interaction (PPI) network were found to cause
the disease (Wang et al., 2010). Genes that contribute to the same, or similar diseases, are
also closer than expected in PPI networks (Barrenas et al., 2009; Gandhi et al., 2006; Goh
et al., 2007).
In single gene analysis there is the possibility that a pathway that contributes to cancer
through the mutation of any one of the pathway members may not be discovered due to
sample heterogeneity (Vogelstein et al., 2013). The multiple hypothesis testing burden at
the pathway level should be lower than at the protein level because, by deﬁnition, there are
fewer pathways than there are genes. Therefore, the power to identify plausible disease gene
candidates should be higher when taking a pathway approach, in comparison to a single
gene approach.
The discovery of pathways involved in cancer can be approached from a graph modelling
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perspective. For example, the identiﬁcation of pathways contributing to cancer can be
represented as a community detection problem in a PPI network. There is no universally
accepted deﬁnition of a community in the network literature. In PPI networks one way of
deﬁning the community detection problem is to ask “which groups of proteins are part of the
same functional pathway?”. Of course, this deﬁnition is loose, but it is applicable to most of
the approaches that have been taken to discover communities in protein interaction networks
(Leiserson et al., 2013b). The community detection problem itself can be approached in
numerous ways. Some approaches take a seed and disperse approach, by growing pathways
based on seed vertices expanding the pathway based on maximising a statistic (Chuang
et al., 2007; Leung et al., 2014; Ozgun et al., 2014). Approaches such as Markov Clustering
(MCL) (Enright et al., 2002), and the Girvan-Newman algorithm (Girvan & Newman, 2002)
partition the graph in to discrete subgraphs. Whereas, other approaches such as: clique
percolation (Palla et al., 2005, 2007), and pseudo clique enumeration (Georgii et al., 2009;
Tsuda & Georgii, 2009) identify overlapping subgraphs. In this study I identiﬁed overlapping
communities of vertices using pseudo clique enumeration (Georgii et al., 2009), and a
k-pseudo clique search algorithm (Palla et al., 2005) to ﬁnd all k-pseudo cliques in the
Human Protein Protein Interaction network 2 (HuPPI2) (Lehne & Schlitt, 2009). I then
investigated whether the resultant communities were enriched with genes that had lower
than expected p-values for a gene-level test.
Two main tests have been used to identify signiﬁcantly mutated genes in TCGA cancer
datasets; MuSiC (Dees et al., 2012), and the set of MutSig algorithms (Lawrence et al.,
2013; Banerji et al., 2012). MutsigCV (Lawrence et al., 2013) is a method that is used to
estimate the extent to which each gene is signiﬁcantly mutated in a set of tumour samples
based upon the somatic mutations, which are unique to the tumour. The earliest iterations of
the mutsig algorithm measured whether each gene was signiﬁcantly mutated by calculating a
background mutation rate which was assumed to be constant across the genome. However,
the background mutation rate is correlated with gene expression levels (Pleasance et al.,
2010), and DNA replication time (Stamatoyannopoulos et al., 2009). MutsigCV extends
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the mutsig method by estimating the background mutation rate for each gene based upon
the number of silent and mutations within each gene. If the numbers of mutations in the
genes are not suﬃcient to properly estimate the background mutation rate, the k-nearest
neighbours of the gene are used to calculate the background mutation rate. This is adjusted
for the mean expression value of the gene across all tissues in the cancer cell line encyclopedia,
and the DNA replication time. Genes that are replicated late during mitosis have a higher
mutation rate than those that are replicated at the start of the DNA replication cycle. I
used the MutSigCV (Lawrence et al., 2013) algorithm to assign a p-value to each gene
that indicated the degree to which each gene was signiﬁcantly mutated. I then used the
PPI network, as prior biological information, and the Dense Module Enumeration (DME)
implementation of the pseudo clique enumeration algorithm (Georgii et al., 2009; Tsuda
& Georgii, 2009) to identify gene sets, or communities, that were concentrated with low
p-values.
The signiﬁcant gene sets, corresponding to the communities, represented functionally
related genes that were not signiﬁcantly mutated at the gene level, but were part of a
signiﬁcantly mutated subnetwork. This approach identiﬁed gene sets that contained genes
that were known to contribute to colorectal cancer and additional candidate genes carrying
functional mutations that may be good candidates for wet-lab cancer study and drug
repurposing. The k-pseudo cliques analysis method is not limited to analysis of cancer
sequencing data. It has many applications in the ﬁeld of complex disease genetics and can
be used to analyse any genome-wide gene-level test statistic data.
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5.1.2 Methods
5.1.2.1 Mutation and network data
I downloaded colorectal cancer mutation annotation format (MAF) ﬁles and clinical data
from Sage Synapse (accession syn1710680) on October 3rd 2013. These ﬁles contained
information in a VCF-like format. Each record (line) corresponded to a mutation. The sample
ID, chromosome, base-position start, base-position stop, variant classiﬁcation, and variant
type data correspond to columns and were available for all mutations. I retained 219 samples
for which age, gender, and mutation data were available. I removed 24 hypermutated samples
which contained more than 500 somatic mutations (Kandoth et al., 2013a). I ignored silent,
synonymous, mutations, but retained protein coding mutations. For each sample I labelled
the genes that carried at least one functional mutation to create the binary mutation matrix
as deﬁned in earlier chapters.
I used the HuPPi2 network (Lehne & Schlitt, 2009) as prior biological information and
to deﬁne the k-pseudo cliques.
5.1.2.2 MutSigCV analysis
I used MutSigCV to identify the genes that were signiﬁcantly mutated in colorectal cancer
adjusted for gene length, expression level, and DNA replication time (Lawrence et al., 2013).
I ran the analysis using the GenePattern Broad Institute server (Reich et al., 2006) using the
default parameters.
5.1.2.3 The HuPPI2 network
The HuPPI2 network (Lehne & Schlitt, 2009) is an example of a meta-protein interaction
network. It was composed of the union of the protein interactions present in six protein
interaction databases; BioGRID, MINT, DIP, IntAct, and HPRD. The network was created in
May 2008. Only protein interactions classed as physical were used. Furthermore, interactions
were retained only if they had been independently corroborated by two publications.
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5.1.2.4 Enumeration of pseudo cliques
Pseudo cliques are a type of graph community deﬁned by their density of edges among
member vertices. A connected subgraph was deﬁned as a pseudo clique if the ratio of the
number of edges to the maximal number of edges, density, was above a user deﬁned density
threshold, α[0,1]. I used ﬁve increasingly relaxed α thresholds to deﬁne pseudo cliques: 0.95,
0.90, 0.85, 0.80, and 0.75. The number of vertices belonging to each pseudo clique denoted
the pseudo clique size. I used Tsudo and Georgii’s DME program (Tsuda & Georgii, 2009;
Georgii et al., 2009) to enumerate all of the pseudo cliques within a weighted graph using a
reverse search. I then loaded each DME results ﬁle in to R along with the mutation data
and the PPI network for further analysis using igraph (Csárdi & Nepusz, 2006).
5.1.2.5 K-pseudo clique deﬁnition
The DME algorithm identiﬁes pseudo cliques of maximal size that satisfy the density threshold.
The result of this is that although many pseudo cliques may be discovered, their gene sets may
only diﬀer by a small number of genes. Therefore, I reduced the number of gene sets and
reduced the correlation between the gene sets by generalising the clique percolation method
(Palla et al., 2005) to pseudo cliques in order to identify k-pseudo clique communities.
In this algorithm the parameter ’k ’ deﬁned the minimum size of a pseudo clique that
could be included in a k-pseudo clique community. For the set of pseudo cliques discovered
at each density threshold and for each value of k, I created the pseudo clique overlap matrix.
This matrix was analogous to the clique overlap matrix from the CFinder algorithm (Palla
et al., 2005). Element Eij indicated the number of vertices, or proteins, shared by pseudo
cliques i and j . For each value of k I set the diagonal elements of the pseudo clique overlap
matrix to 0 and subtracted k − 1 from all oﬀ diagonal elements. This modiﬁed pseudo
clique overlap matrix represented an adjacency matrix of the pseudo cliques of at least size k
that intersected by at least k − 1 proteins. I then used a component decomposition of the
adjacency matrix to identify the k-pseudo cliques. For each k-pseudo clique, its gene set was
found from the intersection of its pseudo clique members. Each k-pseudo clique gene set
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was then taken forward for further analysis. Figure 5.1.2.1 depicts the process of identifying
k-pseudo cliques.
My contribution was to apply the clique percolation method (Palla et al., 2005) to pseudo
cliques, to identify highly interacting communities and to see whether those communities
were enriched with genes with lower than expected p-values for a gene-level test.
Figure 5.1.2.1: The k-pseudo clique search process
Three pseudo cliques that overlap by 3 vertices are combined in to a single k-pseudo clique.
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There are four pseudo cliques where a path can be traced between each pseudo clique to all other pseudo
cliques by intervening pseudo cliques. The vertices that belong to each pseudo clique are indicated by the
colour of the edges. The number of vertices shared by the pseudo cliques is represented as the pseudo clique
- pseudo clique overlap matrix. The orange pseudo clique and the blue pseudo clique share three vertices. In
order to group the pseudo cliques I modify the pseudo clique - pseudo clique overlap matrix. I deﬁne k as
the minimum size of pseudo clique I consider. I set all diagonoal elements in the matrix to 0 and subtract
k − 1 from all oﬀ diagonal elements. The matrix now indicates which of the pseudo cliques of size 4 overlap
by at least 3 vertices. This is an adjacency matrix representation of a network of pseudo cliques. I perform a
component decomposition on this matrix to extract the list of all k-peudo cliques. This process is conducted
in order to reduce the number of gene set tests I measure for their enrichment with low gene level test
p-values.
5.1.2.6 Network permutation
I mapped MutSigCV scores for each gene to corresponding vertices on HuPPI2 (Lehne &
Schlitt, 2009) network. For each pseudo clique I recorded the median MutSigCV p-value of
the belonging genes. In order to establish whether the k-pseudo cliques I discovered were
enriched for genes contributing to colorectal cancer I used a permutation test. I randomly
reassigned the vertex labels in the network, leaving the k-pseudo clique structures unchanged,
and recomputed the median MutSigCV p-value of each k-pseudo clique 10 000 times. A
k-pseudo clique was signiﬁcantly enriched with disease contributing genes if its median
MutSIgCV p-value from the non-permuted network was ranked in the top ﬁve percent (500)
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of its median MutSigCV p-values from the 10 000 network permutations.
The permutation test was required to establish whether any enrichment in gene-level
MutsigCV results I saw in the k-pseudo cliques was due to network structure (a chance
relationship), or because of the functional relationships between proteins encoded by edges
in the network. Any network-based permutation test using a PPI network must break the
functional relationships between proteins in the PPI network. By shuﬄing the vertex labels,
the protein names, the functional relationships indicated by the edges between proteins in the
PPI network would be broken. I used a degree constrained label reassignment procedure to
shuﬄe the vertex labels in the PPI network. It was possible to reassign vertex labels ’within
degree’, but to do so meant vertices of unique degree would never have been reassigned to
other vertices. In order to ensure that vertex labels were reassigned I tried two approaches
based on reassigning vertex labels constrained by vertex degree.
5.1.2.6.1 Absolute degree diﬀerence constrained label reassignment
In this algorithm all vertices of the same degree were simultaneously assigned a new label.
First of all, a random degree, d, was selected from the set of vertex degrees D. I ranked
the set of all vertices, X, according to their absolute degree diﬀerence |d | to d. For each
randomly selected d the set of vertices of degree d was deﬁned as dn. The new vertex labels
xn ⊆ X for dn were selected from the set of all available vertices X according to the |d | to
d using a single-tailed normal distribution with a mean |d | of 0 and standard deviation
of 5. This ensured that all vertices may be selected, and that the labels of vertices with a
degree of d were reassigned with vertex labels of vertices with a degree of d+-10 with a
probability of 0.95. The selected vertex names xn were removed from the sampling pool of
vertices X. A new d was then randomly selected and the above steps were repeated until all
values of X had been re-assigned.
Although this method of degree-constrained network permutation did ensure that vertex
names were likely to be reassigned with the names of vertices of similar degree, there were
problems. The label reassignment procedure aimed to reassign the names of most vertices
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to vertices of the same degree. Under this sampling procedure vertices of high degree, which
were rare, were less likely to be re-assigned another vertex name. In addition, vertices of
degree d were more likely to be assigned the names of vertices with an absolute degree
diﬀerence larger than zero.
5.1.2.6.2 Degree constrained label reassignment
This algorithm randomly re-assigned vertex names of a graph constrained by the degree of
the vertex to be reassigned. It is heavily based upon the degree constrained label shuﬄing
algorithm of Lehne 2011, where two vertices are selected and their labels are swapped. My
method selects two vertices A and B, and assigns the label of vertex B to vertex A. The
label of vertex A is retained in the pool of vertex names to be re-assigned. First of all,
a random vertex v was selected. All vertices were ranked and ordered according to their
absolute degree diﬀerence |v | to v . I randomised the ranks of vertices of identical degree,
so as to eliminate the alphabetical bias when using R’s sorting procedure. New vertex labels
were selected according to a sampling probability. The sampling probability for each vertex
was based on the rank position of each vertex. Using a single-tailed normal distribution with
a mean |v | of 0 and standard deviation of 5 I selected a new vertex x ⊆ X and reassigned
the vertex label and associated metadata to that of vertex v . This procedure ensured that
all vertices were available for selection, and that the metadata of a vertex was likely to be
reassigned to another vertex with 0.95 probability that the two vertices were less than 10
positions apart in the vector of vertices sorted by |v |. I used the degree constrained label
reassignment method 10 000 times to create 10 000 network permutations.
I decided to use vertex label reassignment as the network permutation method, rather
than edge shuﬄing, or a combination of both methods, because of limitations of the DME
program. The DME program may take weeks to run on a relatively small network such as the
HuPPi2 at a low α threshold of 0.75. Degree constrained vertex label reassignment retained
the topology of the network while controlling for vertex degree eﬀects, and breaking any
functional links between adjacent proteins in the network. The resulting permuted networks
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and the original network were isomorphic. Pseudo cliques identiﬁed in the observed network
were applicable to the permuted networks. Using an alternative edge shuﬄing permutation
would have changed the topology of the observed network meaning that permuted networks
and the observed network would not be isomorphic. If edge shuﬄing was used to permute the
observed network the pseudo cliques would have changed, and the very community structures
I wanted to test would have been broken apart. Degree constrained label re-assignment
may not be the most comprehensive network permutation, but it provided an acceptable
way to create permuted networks when it was important that the permuted networks and
the original network be isomorphic. It is of course conceivable that any vertex metric other
than vertex-degree may be used to constrain vertex label permutation. However, I have not
addressed that in this thesis.
5.1.2.7 KEGG enrichment analysis
I aimed to understand if the signiﬁcant results from the k-pseudo clique network-based
approach were more enriched for cancer related genes in when compared with results from a
univariate, single protein, approach. As such, I compared the KEGG pathway enrichment
p-value for a gene set obtained from the k-pseudo clique network-based approach at FDR<0.1
(Benjamini & Hochberg, 1995) to the p-value obtained by the MutSigCV gene set signiﬁcant
at FDR<0.1.
At each α threshold and k I extracted gene lists corresponding to the union of the k-
pseudo cliques that were signiﬁcantly mutated at FDR<0.1. From the univariate MutSigCV
test I extracted the list of genes that were signiﬁcantly mutated at FDR<0.1. I performed
KEGG Disease Pathway enrichment analysis on each of the resulting gene sets using the
Webgestlat online tool (Wang et al., 2013) and the hypergeomteric test. I restricted tests
to pathways containing four or more genes and restricted outputs to include only the gene
sets that passed FDR<0.1. For each α threshold and k the colorectal cancer pathway, and
pathways in cancer enrichment p-values were compared to the enrichment p-value for the
univariate, MutSigCV, test gene set. The k-pseudo clique method was considered to add
162
additional information if the enrichment p-value of the gene sets derived from a k-pseudo
clique analysis was smaller than that obtained from the MutSigCV gene set.
Each k-pseudo clique that contained at least ten proteins and was signiﬁcantly mutated
at FDR<0.1 was subjected to KEGG disease pathway enrichment as above. The disease
pathway in which each k-pseudo clique was most enriched was recorded.





The HuPPI2 network was composed of 3666 proteins (vertices), and contains 6187 pairwise
interactions between the proteins (edges). It had a mean degree of 3.38 (sd=5.32). The
average path length was 5.88, meaning that most vertices can reach any other vertex in
the network by traversing 6 edges. The degree distribution was skewed towards 0, and was
characteristic of other real world networks where most vertices are of low degree and very
few vertices are of high degree (Figure 5.1.3.1).
Figure 5.1.3.1: HuPPI2 network degree distribution






















Vertices of low degree are common, vertices of degree d become less frequent as d increases.
5.1.3.2 Network permutation results
For 1000 vertex label re-assignment permutations I recorded the mean degree of the permuted
vertex label in the original network. I tested the two label reassignment procedures using
1000 test permutations prior to deciding upon the ﬁnal permutation procedure to use in this
analysis. The absolute degree diﬀerence constrained label reassignment procedure did not
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preferentially assign vertex names to vertices of the same degree, it was more likely for a
vertex to be assigned the name of a vertex with an absolute degree diﬀerence of 1 or more
(Figure 5.1.3.2a). The implementation of degree constrained label reassignment achieved
the aim of preferentially randomly assigning vertex names to vertices of similar degree. For
1000 permutations the vast majority of vertex names were reassigned to vertices of the
same degree (Figure 5.1.3.2b). All permutation testing was conducted using the degree
constrained reassignment network permutation method.
Figure 5.1.3.2: Distributions of the absolute degree diﬀerence of permuted vertex labels and
original vertex labels using two permutation methods.
(a) Absolute degree diﬀerence constrained label
reassignment.













(b) Degree constrained label reassignment.






















For each vertex the mean absolute degree diﬀerence between the original label and 1000 permuted labels
was calculated and visualised as a histogram. When using absolute degree diﬀerence constrained label
reassignment (Figure 5.1.3.2a) few vertices had a tendency to swap label with vertices of exactly the same
degree, indicated by a mean absolute degree diﬀerence between 0 and 1. When using degree constrained
label reassignment (Figure 5.1.3.2b) the majority of vertices had a tendency to swap vertex labels with
vertices of the same degree, indicated by a mean absolute degree diﬀerence of 0.
5.1.3.3 Number and type of pseudo cliques identiﬁed at each
density threshold
The frequency distribution of pseudo cliques at the density thresholds; 0.95, 0.90, 0.85, 0.80,
and 0.75; are shown in Figure 5.1.3.3. As the density threshold decreased, the number of
pseudo cliques identiﬁed increased, as did the size of the pseudo cliques. Within each density
threshold the frequency distribution of k-pseudo clique size is shown in Figure 5.1.3.4.
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As the α parameter decreases, the size of discovered pseudo cliques increases. At α=0.80 there is around a
ten-fold increase in the number of pseudo cliques discovered in comparison to α=0.85.
5.1.3.4 Median univariate test statistic permutation tests
Across the 25 diﬀerent combinations of k (3, 4, 5, 6, and 7) and α (0.95, 0.90, 0.85, 0.80,
and 0.75) parameters I discovered 12 k-pseudo cliques that contained a lower than expected
median MutSigCV pvalue at FDR>0.1. Results are shown in Table 5.1.3.1. The 12 pseudo
cliques included 87 unique genes.
5.1.3.5 KEGG enrichment analysis
I wanted to understand whether the k-pseudo clique network-based analysis improved the
detection of known cancer causing genes in comparison to a univariate test. None of the
k-pseudo cliques analysis derived gene sets were more enriched in the colorectal cancer KEGG
pathway than was the MutSigCV gene set at FDR<0.1 (Table 5.1.3.2).
In the uniprotein MutSigCV analysis, I found 12 genes (KRAS, NRAS, TP53, APC,
SMAD4, FBXW7, SMAD2, BRAF, TNFRSF10C, TCF7L2, C17orf97, and CTNNB1) to






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SMAD4, SMAD2, BRAF, TCF7L2, and CTNNB1 ) were part of the KEGG colorectal cancer
gene set (enrichment p-value of 2.34e-18).
Nine of the MutSigCV gene set; KRAS, NRAS, TP53, APC, SMAD4, SMAD2, BRAF,
TCF7L2, and CTNNB1 ; were part of the KEGG pathways in cancer gene set, corresponding
to a hypergeometric enrichment p-value of 1.35e-14. All of the k-pseudo clique analysis
derived gene sets except for three: where k = 4 and α=0.80; k = 5 and α=0.80; and k = 4
and α=0.75 were more signiﬁcantly enriched in the KEGG pathways in cancer gene set, than
was the MutSigCV derived gene set. For seven k-pseudo clique derived gene sets a larger
number of genes in the KEGG pathways in cancer gene set were discovered in comparison to
the MutSigCV derived list (Table 5.1.3.2).
Of the eight signiﬁcantly mutated k-pseudo cliques subjected to KEGG disease pathway
analysis, ﬁve were most enriched in the ‘ErbB signalling’ pathway (Table5.1.5.1). The four
ErbB family proteins (EGFR, ERBB2, ERBB3, and ERBB4) were present in all but one of
these k-pseudocliques (where ErbB4 was absent). The three remaining k-pseudo cliques
were highly enriched in the KEGG ‘Apoptosis’ pathway. These two k-pseudo cliques may
represent two sets of samples with diﬀering routes to cancer.
Table 5.1.3.2: KEGG pathway enrichment validation of MutSigCV and k-pseudo cliques
analysis
Colorectal p-value Pathways in Cancer p-value
α k N proteins N in pathway network N in pathway network
0.95 3 72 7 2.22× 10−9 30 3.55× 10−35
4 76 6 4.16× 10−8 28 1.22× 10−33
5 14 N/A N/A 8 1.13× 10−11
0.90 3 (same as 0.95 k=3) 72 7 2.22× 10−9 30 3.55× 10−35
4 58 6 2.28× 10−8 27 2.08× 10−33
5 (same as 0.90 k=4) 58 6 2.28× 10−8 27 2.08× 10−33
6 (same as 0.95 k=5) 14 N/A N/A 8 1.13× 10−11
7 (same as 0.95 k=5) 14 N/A N/A 8 1.13× 10−11
0.85 3 (same as 0.95, k=3) 72 7 2.22× 10−09 30 3.55× 10−35
4 52 6 1.16× 10−08 23 5.84× 10−28
5 (same as 0.85 k=4) 52 6 1.16× 10−08 23 5.84× 10−28
6 38 N/A N/A 15 9.92× 10−18
7 30 N/A N/A 12 1.62× 10−14
0.80 5 19 N/A N/A 6 2.60× 10−07
6 13 N/A N/A 5 7.51× 10−07
0.75 5 (same as 0.80, k=5) 19 N/A N/A 6 2.60× 10−07
6 (same as 0.80, k=6) 13 N/A N/A 5 7.51× 10−07
= more signiﬁcantly enriched, or a larger number of genes intersecting the KEGG pathway than the MutSigCV derived gene list
= less signiﬁcanlty enriched, or a smaller number of genes intersecting the KEGG pathway than the MutSigCV derived gene list
K-pseudo clique analysis settings that produced identical gene sets are indicated in the k column.
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The vertex colours indicate the percentage of samples that carry at least one functional mutation in the
gene. Orange outlines indicate genes mutated in at least 10% of samples. The gene lists for union of these
subnetworks had the highest enrichment in both the KEGG colorectal cancer, and pathways in cancer gene




Using the k-pseudo cliques analysis I found no gene sets that were more highly enriched
with known colorectal cancer genes than was achieved using the univariate MutSigCV test.
However, in most cases the k-pseudo clique signiﬁcant results were more enriched with
known cancer genes than the results from the MutSigCV analysis (Table 5.1.3.2). This may
indicate that additional mutations that are important for the progression of colorectal cancer
occur in genes known to be important for progression in other cancers. Across individuals
these mutations may occur at a frequency that is too low to be detected at a univariate
level given the current sample sizes available to researchers.
5.1.4.1 Additional colorectal cancer associated genes in the α=0.95
and k=3 k-pseudo cliques
The publicly available KEGG disease pathways were last updated in November 2012. Since
then, many comprehensive sequencing studies of various cancers have been completed.
The KEGG colorectal cancer pathway gene list is a subset of the complete list of genes
contributing to colorectal cancer progression. I wanted to understand if the k-pseudo cliques
analysis had identiﬁed biologically plausible candidate genes for colorectal cancer progression
that were not included in KEGG disease pathways at the time of the most recent update
in November 2012. I obtained the list of 72 genes from signiﬁcant k-pseudo cliques at the
best performing parameter settings, as measured by KEGG pathway enrichment p-values,
where k = 3 and α = 0.95, and conducted a literature search. CDH1 , the CTNNB1 and
CTNNA1 complex, and JUP protein abundances were up-regulated in colorectal tumour
cells in the TCGA colorectal cancer dataset (Zhang et al., 2014). PIK3R1 and PIK3R2 ,
which are isoforms of the p85 regulatory subunit of the PI3K complex, were implicated by
my method in colorectal cancer. Somatic mutation in these genes may lead to a reduction
in the inhibitory eﬀect of the p85 subunit on PI3K activation, ultimately resulting in cell
proliferation in colorectal cancers (Papadatos-pastos et al., 2015). In colorectal cancer the
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PTPRM promoter has been shown to be hyper-methylated in comparison to normal tissue
(Laczmanska et al., 2012). PTPRM is a tumour suppressor, and its hyper-methylation may
play an important role in colorectal cancer tumorigenesis. Methylation of RET has been
associated with colorectal tumour progression from adenoma to cancer (Luo et al., 2013),
and somatic mutation could also lead to RET inactivation (Sjöblom et al., 2006). ERBB2
has been implicated as a druggable target in colorectal cancers (Muzny et al., 2012) and
breast cancers (Koboldt et al., 2012; Slamon et al., 1987). Increased expression of CBL
may play a role in the invasiveness properties of a subset of colorectal cancers (Cristóbal
et al., 2014). JAK1 signalling suppression increases apoptosis in KRAS mutant colorectal
cancers (Kalimutho et al., 2012). The eﬀects of these genes seem to apply to speciﬁc
cancer subtypes and not across all colorectal cancers. These associations were discovered by
the k-pseudo cliques analysis method and not by the univariate MutSigCV method. I have
demonstrated how the k-pseudo cliques method identiﬁed additional genes in comparison to
the univariate test, which are known to contribute to cancer. In addition these associations
were not present in the KEGG colorectal cancer gene set, nor the KEGG pathways in cancer
gene set.
5.1.4.2 Cancer related signalling pathways
The group of 11 genes identiﬁed by the k-pseudo cliques analysis at the density=0.95 and
k=3 (Figure 5.1.3.5b) parameter settings seemed to represent the extrinsic TRAIL induced
Apoptosis pathway (Ghavami et al., 2009), and 10 of these genes were part of the KEGG
Apoptosis pathway. The k-pseudo clique containing 61 genes at α=0.95 and k=3 contained
the ErbB family of receptors. MutSigCV (Lawrence et al., 2013) did not ﬁnd any of the ErbB
protein family to be signiﬁcantly mutated. This ﬁnding may indicate genetic heterogeneity in
colorectal cancer and the possibility of treating colorectal cancer using drugs and monoclonal
antibodies that bind to ErbB receptors using a targeted approach.
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5.1.4.3 Utility for complex disease genetics discovery
I used the KEGG colorectal cancer pathway enrichment analysis to compare the MutSigCV
(Lawrence et al., 2013) method to identify signiﬁcantly mutated genes in cancer to the
network-based k-pseudo clique analysis method. I showed that the k-pseudo clique analyses
in seven out of ten cases outperformed the MutSigCV analysis in KEGG pathways in cancer
gene set enrichment, and the number of pathways in cancer genes recovered. The additional
cancer candidate genes supplied by the k-pseudo clique methods may be false positives.
However, given the ﬁndings that k-pseudo clique gene sets were enriched in colorectal cancer
genes and the more recent literature linking signiﬁcant k-pseudo clique gene sets to colorectal
cancer, this method may be useful for uncovering new complex disease genetics by prioritising
gene-level tests.
5.1.4.4 K-pseudo cliques analysis future improvements
The k-pseudo cliques method may perform even better with a more complete protein
interaction network such as the irefweb (Turner et al., 2010), or humanNet (Lee et al., 2011).
The k-pseudo clique method is limited by its reliance upon the DME program (Georgii et al.,
2009). The time to enumerate all pseudo cliques within a graph, at any α, increases with
the number of vertices and edges of the graph. The pseudo clique enumeration time also
increases as α decreases (Georgii et al., 2009). K-pseudo clique analyses of large graphs
may be extremely time consuming. The DME algorithm reverse search methodology means
that for each dense module all possible single vertex extensions to the module are tested for
satisfaction of the density criterion. This process can be parallelised (Georgii et al., 2009),
but that is beyond the scope of this study. Parallelisation would decrease DME run-time,
especially at lower α threshold, making this method more appropriate for analysis of large,
and dense biological networks.
Setting the optimal parameters for the k-pseudo cliques analysis is not an easy task. For
analysis of k-cliques (Palla et al., 2005), others decided that parameter settings for k-clique
discovery in an unweighted network were optimal when the size of the second largest k-clique
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was at least half the size of the largest k-clique (Palla et al., 2005). However, in the case of
k-pseudo cliques analysis the intention was to reduce a single gene multiple testing burden
while discovering well deﬁned communities of functionally related genes. Any k-pseudo
cliques that were found to be signiﬁcantly mutated through permutation, but not at the gene
level, have provided useful information regardless of their size. The functional interpretation
of a k-pseudo clique is another matter, and may be easier for smaller k-pseudo cliques. In
which case, choosing analysis parameters that do not result in a ’giant community’ (Palla
et al., 2005) may be preferred.
The k-pseudo clique analysis method is not limited to its use in analysis of cancer data,
as is the MutSigCV tool. K-pseudo cliques analysis can be conducted using a dataset from
which gene scores can be obtained and an appropriate biological network. This means that
k-pseudo cliques analysis is appropriate for the analysis of: gene expression microarray data;
GWAS data; RNA-seq; proteomic data; and metabolomic data. It could also be used to
reﬁne polygenic risk score models (Purcell et al., 2009), by identifying which genes with
p-values in the range of 1× 10−5- 1× 10−7 are the best potential disease gene candidates,
thus improving the signal to noise ratio in polygenic risk models.
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5.1.5 Conclusion
By using the k-pseudo cliques analysis method, the HuPPI2 PPI network to analyse the
colorectal cancer Pan-Cancer dataset, and the KEGG disease pathways as gold standards
for cancer pathway knowledge, I identiﬁed fewer genes known to contribute to colorectal
cancer as the state of the art univariate method MutSigCV. However, the k-pseudo cliques
analysis method outperformed the MutSigCV analysis for enrichment in genes from the
KEGG pathways in cancer gene set at most parameter settings The k-pseudo clique analysis
should now be conducted using a more comprehensive PPI network such as the irefweb
network (Turner et al., 2010), or humanNet (Lee et al., 2011) in order to provide additional
high quality prior biological information and demonstrate that the results are not network
speciﬁc.
By integrating gene level test data with prior biological information in the form of a
protein interaction network I was able to detect genes contributing to colorectal cancer
subtypes that are part of the same, or closely related biological pathways. K-pseudo cliques
analysis supplied additional candidate genes for colorectal cancer progression, which may be
important for progression of undeﬁned colorectal cancer subtypes. In future work I could
investigate if mutations in particular subnetworks are important for discriminating between
cancer subtypes. For instance, in endometrial carcinoma that PTEN mutations are associated
with endometrioid tumours and that TP53 mutations are associated with serous high-grade
tumours, mutations in these genes being almost mutually exclusive.
The candidate disease genes suggested by the k = 3, and α = 0.95 parameter settings
were often implicated only in certain cancer subtypes. This implies that, in some cases,
k-pseudo cliques represent a pathway that when subjected to perturbations in diﬀerent genes
across patients results in colorectal cancer, but subtly diﬀerent types of colorectal cancer.
One possible avenue for further research would be to investigate if there are PPI subnetworks
within which proteins are either mutated in one cancer or another, but never both cancer
types. This approach may be useful for analysis of heterogeneous diseases where many
subtypes have been categorised using the same name. The k-pseudo clique method is generic
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and can be used to analyse complex disease data of any modality provided that gene level
scores can be obtained.
Table 5.1.5.1: KEGG enrichment of signiﬁcantly mutated k-pseudo cliques larger than ten
proteins.
α k N proteins Pathway Gene names intersecting with the pathway. raw p-value adjusted p-value
0.95, 0.9, 0.85 3 61 ErbB signaling pathway PIK3R1, CBLB, ERBB2, PTK2, CBL, ERBB4 3.25× 10−31 1.56× 10−29
SRC, EGFR, ABL1, GRB2, PLCG1, SHC1
CRK, PIK3R2, GSK3B, NRG1, STAT5A, ERBB3, GAB1
0.95, 0.9, 0.85 3 11 Apoptosis CASP3, TNFRSF10B, TNFSF10, FASLG, TNFRSF10A 1.35× 10−23 9.45× 10−23
CASP8, CASP10, FADD, CFLAR, FAS
0.95, 0.90, 0.85 4 (0.90, and 0.85 k=5) 45 ErbB signaling pathway PIK3R1, CBLB, ERBB2, PTK2, CBL, ERBB4 5.78× 10−32 2.14× 10−30
SRC, EGFR, ABL1, GRB2, PLCG1, SHC1
CRK, PIK3R2, STAT5A, NRG1, ERBB3, GAB1
0.95,0.90 (0.95 k=5), 6, (0.90 k=7) 14 ErbB signaling pathway GRB2, PLCG1, SHC1, CRK, PIK3R1, ERBB2 1.69× 10−24 3.72× 10−23
ERBB3, PTK2, CBL, SRC, EGFR
0.85 6 38 ErbB signaling pathway PIK3R1, CBLB, ERBB2, PTK2, CBL, ERBB4 6.28× 10−29 2.14× 10−27
SRC, EGFR, ABL1, GRB2, PLCG1, SHC1
CRK, PIK3R2, ERBB3, GAB1
0.85 7 30 ErbB signaling pathway GRB2, ABL1, PLCG1, SHC1, CRK, PIK3R2 1.28× 10−28 4.03× 10−27
PIK3R1, ERBB2, ERBB3, PTK2, CBL, GAB1
ERBB4, SRC, EGFR
0.8 5 19 Apoptosis CASP3, TNFRSF10B, TNFSF10, FASLG, RIPK1, TNFRSF10A 5.48× 10−28 4.38× 10−27
CASP8, BID, TRADD, FADD, CASP10, FAS, CFLAR
0.8 6 13 Apoptosis TNFRSF10B, TNFSF10, FASLG, RIPK1, CASP8, BID 5.61× 10−26 4.49× 10−25




candidate disease genes using
Region Growing Analysis.
5.2.1 Introduction
Genome-wide association studies (GWAS) aim to identify common genetic variants that
distinguish a population of individuals (cases) that have a particular trait or disease from
a population of healthy individuals who do not have the trait (controls) (McCarthy et al.,
2008). Single nucleotide polymorphisms (SNPs) are loci of bi-allelic variation in the genome.
The minor allele frequency for a SNP to be considered common is usually at least one percent.
Cases and controls are genotyped at each SNP, the total number of which often exceeds 500
000. GWAS are conducted as a logistic regression (or more commonly a Cochran-Armitage
trend test (Cochran, 1954; Armitage, 1955)) where for each genotyped SNP the number
of copies of the minor allele are regressed onto the disease status (control/case) for all
individuals. Single nucleotide polymorphism p-values are then corrected by the number of
tests, resulting in the identiﬁcation of the SNPs that predict disease status.
The SNPs associated with disease status are often located outside of genes and may be
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correlated (in linkage disequilibrium (LD)) with the causal genes or SNPs.
Genome-wide association studies have been one of the most successful high-throughput
genomic analysis methods of the past decade. They have identiﬁed thousands of common
risk loci that contribute to a variety of complex diseases. However, the variants discovered
so far typically explain a small proportion of the heritable variation of each complex disease.
Explanations for this so-called missing heritability include rare genetic variants with large
eﬀect sizes that are likely to be too rare to pass GWAS quality control procedures (Manolio
et al., 2009; McCarthy et al., 2008). An alternative explanation is that common variants
of decreasingly small eﬀect size account for the missing heritability of complex diseases as
suggested for schizophrenia by Purcell et al. (2009). A combination of both is possible. The
undiscovered common variants may have an eﬀect size that is too small to be detected at
the genome-wide signiﬁcance level ( p < 5× 10−8). In order to address the sample size issue
many studies have combined genome-wide samples across studies in so-called mega-analyses.
The Wellcome Trust Case-Control Consortium (WTCCC1) (Burton et al., 2007) used the
mega-analysis methodology to identify the common variants associated with seven major
complex diseases including rheumatoid arthritis (RA). However, in all cases the total heritable
genetic risk of each disease remained unexplained.
One reason that the total heritable risk was not explained may be that the GWAS
signiﬁcance threshold (p < 5× 10−8) to account for multiple tests was too stringent. It is
known that genes and their protein products do not perform their biological function alone
in the cell. Proteins function as part of biochemical pathways. A malfunction to any one
of the genes in a pathway may lead to the same disease. This scenario may describe the
genetic heterogeneity of a complex disease, where diﬀering genetic causes give rise to the
same disease. This can explain why GWAS may not detect some of the SNPs associated
with a disease. For each causal gene in a pathway only a subset of cases may carry the
disease causing variant, with the remaining cases carrying variants in other genes in the
pathway (Leiserson et al., 2013b). By using protein interaction data to identify pathways
that are enriched for gene-level disease associations additional genes that contribute to the
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disease may be discovered.
Protein interaction databases contain records of thousands of physical interactions between
proteins. The physical interactions recorded in these databases can be represented as a
graph where each protein in each interaction is represented by a vertex and each interaction
between two proteins is represented by an edge. The graph representation of the protein
interaction network enables graph theoretic analyses to be applied to the network to gain
new insights into disease mechanisms and genetics.
5.2.1.1 Network-based analysis of GWAS data
The ﬁeld of using network-based analyses for identiﬁcation of genes contributing to complex
diseases has been outlined in the introduction ( 1.11.4 on page 46). However, numerous
approaches have been developed to prioritise candidate genes from GWAS data. The methods
outlined below use an array of diﬀerent PPI network analysis strategies and methods of
deriving statistical signiﬁcance of candidate genes or subnetworks.
The dmGWAS (Jia et al., 2011) method uses a seed and expand approach to identify
’modules’ in a PPI network that are enriched for gene level GWAS associations. It iteratively
adds genes to a module if it increases the module’s association score above a threshold rate.
The Network Interface Miner for Multigenic Interactions (NiMMI) (Akula et al., 2011) ﬁrst
derives gene level association test statistics using VEGAS (Liu et al., 2010). It then deﬁnes
small subnetworks of interacting protein pairs. Each subnetwork then includes proteins that
are two edges away from one of the originating protein interaction pair. For each subnetwork,
the genes are weighted using a modiﬁed google PageRank algorithm (Page et al., 1999).
The gene weights are combined with the gene-level p-values, and a subnetwork Z-score is
created. Using the NIMMI method to analysis Crohn’s disease GWAS data Akula et al.
(2011) identiﬁed Crohn’s disease associated genes that were not found using single SNP, or
gene level association tests.
The HYbrid SeT (HYST) (Li et al., 2012) analysis interrogates pairs of genes that are
connected in a PPI network to identify associated gene pairs in which both genes were
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not associated with the disease at the univariate level. In a Crohn’s disease dataset, they
successfully identiﬁed a triplet group of JAK2, STAT3, and CCL2. These three genes are
part of the JAK-STAT pathway involved in Crohn’s disease, and were not identiﬁed by SNP
tests, or gene-level tests (Li et al., 2012).
Sharma et al. (2013) developed the GWAS-based Comorbidity Method (GCM) to explain
some of the missing heritability of co-morbid complex diseases using molecular triangulation
(Krauthammer et al., 2004), and jActiveModules (Ideker et al., 2002) to prioritise disease
gene candidates for follow up studies. They discovered new associations between cholesterol
levels and a SNP (rs234706, p = 110−5) in the CBS gene.
The jActiveModules cytoscape application has also been used by Baranzini et al. (2009)
to analyse Multiple Sclerosis (MS) GWAS data, where they conﬁrmed links to immunological
pathways and discovered potential links to neural pathways.
5.2.1.2 Study outline
I ﬁrst used methods developed by Lehne et al. (2011) to derive gene level associations from
SNP data. Then I used Region Growing Analysis (RGA) described in Lehne (2011) to analyse
RA GWAS data from the WTCCC1 study (Burton et al., 2007) in order to prioritise the
gene-level associations and provide additional candidate genes for RA.
Region Growing Analysis is a de-novo pathway discovery algorithm. RGA integrates
gene-level test statistic data with PPI network data in order to identify sections of the PPI
network that are enriched for a labelled set of genes. The non-labelled genes, by deﬁnition
are additional candidate disease genes. A set of seed genes is ﬁrst deﬁned. The seed genes
are labelled on a PPI network. From each seed gene a region is originated. The genes that
are adjacent to a seed gene, or a path distance of two away from a seed gene are incorporated
in to the region. This process continues until no additional genes can be included in the
region. Regions that overlap are merged together. The signiﬁcance of a region is determined
depending on the size of the region. RGA is applied to 10 000 randomised networks and
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the size of largest region discovered in each permutation is recorded to create an empirical
distribution of the largest region size. A region discovered in the non-permuted network is
signiﬁcant if its size is larger than 95 percent of the largest regions discovered in the 10 000
randomised networks.
5.2.2 Methods
5.2.2.1 The WTCCC RA dataset
Data were downloaded from the Wellcome Trust Case Control Consortium (WTCCC) website
in 2007. There were 1860 Rheumatoid Arthritis (RA) cases, and 2938 control samples
retained after quality control procedures that rejected non-Caucasian ancestry, cryptic
relatedness, sample duplication and contamination (Burton et al., 2007). The Aﬀymetrix
GeneChip 500k Mapping Array Set was used to genotype all samples. From the initial set of
500568 SNPs present on the Aﬀymetrix GeneChip, 392575 SNPs were carried forward to
association analysis. Reasons for SNP exclusion included a minor allele frequency (MAF)
<0.01, missing genotyping or genotyping problems identiﬁed through genotyping cluster
plots. Single nucleotide polymorphisms from the Major Histocompatibility complex (MHC)
region were removed (chromosome 6, position 25,930,839 to position 33,495,825, NCBI
GRCh37 assembly). The MHC region showed high association with RA status across its
length (Burton et al., 2007). It is diﬃcult to identify individual SNP association signals in
this gene dense portion of chromosome 6, due to strong LD (correlation) between the SNPs.
5.2.2.2 Gene score generation
The method used to generate gene scores was developed by Lehne et al. (2011) and is
described in this section. RGA requires a gene list as its input. In order to generate a ranked
list of genes from GWAS data a single association score must be assigned to each gene. After
WTCCC SNP quality control there remained more than 300 000 SNP tests. Firstly I assign
each gene a score derived from the surrounding SNPs. Then SNPs were assigned to the
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closest gene within a 40 kilobase window upstream, or downstream of the gene. More recent
methods also take account of LD among SNPs when assigning SNPs to genes (Christoforou
et al., 2012; Dudbridge & Koeleman, 2004; Conneely & Boehnke, 2007).
Once SNPs were assigned to genes, p-values were obtained for each gene based on the
maximum chi-square value (χ21) for any SNP assigned to the gene, the mean χ
2
1 of the
SNPs assigned to the gene, or the median χ21 from the top quartile of SNPs assigned to the
gene. When calculated from the original dataset, whole gene test statistics were subject
to gene length eﬀects, the LD structure of SNPs, and number of SNPs per gene eﬀects
(Lehne et al., 2011). A longer gene is more likely to appear associated with the trait of
interest when compared to a shorter gene because it is likely to contain more SNPs than
a shorter gene (Lehne et al., 2011). In order to control for this problem, a permutation
approach was chosen to obtain empirical p-values for the association of each gene with RA
case status. Five hundred thousand case/control label permutations were carried out using
PLINK (Purcell et al., 2007), giving an empirical distribution of 500 000 χ21 values for each
SNP. New gene wide p-values were calculated as the proportion of permuted datasets with
χ21 statistics higher than that of the original data. Three sets of gene-wide p-values were
created; for the maximum χ21 assigned to the gene (maxT); the median χ
2
1 of SNPs assigned
to the gene (meanT); and the median p-value of the top quartile of χ21 of SNPs assigned to
the gene (topQ). These three sets of gene-wide p-values were used to create three sets of
gene ranks: the smallest p-value being ranked ﬁrst. The three gene rank sets were analysed
separately using RGA.
5.2.2.3 Region Growing Algorithm
The Region Growing Algorithm was developed by Lehne (2011) and Christopher Tebbe, and
is described in this section. From a set of gene ranks numerous ranked lists were generated
to include the top ranked genes according to the threshold α, where α was set at 10, 20, 30,
40, 50, 60, 70, 80, 90, 100, 200, 500, 1000, and 2000 genes. These gene lists contained the
seed genes, all other genes were non-seed genes. Once genes are deﬁned as seeds, they are
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labelled on the PPI network (Figure 5.2.2.1a). The region growing algorithm then begins
at all seed genes. RGA interrogates all of the adjacent vertices of the seed genes. If any
adjacent vertices are seed genes, or adjacent to two or more seeds genes, then they are
included in the region (Figures 5.2.2.1a, and 5.2.2.1b). This procedure is repeated for all
vertices newly included in the region until no further vertices can be added (Figure 5.2.2.1c).
Regions that intersect one another are fused to create a single larger region. When no
additional genes can be included in any region, the number of vertices (genes) in each region
is recorded as the region size.
The region growing algorithm ﬁnds regions composed of seed genes, and non-seed genes
with at least two seed gene neighbours, the so-called outliers. The statistical signiﬁcance of
a region is achieved by using a degree-constrained label shuﬄing approach very similar to
that which was used in Section 5.1.2.6.2 on page 161. For each permutation, the labels of
all vertices are shuﬄed within the network and the region growing algorithm is run. The
size of the largest region for each permutation is recorded. Labels are more likely to be
swapped between vertices of similar degree than those of dissimilar degree. In each permuted
network, the edges no longer represent the true physical interactions between the vertices.
The permutation procedure removes the biological information about protein interactions
encoded in the network by the edges. The process of degree-constrained label shuﬄing and
region discovery in each permuted network was repeated 10 000 times.
Statistical evaluation of the regions was achieved through permutation testing. For each
observed region, an empirical p-value was derived by recording the proportion of the largest
regions found in the 10 000 randomised networks that were larger than the observed region.
Observed regions with an empirical p-value <0.05 were interpreted as signiﬁcantly large.
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Figure 5.2.2.1a: Genes ranked within a user deﬁned threshold α are seed genes. Starting from a seed gene
A, RGA visits all neighbours. Neighbours which are seed genes, or are connected to two or more seed genes
are included in the region. Figures 5.2.2.1b, and 5.2.2.1c: RGA is applied iteratively to all new genes added
to the region. All seed genes originate their own region. Any intersecting regions are fused.
5.2.3 Results
Using the maxT gene ranks, there was a signiﬁcant region found at α ∈ {200, 300, 350}.
The region was largest at α=350, and it contained 27 vertices (p=0.0247) (Figures 5.2.3.2a
and 5.2.3.2b, and Table 5.2.6.1 on page 193). Using the topQ gene ranks, a signiﬁcant region
was identiﬁed at α ∈ {30, 40, 50, 60, 70, 80, 90, 100, 200} (Figures5.2.3.3a and 5.2.3.3b).
The region increased in size up to α=200 where it consisted of 10 vertices (p=0.0403)
(Table 5.2.6.2 on page 194). Using the meanT gene ranks, a signiﬁcantly large region of six
genes was identiﬁed at α ∈ {60,70,80,90,150}. The region was composed of six vertices
when RGA was applied to gene lists at α=60 through to α=150. The summary statistics
for this region (Table 5.2.6.3 on page 194) were interpreted from the α threshold at which
it attained the best rank (Figures 5.2.3.4a and Figure 5.2.3.4b). At α=60, the six gene
region’s p-value was p=7.70× 10−03.
The intersection of the signiﬁcantly regions found using the maxT, meanT and topQ
gene-wide p-value ranking strategies included six genes (Figure 2.5 and Table 2.4); CSF2RB,
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IL2, IL2RB, IL2RA, LCK, and SHC1.
Figure 5.2.3.1: Max T permutation results and signiﬁcant regions
(a) Max T permutation results
A highly ranked large region found using maxT ranks at α=350. The largest original dataset region size and
rank against the number of top ranked genes designated as RGA seeds (alpha). Regions below the cut-oﬀ
were within the 500 largest achieved by 10 000 network label shuﬄing permutations. The region at α=350

























(b) Max T region
Rheumatoid Arthritis associated region in HuPPI2 using maxT ranks. The signiﬁcant region of 27 genes
found using maxT ranks at α=350. Physical interactions between gene products are represented by red
edges. ‘seed’ genes (genes with ranks below the α threshold) were coloured red.
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Figure 5.2.3.2: Top Q permutation results and signiﬁcant region
(a) Top Q permutation results
A highly ranked large region found using topQ ranks at α=200. The largest region rank and size against the
number of top ranked genes designated as RGA seeds (alpha). Regions below the cut-oﬀ were within the
500 largest achieved by 10 000 network label shuﬄing permutations. The region at α=200 was ranked










(b) Top Q region
Rheumatoid Arthritis associated region in HuPPI2 using topQ ranks. The signiﬁcant region of 10 genes
found using topQ ranks at α=200. Physical interactions between gene products are represented by red
edges. ‘seed’ genes (genes with ranks below the α) were coloured red.
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Figure 5.2.3.3: Mean T permutation results and signiﬁcant region
(a) Mean T permutation results
A highly ranked large region was found using meanT ranks at α= 60. The largest region size and rank
against the number of top ranked genes designated as RGA seeds (alpha). Regions below the cut-oﬀ were
within the 500 largest achieved by 10 000 network label shuﬄing permutations. The region at α=60 was







(b) Mean T region
Rheumatoid Arthritis associated region in HuPPI2 using meanT ranks. The signiﬁcant region of 6 genes
found using meanT ranks at α=60. Physical interactions between gene products are represented by red
edges. ‘seed’ genes (genes with ranks below the α threshold 60) were coloured red.
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5.2.4 Discussion
The three diﬀerent ranking strategies maxT, meanT and topQ cannot be interpreted as
correct in isolation. All three strategies must be used in RGA and the results compared.
Each ranking strategy assumes a genetic architecture. As I do not know the true genetic
architecture of RA, the gene products found in signiﬁcantly large region using the maxT,
meanT and topQ gene-wide p-value ranking strategies are an approximation of the most
promising candidate genes contributing to RA.
RGA has identiﬁed a subnetwork consisting of IL2, IL2RA and IL2RB that may contribute
to RA. These genes were not associated with RA at the genome-wide signiﬁcance level in
the WTCCC GWAS (Burton et al., 2007), but associations with RA have been replicated at
nominal p-values for association by Stahl et al. (2010) (IL2 (rs6822844 4q27 p=7.00×10−04),
IL2RA (rs2104286 10p15, p=2.00× 10−04) and IL2RB (rs3218253 22q12 p=2.00× 10−03)).
IL2RB, and IL2RA are attractive candidate genes for RA because they encode proteins
forming a complex (IL2R), a receptor required for the signal transduction of IL2 (H. P. Kim,
Imbert, & Leonard, 2006). The IL2 / IL2R receptor system is involved in a number of
immune processes including T-cell proliferation following antigen encounter, and regulatory
T-cell function (H. P. Kim, Imbert, & Leonard, 2006). The three remaining genes in the
subnetwork (LCK, CSF2RB and SHC1) were not found to be previously associated with
RA by searching Entrez Gene (Maglott, 2004) and the Online Inheritance in Man (OMIM)
(Hamosh et al., 2005) databases.
Region Growing Analysis is heavily reliant upon the quality and size of the network which
is analysed. The HuPPI2 (Lehne & Schlitt, 2009) network represents less than 20 percent of
all human protein coding genes. This means that genes involved in the disease process may
be overlooked. As with many of the protein interaction meta-databases, HuPPI2 (Lehne &
Schlitt, 2009) represents the union of physical protein interactions across all tissues. Some
researchers have found that by using tissue speciﬁc networks disease gene prioritisation results
can be improved (Jiang et al., 2009; Magger et al., 2012). In addition, the HuPPI2 network
includes only protein interactions. Biochemical interactions such as transcription factor
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binding may play an important role in complex diseases, but they are not represented in the
HuPPI2 network. Networks such as Multinet (Khurana et al., 2013) that include protein-DNA
physical interactions from the Encyclopdia of DNA Elements (ENCODE) (Gerstein et al.,
2012) project will allow networks researchers to explore the role of protein interactions and
gene expression regulation simultaneously.
Region Growing Analysis uses a unique network search strategy. By allowing an iterative
search of gene neighbours two edges away from region members the discovery of regions
composed of long chains of proteins is possible. This cannot be said for other methods
that restrict the network search to two edges (NiMMI (Akula et al., 2011)), or gene pairs
(HYST (Li et al., 2012)). However, The HyperModules software (Leung et al., 2014), takes
a similar approach to Region Growing Analysis by labelling mutated genes in a PPI network
as seed genes and then iteratively expanding the region by adding additional neighbouring
genes if there is an increase in the correlation of the presence of a mutation in the module
with a continuous, or categorical clinical variable. Leung et al. (2014) found 19 subnetworks
in TCGA ovarian cancer exome sequence data that showed diﬀerential rates of survival in
patients that carried mutations within the modules in comparison to those who did not.
Ozgun et al. (2014) use a similar approach to identify subnetworks composed of mutually
exclusively mutated genes in TCGA somatic mutation data.
5.2.5 Conclusions
Using GWAS and incorporating additional biological information in the form of a PPI network
and the network based analysis RGA, I have identiﬁed a promising candidate region of six
candidate RA genes, which included genes that had previously been found to be associated
with RA at a nominal level using GWAS (Burton et al., 2007; Stahl et al., 2010). This may
be an example of genetic heterogeneity where a mutation in any one of the members of the
subnetwork confers additional RA risk.
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Region growing analysis may be improved by considering more than one region in the
observed network for statistical signiﬁcance. This may allow the discovery of further plausible
candidate genes. Additional candidate genes may also be discovered by applying RGA to
tissue speciﬁc networks, or those which include multiple types of biochemical interactions.
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5.2.6 Supplementary Materials
Table 5.2.6.1: Genes within the signiﬁcant 27 gene region found using a rank threshold of
α=350 based on maxT gene-wide empirical p-value ranks.
Gene maxT rank maxT p-value Chro Start End
IL2RB 12 4.20× 10−05 22 20486973 20511039
IL2RA 21 3.06× 10−47 10 5979490 6030662
RGS16 44 2.75× 10−03 1 153804224 153810014
SOCS1 99 2.84× 10−03 16 11266017 11267782
POU2F1 172 0.03 1 138436084 138642676
NCOA2 190 0.01 8 66517566 66809329
STAT1 196 0.02 2 183693413 183738626
NR2F2 223 0.01 15 72999792 73013983
GTF2B 231 0.01 1 87435703 87474719
GTF2E1 291 0.14 3 117835641 117875998
CSF2RB 314 3.04× 10−03 22 20271284 20300485
EGFR 979 0.09 7 54924934 55112834
EP300 1829 0.23 22 24453007 24540433
IL2 3119 0.19 4 119099231 119104256
NR3C1 5767 0.37 5 137804733 137962312
LYN 6968 0.34 8 52260576 52392001
JAK2 7674 0.64 9 4940783 5083727
GTF2E2 8939 0.55 8 28980483 29060402
PIAS1 9014 0.56 15 45180222 45311150
ESR1 10236 0.71 6 149573851 149986188
TBP 12153 0.80 6 168368477 168387004
PDGFRB 12810 0.79 5 144641381 144683476
JAK1 13041 0.71 1 63407815 63541120
CREBBP 13888 0.94 16 3743994 3898607
LCK 14784 0.98 1 30833080 30867241
AR NA NA X 60592006 60772474
SHC1 NA NA 1 126296519 126308704
The table shows the gene symbol (gene);, The gene ranks according to maxT gene-wide empirical p-values
(maxT rank); The gene-wide maxT empirical p-values (maxT p-value); The chromosome on which genes
are located (chro), the start and end position of genes (start/end) and full gene names providing
information about gene function (info).
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Table 5.2.6.2: Genes within the signiﬁcant region of 10 genes found using a rank threshold
of α=200 and topQ gene-wide empirical p-value ranks.
gene topQ rank topQ p-value Chro start end
IL2RB 12 4.20× 10−05 22 20486973 20511039
IL2RA 25 3.06× 10−04 10 5979490 6030662
RGS16 74 2.75× 10−03 1 153804224 153810014
CSF2RB 79 3.04× 10−03 22 20271284 20300485
PTPRC 195 9.42× 10−03 1 169775365 169893778
IL2 3112 0.19 4 119099231 119104256
LYN 5247 0.34 8 52260576 52392001
LCK 14791 0.98 1 30833080 30867241
PTPN6 NA NA 12 6911844 6928943
SHC1 NA NA 1 126296519 126308704
The table shows the gene symbol (gene); The gene ranks according to topQ gene-wide empirical p-values
(topQ rank); The gene topQ gene-wide empirical p-values (topQ p-value); The chromosome on which genes
are located (chro), The start and end position of genes (start/end) and full gene names providing
information about gene function (info).
Table 5.2.6.3: Genes within the signiﬁcant 6 gene region found using a rank threshold of
α=60 based on meanT gene-wide empirical p-value ranks
gene meanT rank meanT p-value chro start end
IL2RB 12 4.20× 10−5 22 20486973 20511039
IL2RA 25 3.06× 10−04 10 5979490 6030662
CSF2RB 79 3.04× 10−03 22 20271284 20300485
IL2 3112 0.19 4 119099231 119104256
LCK 14791 0.98 1 30833080 30867241
SHC1 NA NA 1 126296519 126308704
The table shows the gene symbol (gene); The gene ranks according to topQ gene-wide empirical p-values
(topQ rank); The gene topQ gene-wide empirical p-values (topQ p-value); The chromosome on which genes
are located (chro), The start and end position of genes (start/end) and full gene names providing





6.1 Overview of the thesis
Chapter 1 introduced the topic of research undertaken in this thesis. First an introduction
to cancer exome sequencing and TCGA and Pan-Cancer projects were given, followed by
an overview of machine learning methods in the context of cancer gene discovery. An
introduction to graph theory and protein interaction networks was given, and also discussed
in the context of prioritisation of complex disease gene candidates. An outline of the key
research goals was then given.
Chapter 2 described the exploratory analyses conducted on TCGA colorectal cancer
exome sequence data from June 2012, December 2012, and from the Pan-Cancer analysis
project. Non-metric multidimensional scaling and PCA were used to explore the technical
eﬀects in the three datasets. A sequence technology eﬀect was discovered in TCGA datasets
that was reduced in the Pan-Cancer dataset. This led to the decision to use the Pan-Cancer
exome sequence data for all further cancer analysis undertaken in the thesis.
Chapter 3 explored the problem of discovering mutations that correlate with cancer grade
and stage across cancer types. Logistic regression models were created to identify the genes
carrying functional mutations that were associated with low grade and high grade tumours
(the same was done for low stage and high stage tumours). This was done across, and
within three types of adenocarcinoma (ovarian adenocarcinoma, renal cell carcinoma, and
endometrial carcinoma). Functional mutations in TP53 were associated with a high grade
status across adenocarcinomas. In endometrial carcinoma previously known associations
between TP53 mutations and high grade status, and PTEN mutations and low grade status
(Garcia-Dios et al., 2013) were conﬁrmed. Across and within adenocarcinomas there were no
mutated genes associated with cancer stage when adjusting for the covariates age, gender,
grade, and tumour type.
Chapter 4 applied a Random Forest approach to predict the class membership of Pan-
Cancer samples using exome sequence data. In Chapter 4.1 Pan-Cancer samples were assigned
to one of ﬁve high-order cancer types (adenocarcinoma, squamous cell carcinoma, urothelial
carcinoma, a brain cancer, and a blood cancer) and mutated genes that discriminated
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each cancer type from all others were identiﬁed. The genes that were most discriminatory
between cancers were those that were mutated almost exclusively in a single cancer type
(Kandoth et al., 2013a) including VHL (renal clear cell adenocarcinoma), APC (colorectal
adenocarcinoma), and DNMT3A (acute myeloid leukaemia).
Chapter 4.2 developed the work from Chapter 4.1 and investigated the feasibility of
creating a tool to predict the origin of metastatic cancers of unknown primary origin (CUP)
in order to help guide the treatment choices of clinicians. Using the Pan-Cancer somatic
mutation data, Random Forest models were created which assigned Pan-Cancer primary
tumours of known origin to their tissue with around 70 percent accuracy.
Chapter 5 tackled the problem of candidate disease gene prioritisation for complex diseases
by using network based approaches. Chapter 5.1 described the development of k-pseudo
cliques analysis : a network-based method to prioritise disease gene candidates by integrating
gene-level test statistics (from MutSigCV (Lawrence et al., 2013)) with PPI network data. K-
pseudo cliques analysis ﬁnds communities of highly interacting proteins, called pseudo-cliques,
in a PPI network using the DME pseudo clique enumeration software (Georgii et al., 2009;
Tsuda & Georgii, 2009). Pseudo-cliques that overlap by k − 1 proteins are grouped to give a
set of k-pseudo cliques. The k-pseudo cliques are tested for enrichment with low p-values
from gene level test statistics using a vertex label re-assignment permutation test. K-pseudo
cliques that contained lower than expected MutSigCV test statistics were discovered. The
‘signiﬁcant’ k-pseudo cliques composed of at least ten proteins were enriched for either the
KEGG Apoptotsis pathway, or ErbB signalling pathway (Kanehisa & Goto, 2000; Kanehisa
et al., 2014).
Chapter 5.2 described an investigation into candidate disease gene prioritisation by
integrating gene-level genetic association data derived from a genome wide association
study (GWAS) and PPI network data. Region Growing Analysis (RGA) (Lehne, 2011) was
used to demonstrate that genes associated with rheumatoid arthritis (RA) are clustered in
the HuPPI2 network (Lehne & Schlitt, 2009). A signiﬁcant subnetwork of six genes was
discovered. It included three genes known to be associated with rheumatoid arthritis (IL2RA,
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IL2, and IL2RB) and three additional RA candidate disease genes.
6.2 Research aims revisited
At the end of Chapter 1 three research aims were outlined. These are now revisited to
ascertain whether they have been fulﬁlled.
• Identify mutated genes associated with grade, and stage across cancers
This was addressed in Chapter 3. Cancer grade was dichotomised in to low and high
categories to mitigate inter-pathologist variation in tumour grading. Cancer stage was
dichotomised in the same way (low stage / high stage) to distinguish cancers that were
conﬁned to the primary tissue and those that had spread beyond. Logistic regression was
used to ﬁnd that TP53 mutations are associated with high grade status across three types of
adenocarcinoma (ovarian adenocarcinoma, renal cell carcinoma, and endometrial carcinoma).
No mutated genes were associated with cancer stage when adjusted for age, gender, cancer
grade and cancer type. The aim was met, however other approaches may have more success.
• Identify the mutated genes that discriminate ﬁve high-order cancer types (adenocarci-
nomas, squamous cell carcinomas, urothelial carcinomas, blood, and brain cancers)
from one another
This aim was tackled in Chapter 4.1. The route taken to identify the mutated genes that
discriminated the ﬁve cancer types from one another was to use ten pairwise Random
Forest analyses. The Random Forest is designed as a classiﬁcation algorithm, but it
also simultaneously performs feature selection, to identify the set of features which best
discriminate between the two cancer types included in each comparison. For each comparison
the data was divided into a two thirds training set for model building and one third test
set for model evaluation. The majority class in the training set was down-sampled to be
equal to the minority class. This was because of the severe class imbalances across cancer
types. It was found to be most severe between urothelial carcinoma (89 samples) and
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adenocarcinoma (791 samples) cancer types. All Random Forest models performed with
classiﬁcation accuracy above 0.7 and included mutated proteins. However, the biological
interpretation of how mutations among the proteins interact to discriminate the cancer types
needs to be investigated further.
The aim to produce a tool to discriminate between cancers of diﬀerent tissue types based
on whole exome sequence data was achieved in Chapter 4.2. The approach used protein
features, variant frequency features, and transition and transversion frequency features to
discriminate between the ten Pan-Cancer solid tumour types. This time a ten class multi-class
Random Forest was used to discriminate between the ten cancer classes and identify the
features that discriminated between the cancers. Two thirds of the dataset was used for
model building (the training set) and one third was used for model evaluation (the test
set). Two sampling schemes were used to balance the cancer classes in the training set.
The ﬁrst involved downsampling classes to be equal to the minority class (bladder urothelial
carcinoma). The second strategy used a combination of up-sampling and down-sampling to
create a larger training set. The Random Forest models based on the two sampling schemes
performed similarly. Most of the variant frequency, transition and transversion frequency
features were included in the classiﬁcation models indicating that mutation frequency is a
good discriminator between cancer types. Genes that are exclusively mutated in certain
cancer types were also included in the models including VHL (renal clear cell carcinoma),
APC, and KRAS (colorectal adenocarcinoma).
• Use prior biological information in the form of a protein interaction network to suggest
new complex disease gene candidates
The ﬁnal research aim was addressed in Chapter 5. K-pseudo cliques analysis was performed
in Chapter 5.1. It prioritised candidate disease genes by integrating PPI network data with
gene level test statistics. Network-based methods have been used successfully to discover new
disease genes in complex diseases (Akula et al., 2011; Li et al., 2012) and cancer (Chuang
et al., 2007; Cerami et al., 2010; Hofree et al., 2013). However, k-pseudo cliques analysis
is the only method to enumerate all pseudo cliques in a PPI network, identify overlapping
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pseudo cliques known as k-pseudo cliques, and identify which of the k-pseudo cliques are
enriched for low p-values from gene-level tests. Firstly, pseudo cliques were identiﬁed using
the DME software (Georgii et al., 2009) at densities (α) ranging from 0.95 to 0.75 in
descending steps of 0.05. Then the clique percolation approach used in CFinder (Palla et al.,
2005, 2007) was used to identify k-pseudo cliques: pseudo cliques that overlapped by k − 1
genes. MutSigCV (Lawrence et al., 2013) was used to measure the extent to which each
gene was signiﬁcantly mutated in the Pan-Cancer colorectal cancer exome sequence data.
MutSigCV p-values were assigned to each gene in the PPI network. The median p-value of
the genes was computed for each k-pseudo clique. A vertex label reassignment procedure was
used to create 10000 permuted networks where the median p-value of each k-pseudo clique
was recorded. An empirical p-value was assigned to each k-pseudo clique in the observed
network. This corresponded to its rank among the permuted scores divided by 10000. A
k-pseudo clique was deemed to be signiﬁcant at an FDR< 0.1 (Benjamini & Hochberg,
1995).
Twelve signiﬁcant k-pseudo cliques were discovered that in total contained 87 genes.
Lists of genes derived from the signiﬁcant k-pseudo cliques at each parameter setting often
outperformed the MutSigCV results in terms of enrichment in the KEGG ‘pathways in cancer’
gene set. The k-pseudo cliques settings where α=0.95 and k=3 performed best. Two
signiﬁcant k-pseudo cliques were discovered at α=0.95 and k=3. One of which contained all
four ErbB signalling proteins (EGFR, ERBB2, ERBB3, and ERBB4) which were not found
to be signiﬁcantly mutated by MutSigCV.
Region Growing Analysis was used to prioritise gene-level associations derived from GWAS
data in the WTCCC rheumatoid arthritis dataset (Burton et al., 2007) using prior biological
information in the form of the HuPPI2 (Lehne & Schlitt, 2009) PPI network. Region Growing
Analysis conﬁrmed a subnetwork of interacting proteins (IL2RA, IL2RB, IL2) that were
known to contribute to the disease. Association p-values for single nucleotide polymorphisms
close to these three genes did not achieve genome-wide signiﬁcance in the WTCCC GWAS
(Burton et al., 2007). Three other genes (LCK, CSF2RB, and SHC1) were included in the
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subnetwork that had not previously been associated with rheumatoid arthritis. The RGA
method therefore successfully prioritised disease genes and suggested additional candidate
genes by integrating gene-level test statistics with PPI network data.
6.3 Contributions
The key contributions of this thesis are listed below.
• The association between TP53 functional mutations and high cancer grade across
three types of adenocarcinoma (ovarian adenocarcinoma, renal cell carcinoma, and
endometrial carcinoma) when adjusted for cancer type, age, gender, and stage.
• A Random Forest model that can be used to predict the tissue of origin of cancers of
unknown primary origin using whole exome sequence data.
• A method to prioritise candidate disease genes (k-pseudo cliques analysis) based on
gene level test statistic data and protein interaction network data.
6.4 Limitations
In Chapter 3 TCGA tumour grade was treated as the outcome, but grading is a subjective
measure with signiﬁcant inter-pathologist variation (Al-Aynati et al., 2003; Engers, 2007). It
was not possible to account for inter-pathologist variation in grading because the pathology
reports for each tumour were censored. Even after dichotomising the cancer grade in to low
and high categories inter-pathologist variation in tumour grading may have prevented some
of the features that associated with tumour grade from being identiﬁed.
Chapter 4.1 identiﬁed sets of genes that discriminate between ﬁve cancer types. However,
the interpretation of how these mutated genes interact to discriminate between the cancer
types is not easily understood when up to 100 proteins were included in some models.
The Random Forest models developed in Chapter 4.2 to assign CUP to their tissue of
origin based on exome sequence data have limitations. The Pan-Cancer data that was used
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to create the models is not a complete set of cancer types. Additional data are needed to
validate these results in CUP.
The k-pseudo cliques analysis developed in Chapter 5.1 is limited by its reliance upon the
Dense Module Enumeration (Georgii et al., 2009; Tsuda & Georgii, 2009) (DME) algorithm
to ﬁnd the pseudo-cliques. DME Computation time increases as the density and size of the
input network increases. This may prohibit the analysis of larger networks.
The Region Growing Analysis that was used in Chapter 5.2 uses the size of the largest
region in the observed network ranked among the sizes of the largest regions achieved in
each of 10000 permuted networks to derive statistical signiﬁcance. Therefore only a single
region can achieve statistical signiﬁcance.
6.5 Future work
Future work will involve the extension and improvement of analyses and methodologies
presented in this thesis. Chapter 3 investigated the mutated genes associated with cancer
grade in the Pan-Cancer dataset. However, tumour grading is subject to signiﬁcant inter-
pathologist variation (Al-Aynati et al., 2003; Engers, 2007). Work has begun to account
for this variation by using the grade annotations of a single expert pathologist (Dr Salvador
Diaz-Cano) based on pathology slides available from the cancer digital slide archive (Gutman
et al., 2013) instead of TCGA grade annotations. The same logistic regression analyses will
then be conducted.
The Random Forest model to assign a tissue of origin to CUPs must be validated using a
set of CUPs that have undergone whole exome sequencing. Genomics England is undertaking
the genome sequencing of cancers of unknown primary which can be used to validate the
Random Forest models when the data becomes available. The exome sequence analysis of
21 TCGA cancer types has recently been standardised (Lawrence et al., 2014). The data
could be used to create a more comprehensive prediction model.
The k-pseudo cliques analysis developed in Chapter 5.1 requires a more scalable approach
to pseudo clique discovery if it is to be applied to large PPI networks. A further development
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may be to sacriﬁce the solution to the pseudo-clique enumeration problem that is achieved
by DME (Tsuda & Georgii, 2009), for a heuristic approach which may be faster for dense
networks.
The Region Growing Analysis that was used in Chapter 5.2 may be improved by considering
more than one region for statistical signiﬁcance. A more appropriate approach may be to
rank all regions discovered across 10000 permutations, and consider any region from the
non-permuted network as signiﬁcant if it is larger than the nth largest region achieved by
network permutation.
An extension to the methods applied in Chapters 3 and 5 to identify subnetworks within
a PPI network which exhibit association with a binary outcome could be developed. A set
of seed genes is established using logistic regression to identify genes that are signiﬁcantly
associated with the outcome once adjusted for relevant covariates. The seed genes are
mapped on the PPI network. Starting from a seed gene the logistic regression analysis is
repeated after adding an adjacent gene to the model. AIC (Akaike, 1974) is used to decide
whether or not to include the adjacent gene in the subnetwork. In this way, all genes adjacent
to the subnetwork members are tested. The analysis is repeated until no further genes can
be added to the model. Such a method would identify subnetworks of mutated genes that
are independently associated with an outcome.
6.6 Concluding remarks
This thesis has contributed to the understanding of the molecular correlates of cancer grade
across multiple cancers. It has identiﬁed sets of genes which potentially discriminate between
high-order cancer types, which in turn led to the development of a tool which could be
used to annotate CUP with a tissue of origin. In the future this may aid patient care. The
k-pseudo cliques analysis developed in this thesis has application beyond cancer and may be
used to prioritise candidate genes for any complex disease.
The further development of biomarkers and clinical cancer tests may require more
comprehensive phenotypic information, as phenotypic information is usually more informative
203
than genomic information for clinical classiﬁcation tasks. Projects like Genomics England
should provide an excellent basis for the development of such tests through the integration
of electronic health records with patient genomic data.
Gene-level analyses of exome sequence data in cancer have been successful in identifying
some of the mutations that cause cancer. However, the comprehensive set of molecular
alterations that cause cancer and contribute to cancer progression is likely to include other
types of mutation. Whole genome sequencing may identify mutations in transcription
factor binding sites, and methylation data may indicate genes which have been silenced in
cancer. Even by integrating the analyses of these diﬀerent data types, genetic heterogeneity
may prevent the discovery of causative mutations using univariate tests. Where genetic
heterogeneity is present in integrated datasets, network-based approaches have the potential
to disentangle some of that heterogeneity and improve our understanding of the causes of
cancer, and other complex diseases.
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